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ABSTRACT 
 
KRYSTLE D. STRAND:  Detrimental and Beneficial Effects of Interferon-gamma on 
Oligodendrocytes and the Myelination/Remyelination Process 
(Under the direction of Brian Popko) 
 
    Interferon-gamma (IFN-γ) is a pro-inflammatory cytokine that is believed to play a key 
role in the pathogenesis of immune-mediated demyelinating disorders of the central nervous 
system by exerting direct deleterious effects on oligodendrocytes, the myelinating cells of the 
CNS.  Increasing evidence predicts that the effect of IFN-γ on oligodendrocytes in culture 
and in vivo will depend on the developmental stage of the cells and the timing of IFN-γ 
expression relative to myelination/remyelination.  We hypothesize that selected genes will be 
expressed by developmentally different oligodendrocytes when exposed to IFN-γ.  In order to 
elucidate the molecular mechanisms driving these effects, we used microarrays to 
quantitatively compare the transcriptional response of 1) cultured developing and mature 
primary oligodendrocytes exposed to IFN-γ, and 2) the corpus collosum exposed to IFN-γ in 
vivo during, and two weeks following, a cuprizone-induced demyelinating insult, measured 
at the point of peak demyelination and at the crest of remyelination.  There was a significant 
change in the expression of numerous genes in both the in vitro and in vivo systems as a 
result of IFN-γ exposure.  Most dramatic were changes in the expression of genes involved in 
antigen presentation and protein processing, the immune response, the endoplasmic reticulum 
stress response, apoptosis, and the oxidative stress response.  Moreover, immature 
oligodendrocytes appeared more responsive and vulnerable than mature oligodendrocytes to 
IFN-γ exposure in vitro, and the timing of IFN-γ induction influenced the transcriptional 
 iv
response in vivo.  Early IFN-γ exposure demonstrated evidence of a deleterious effect, while 
later IFN-γ suggested a protective effect, particularly during remyelination. 
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CHAPTER ONE 
 
INRODUCTION 
 
 
    Myelin is a multilammelar sheath comprised of 70% lipid and 30% protein that serves to 
wrap neuronal axons in up to 1mm internode increments leaving 1µm of bare axon between 
internodes known as nodes of Ranvier (Smith, 1996).  In the peripheral nervous system 
(PNS), axons are myelinated by Schwann cells, and each Schwann cell forms a single 
internode (Smith, 1996).  In the central nervous system (CNS), oligodendrocytes (OLs) 
produce myelin.  The conservation of space in the CNS is of much more importance, and a 
single OL can extend up to 50 membrane processes myelinating several different axons 
(Raine, 1997; Smith, 1996).   
    The term salutatory conduction is used to describe the series of depolarizing events that 
occur along the axon at the nodes of Ranvier.  Sodium channels are clustered in high density 
at the nodes, resulting in low membrane resistance, which allows rapid charging and 
discharging and results in extremely fast propagation of electrical impulses down the axon.  
It is these electrical impulses that signal the release of neurotransmitters between axon 
terminals and dendrites, providing a line of communication between neurons (Smith, 1996).   
    Not all axons are myelinated, and those that aren’t do not have the high density clustering 
of sodium channels, and therefore, propagate electrical impulses much more slowly (Smith, 
1996).  There are several neuropathies in which axons become demyelinated and the 
disruption to neuronal communication has marked phenotypic consequences.   
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    In the CNS, the most common demyelinating disease is multiple sclerosis (MS), affecting 
over 2.5 million people world-wide with a bias for females (1.6:1) and persons of Northern 
European decent residing in temperate climates during the first 15 years of life (1 in 1000) 
(Compston and Coles, 2002; reviewed in Noseworthy, 1999).  The onset of symptoms, which 
can be sensory, motor, visual, and/or autonomic, most often occurs in the second to forth 
decade of life.  In 15% of MS cases, there is a steady progression of symptoms from the time 
of onset, but the majority of cases (85%) begin as relapsing-remitting with exacerbations 
generally lasting weeks followed by periods of nearly complete recovery lasting months to 
even years.  Over time the number of partially remyelinated and fully demyelinated lesions 
increases such that patients no longer experience distinct recovery periods and enter a 
secondary progressive phase of the disease (Trapp et al., 1999).  The etiology and 
contributing factors of MS remain elusive, in part due to the extreme variability of symptoms 
and rate of progression.  It is now, however, widely accepted that MS is an autoimmune 
inflammatory disorder with both environmental and genetic elements influencing its course 
(Noseworthy, 1999; Raine, 1994). 
    The CNS is normally naïve to components of the immune system, protected by the blood-
brain barrier (BBB) (Crone, 1986); however, in MS the BBB is compromised allowing 
infiltration of T cells and macrophages (Raine, 1994; Rodriquez and Scheithauer, 1994).  
These cells along with reactive astrocytes have been found at sites of demyelination, and 
biopsied lesions have indicated that OLs, not myelin itself, are the target of attack (Rodriguez 
and Scheithauer, 1994; Rodriguez et al., 1993).  Moreover, examination of cerebral spinal 
fluid (CSF) from MS patients revealed antibodies to several myelin components, including 
myelin basic protein (MBP) and proteolipid protein (PLP) (reviewed in Miller et al., 1995).  
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The primary animal model for MS, experimental autoimmune encephalomyelitis (EAE), can 
be induced by immunizing animals with myelin or one of its components (Roland and 
McFarland, 1995).  While not a perfect model for MS (reviewed in Steinman, 1999), EAE is 
T cell-mediated and displays many of the immunological, clinical, and pathological features 
and nuances of MS (Roland and McFarland, 1995).   
    One of the complicating factors, and likely significant contributors, to immune-mediated 
demyelination is the ectopic secretion of cytokines and growth factors by infiltrating immune 
cells.  Significant clinical and experimental evidence has implicated the pro-inflammatory 
cytokine interferon-gamma (IFN-γ) in the pathogenesis of MS and EAE (reviewed in 
Steinman, 2001; Baerwald et al., 1999; reviewed in Popko et al., 1997).  IFN-γ has been 
detected in and around demyelinated lesions and in the CSF of MS patients.  Furthermore, 
administration of IFN-γ as a therapeutic agent instead caused rapid progression of the disease 
(Panitch, 1992; Panitch et al., 1987).   
    IFN-γ is a Type II pro-inflammatory cytokine and fundamental regulator of the immune 
and inflammatory responses that is expressed exclusively by T cells and natural killer cells 
and regulates their preponderance in response to injury or infection (reviewed in St. Pierre et 
al., 1996).  It is a 34- to 50-kDa secreted protein that upon non-covalent homodimerization 
binds dimerized α and β subunits of its receptor, which is expressed by all cells types except 
erythrocytes (Tau and Rothman, 1999).  Ligand-receptor binding initiates an intracellular 
signal transduction cascade whereby Janus protein tyrosine kinases (JAKs) associated with 
the receptor become phosphorylated.  Signal transducer and activator of transcription-1 
(STAT1) molecules bind phosphorylated JAKs and also become phosphorylated.  
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Phosphorylated STAT1 is then translocated to the nucleus where it binds γ-activation sites 
(GAS) and induces IFN-γ-sensitive genes containing GAS elements (Shuai et al., 1993). 
    Oligodendrocyte progenitor cells (OPCs) arise from the subventricular zone in the CNS 
(reviewed in Barres, 1999; McKinnon and Dubois-Dalcq, 1996) and migrate into areas of the 
CNS destined for myelination, where they then proliferate and differentiate into postmitotic 
mature OLs.  Distinct stages of differentiation have been immunologically identified, 
beginning with PSA-NCAM+ preprogenitors (Grinspan et al., 1990; Ben-Hur et al., 1998), 
followed by A2B5+ early progenitors (Raff et al., 1978), O4+ late progenitors/pro-
oligodendrocytes (Dubois-Dalcq, 1987), galactocerebroside+ oligodendrocytes (Raff et al., 
1978), and O1+ mature oligodendrocytes (Schachner et al., 1981; Sommer and Schachner, 
1981) .   
    The survival, proliferation and differentiation of OPCs is regulated by numerous 
extracellular cues.  Platelet-derived growth factor (PDGF) (Noble et al., 1988; Raff et al., 
1988) and basic fibroblast growth factor (bFGF) (McKinnon, 1990) promote progenitor cell 
survival (Barres et al., 1992) and insulin-like growth factors (IGFs), neurotrophin-3 (NT-3), 
ciliary-neurotrophic factor (CNTF), leukemia inhibitory factor (LIF) and interleukin-6 (IL-6) 
promote the survival of mature cells (Barres et al.,1993).  bFGF sustains high levels of 
PDGF-α receptors, the sole isoform expressed by OPCs and OLs (de Vries, 2000).  In vitro, 
differentiation of progenitors can be stimulated by removing PDGF and bFGF from the 
culture medium (McKinnon et al., 1990, 1993), and this process is facilitated by IGF-1 and 
thyroid hormones (McMorris et al., 1986; Barres et al., 1992, 1994).  PDGF-α knockout 
mice display hypomyelination and a decrease in the number of both progenitor cells and 
mature OLs (Fruttiger et al., 1999). 
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    Several transcription factors have also been found to be transcriptionally regulated during 
various stages of progenitor differentiation and myelination (reviewed in Wegner, 2001).  
Members of the basic helix-loop-helix family, OLIG-1, OLIG-2, and OLIG-3 are expressed 
early in OL differentiation (Takebayashi et al., 2000; Zhou et al., 2001), while the expression 
of NKX6-2, a homeodomain protein, is restricted to mature OLs and parallels that of MBP 
and PLP proteins during postnatal brain development (Komuro et al., 1993; Awatramani et 
al., 1997).  Still others, such as POU3F1, are expressed only transiently to activate myelin-
associated genes (Collarini et al., 1992).   
    Exposing developing and mature OLs to IFN-γ in vitro has been shown to have varied, but 
principally detrimental consequences.  Vartanian et al. (1995) reported apoptotic death in 
both immature and mature primary rodent OL cultures; whereas Agresti et al. (1996) 
determined IFN-γ only caused progenitor cells to halt mitosis and differentiation.  Still others 
observed a retraction of membrane processes and flattened cell bodies in response to IFN-γ 
treatment of the MOCH-1 OL cell line (Li et al., 1995).   Previous studies from our lab have 
indicated that immature cells of the O2-A cell line die by apoptosis after two days of IFN-γ 
exposure and mature cells die by necrosis after four to seven days (Baerwald and Popko, 
1998).   
    In vivo, direct delivery of IFN-γ to the CNS of rodents (reviewed in Popko et al., 1997) 
stimulated major histocompatibility complex (MHC) expression (Wong et al., 1984; Sethna 
and Lampson, 1991; Steiniger and van der Meide, 1988).  Evidence from these studies also 
suggests IFN-γ may induce cell adhesion molecule expression in endothelial cells of the 
blood-brain barrier, which may potentially play a role in the perturbation mediating 
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transepithelial migration of inflammatory cells into the CNS (Simmons and Willenborg 1990, 
Wong and Dorovini-Zis 1992, Steffen et al. 1994, McCarron et al. 1993).   
    Several transgenic lines of mice have been generated to examine the effects of ectopic 
IFN-γ expression in the CNS.  Mice expressing IFN-γ under the transcriptional control of the 
oligodendrocyte-specific MBP promoter (MBP/IFN-γ) display a tremoring phenotype, severe 
hypomyelination, and astrogliosis (Corbin et al., 1996).  Expression of IFN-γ in these mice is 
induced at the time of myelin production; however, the onset of MS occurs in adulthood after 
myelination has been established.  Moreover, in MS and EAE, oligodendrocytes are bathed 
in IFN-γ; rather than synthesizing and secreting the cytokine.  In an effort to create a more 
accurate model for adult onset demyelination, transgenic animals expressing IFN-γ in 
astrocytes under the tetracycline-inducible system were developed (Lin et al., 2004).  This 
model provides temporal and spatial control of IFN-γ expression and permits evaluation of 
the effects of IFN-γ on mature OLs and myelination.   
    In MS and EAE, T cells and macrophages infiltrate the CNS and invoke the induction of 
cytokines and other immune response molecules.  Demyelination by the toxicant cuprizone, 
however, is largely non-immune-mediated (Matsushima and Morell, 2001).  Combining the 
cuprizone model of demyelination with the tetracycline-inducible model of IFN-γ has 
spawned an excellent system for studying the effects of a single cytokine, induced at 
different time points, on the demyelination and remyelination processes (Lin et al., 2006).   
       During remission, oligodendrocyte progenitor cells (OPCs) migrate to areas of 
demyelination where they differentiate into mature oligodendrocytes (OLs) and extend 
membrane processes that become the myelin sheath wrapping bare axons and restoring signal 
transduction (Mason et al., 2000; Matsushima and Morell, 2001).  A single OL can extend up 
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to approximately 50 myelin processes, which requires the synthesis of enormous amounts of 
plasma membrane lipid and protein (Smith, 1996). 
     In non-pathological situations, oligodendrocytes do not constitutively express antigen 
presenting molecules; however, in the presence of IFN-γ, MHC class I is markedly induced 
(Wong et al. 1984, Suzumara et al. 1986, Calder et al. 1988, Satoh et al. 1991, Massa et al. 
1993, Li et al. 1995).  MHC class I is a trimolecular complex that is assembled in the 
endoplasmic reticulum (ER) and consists of the MHC class I heavy chain, beta-2 
microglobulin (β2M), and a peptide antigen.  The complex is transported out of the ER to the 
cell surface via the secretory pathway involving the transporter TAP, but only when correctly 
assembled by protein folding chaperones.  At the cell surface, MHC-bound antigen is 
presented to and recognized by circulating T cells.   
    Evidence suggests that robust MHC synthesis in OLs is detrimental.  MHC class I was 
upregulated in the MBP/IFN-γ mice (Corbin et al., 1996), particularly enhanced in white 
matter tracts (Baerwald et al, 2000), and phenotype severity strongly correlated with the level 
of MHC class I induction (Corbin et al., 1996).  Transgenic animals with MHC class I heavy 
chain expression targeted to OLs exhibit severe hypomyelination (Turnley et al., 1991; 
Yoshioka et al., 1991).  The heavy chain is restricted to oligodendrocyte perikarya (Power et 
al., 1996) and is not transported past the ER, which is likely due to improper assembly of the 
trimolecule complex (Baerwald et al., 2000).  In the jimpy mouse, oligodendrocytes express a 
mutant form of PLP, which accumulates in the ER and results in severe hypomyelination and 
apoptotic cell death of oligodendrocytes (Gow et al. 1994, 1996, 1998; Tosic et al., 1996; 
Skoff, 1995).  Over expression of wild-type PLP also leads to aberrant myelin formation 
(Readhead et al., 1994; Kagawa et al., 1994).   
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    Since actively myelinating oligodendrocytes must synthesize copious amounts of 
membrane lipid and protein via the secretory pathway, the deleterious effects of robust MHC 
class I expression may be a result of ER overloading and stress (Southwood et al., 2002; 
Leegwater et al., 2001; Popko and Baerwald, 1999).  Concordantly, recent experiments in 
which IFN-γ was ectopically expressed in astrocytes during cuprizone-induced demyelination 
demonstrated evidence of an ER stress response in remyelinating OLs of the corpus collosum 
(Lin et al., 2005).  The folding chaperones BIP and CHOP were increased in IFN-γ-
expressing animals during remyelination and the phosphorylation of eIF2α, which halts most 
protein synthesis, was also increased (Lin et al., 2005). 
    IFN-γ expressed in mice heterozygous for the ER stress response kinase PERK (pancreatic 
ER kinase), did not survive as long as non-IFN-γ expressing PERK+/- animals (Lin et al., 
2005).  Furthermore, PERK+/- mice carrying the IFN-γ transgene were treated with cuprizone 
and IFN-γ was induced at the time of demyelination (Lin et al., 2006).  These mice possessed 
fewer OLs and displayed an increase in the pro-apoptotic gene caspase-3 in the corpus 
collosum during the remyelination phase (Lin et al., 2006).   
    Although there is considerable clinical and experimental evidence indicating IFN-γ is 
detrimental in MS, to cultured OLs, and myelination in vivo, the complete role of IFN-γ 
remains controversial.  Moreover, data suggests its effect may be time- and dose-dependent.  
IFN-γ levels in the CNS correlate with the severity of EAE (Renno et al., 1994) and the 
number of T cells secreting the cytokine increases just before the onset of symptoms 
(Issazadeh et al., 1995; Mustafa et al., 1991).  Unexpectedly, however, antibodies to IFN-γ 
worsened the disease pathogenesis (Duong et al., 1992; Voorthius et al., 1990; Billiau et al., 
1988) and intraventricular treatment of IFN-γ to rodents with active EAE reduced disease 
 9
severity (Voorthius et al., 1990).  Furthermore, IFN-γ or IFN-γ receptor knock-out mice were 
more sensitive to EAE (Ferber et al., 1996; Willenborg et al., 1996).   
    Asymptomatic lines of mice expressing low levels of IFN-γ in OLs from the time of MBP 
synthesis were resistant to cuprizone-induced demyelination (Gao et al., 2000).  Additionally, 
recent studies have shown that IFN-γ induction commensurate with cuprizone-induced 
demyelination results in fewer repopulating OLs and reduced remyelination; whereas, IFN-γ 
induction at the time the corpus collosum is fully demyelinated results in a greater number of 
migrating OLs and enhanced remyelination (Lin et al., 2006 and unpublished data). 
    It has been thought that the progenitor cells responsible for repopulating and remyelinating 
areas of demyelination undergo the same course of maturation as progenitors during 
development.  There is now evidence to suggest that this may not be the case (reviewed in 
Balabanov and Popko, 2005; Arnett et al., 2004; Stidworthy et al., 2004; Franklin et al., 
2002).  Whether IFN-γ is harmful or beneficial to oligodendrocytes and myelination/ 
remyelination may depend on the dose and timing of its expression relative to the 
demyelinating event. 
 
 
 
 
 
 
CHAPTER TWO 
EFFECTS OF INTERFERON-GAMMA ON IMMATURE AND MATURE 
OLIGODENDROCYTES IN VITRO 
 
INTRODUCTION 
    Proper neuronal signal conduction in the central nervous system (CNS) requires structural 
integrity of the myelin membrane ensheathing axonal processes, and in the CNS, axons are 
myelinated by oligodendrocytes (OLs).  The loss of myelin results in several neuropathies, 
including multiple sclerosis (MS) in humans and experimental autoimmune 
encephalomyelitis (EAE) in rodents.  Based on clinical and experimental evidence, the pro-
inflammatory cytokine interferon-gamma (IFN-γ) has been implicated in the pathogenesis of 
such immune-mediated demyelinating disorders (reviewed in Popko et al., 1997; reviewed in 
Popko and Baerwald, 1999; reviewed in Steinman, 2001).  Whereas the CNS is normally 
naïve to IFN-γ, in these disorders IFN-γ-secreting T cells migrate across a disrupted blood-
brain-barrier (Miller et al., 1995; reviewed in Roland and McFarland, 1995), and indeed, 
IFN-γ  has been detected in the cerebral spinal fluid and in and around demyelinated lesions 
of individuals with MS.  Furthermore, IFN-γ administered as a therapeutic agent to MS 
patients instead rapidly worsened the disease course (Panitch et al., 1987; Panitch, 1992).   
     Oligodendrocyte progenitor cells (OPCs) arise from the subventricular zone in the CNS 
(reviewed in Barres, 1999; McKinnon and Dubois-Dalcq, 1996).  OPCs migrate into areas of 
the CNS destined for myelination, where they then proliferate and differentiate into 
postmitotic mature OLs.  Distinct stages of differentiation have been immunologically 
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identified, beginning with PSA-NCAM+ preprogenitors (Grinspan et al., 1990; Ben-Hur et 
al., 1998), followed by A2B5+ early progenitors (Raff et al., 1978), O4+ late progenitors/pro-
oligodendrocytes (Dubois-Dalcq, 1987), galactocerebroside+ oligodendrocytes (Raff et al., 
1978), and O1+ mature oligodendrocytes (Schachner et al., 1981; Sommer and Schachner, 
1981) .   
    Many extracellular cues play a role in proper progenitor proliferation and survival.  
Platelet-derived growth factor (PDGF) (Noble et al., 1988; Raff et al., 1988) and basic 
fibroblast growth factor (bFGF) (McKinnon, 1990) promote progenitor cell survival (Barres 
et al., 1992), with bFGF maintaining high levels of PDGF-α receptors, the sole isoform 
expressed by OPCs and OLs (de Vries, 2000).  In vitro, removal of PDGF and bFGF from 
culture medium stimulates OPC differentiation (McKinnon et al., 1990, 1993).  Furthermore, 
insulin-like growth factor-1 (IGF-1) and thyroid hormones facilitate this process (McMorris 
et al., 1986; Barres et al., 1992, 1994).  PDGF-α knockout mice display hypomyelination and 
a decrease in the number of both progenitor cells and mature OLs (Fruttiger et al., 1999).  
Barres et al. (1993) have also shown that IGFs along with neurotrophin-3 (NT-3), ciliary-
neurotrophic factor (CNTF), leukemia inhibitory factor (LIF) and interleukin-6 (IL-6) 
promote OL survival in vivo.   
    Despite the substantial knowledge gained regarding environmental and extracellular 
factors influencing the survival, proliferation, and development of oligodendrocytes, the 
intracellular responses of these cells to such cues, and the pathways into which these 
responses are organized remain elusive.  Several transcription factors undergo changes in 
expression during various stages of progenitor differentiation and myelination (reviewed in 
Wegner, 2001).  Members of the basic helix-loop-helix family, OLIG-1, OLIG-2 and   
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OLIG-3 are expressed early in OL differentiation (Zhou et al., 2001).  The expression of 
NKX6-2, a homeodomain protein, is restricted to mature OLs and parallels that of MBP and 
PLP proteins during postnatal brain development (Komuro et al., 1993; Awatramani et al., 
1997).  Still others, such as POU3F1, are expressed only transiently to activate myelin-
associated genes (Collarini et al., 1992).   
    In recent years, there has been a torrent of new sequence information for several model 
organisms, including yeast, fly, mouse, rat, and human (reviewed in Lander and Weinberg, 
2000).  Much of the sequenced genomes represents characterized genes; however, a large 
portion contains information for genes of unknown function or expressed sequence tags 
(ESTs).  The advent of such a wealth of new sequence information has fostered the 
development of microarray technology, which has become a powerful tool for 
simultaneously comparing the expression of thousands of genes across genetic and 
environmental parameters.  In this study, we have employed microarray technology to 
scrutinize gene expression changes of OPCs in response to IFN-γ exposure during an early 
and later stage of differentiation. 
 
MATERIALS AND METHODS 
Primary Oligodendrocyte Isolation and Cytokine Incubation 
    Oligodendrocyte progenitor cell cultures were maintained according to previously 
established protocols (McKinnon et al., 1990).  Briefly, primary mixed glial cultures were 
established from postnatal day two (PND2) Sprague-Dawley rats (Taconic Farms, NY) and 
immunoselected for A2B5+ early (O2A) progenitor cells.  Purified cells were plated on poly-
L-ornithine-coated (100µg/ml, Sigma) Falcon dishes (Becton Dickenson) at 37°C in a 
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humidified atmosphere of 90% air/10% CO2 and cultured in DMEM with 4.5g/L D-glucose, 
50U/ml penicillin and 50µg/ml streptomycin (Gibco/BRL, Bethesda, MD), 50µg/ml 
transferrin, 30nM sodium selenite, 30nM triiodothryonine (T3), 50ng/ml bovine insulin and 
100µg/ml bovine serum albumin (basal defined medium, BDM).  Cells were expanded as 
A2B5-immunoreactive progenitors in BDM containing 10ng/ml PDGF and 5ng/ml FGF-2 
(R&D, Inc., Minneapolis, MN).  Growth factors were replenished every 48 hours and the 
culture medium was replenished every four days.  After three days, progenitor differentiation 
was initiated by switching the cells to medium without PDGF and FGF-2.  Recombinant rat 
IFN-γ (100U/ml, Gibco BRL, Gaithersburg, MD) was added to cells either at the time of 
switching to PDGF- and FGF-2-free media (immature OLs) or after cells had been allowed to 
differentiate for three days (mature OLs).  Total RNA was isolated from cell cultures using 
TRIzol Reagent (Gibco BRL), then further purified through an RNeasy column (QIAGEN). 
 
Immunocytochemistry 
    Monoclonal antibodies A2B5, O4 and O1 were obtained from hybridoma cell lines as 
supernatant fluids (Eisenbarth et al., 1979; Sommer and Schachner, 1981, respectively).  
Anti-bromodeoxyuridine (BrdU) was purchased from Sigma and rabbit MBP antisera was a 
gift from David Colman (Mt. Sinai, NY).  To identify the stage of progenitor differentiation 
at the time of RNA isolation, cells were fixed in 2% paraformaldehyde for 10 min, exposed 
to primary antibodies for 30 min, washed in phosphate-buffered saline (PBS; 10mM sodium 
phosphate, 0.15mM NaCl, pH 7.2), detected by incubating in secondary anti-mouse IgM-
RITC and IgG-FITC antibodies (Pierce, Rockford, IL) for 30 min at room temperature.  
Coverslips were mounted on glass slides in 10mM Tris, pH 8.6, 90% glycerol, 2% 1-4-
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diazabicyclo(2.2.2) octane (Sigma) and visualized with a Zeiss Axiovert 100TV inverted 
fluorescent microscope equipped with a 40X Achrostigmat objective (McKinnon et al., 
1990).    
 
RNA Amplification, Labeling, and Microarray Hybridization 
    From each cell culture, 100ng of total RNA was used to synthesize cDNA according to the 
GeneChip® Eukaryotic Small Sample Target Labeling Protocol (Affymetrix).  Two rounds of 
amplification were conducted using T7-(dT)24 primer (Life Technologies).  Biotinylated 
cRNA was then generated using the BioArray High Yield RNA Transcription Kit (Life 
Technologies), then subsequently fragmented in 5X fragmentation buffer (200mM Tris-
acetate pH 8.1, 500mM KOAc and 150mM MgOAc) at 94°C for 35 min. 15µg of fragmented 
cRNA was added to hybridization cocktail (50pM control oligonucleotide [B2, BioB, BioC, 
BioD and Cre], 0.01mg/ml herring sperm DNA, 0.5mg/ml acetylated BSA, 100mM MES, 
1M [Na+], 20mM EDTA and 0.01% Tween 20).  10µg of cRNA in cocktail was hybridized 
to each array for 16 hours at 45°C in the GeneChip® Hybridization Oven 640 (Affymetrix).  
Microarrays were then washed, stained with R-phycoerythrin streptavidin in the GeneChip® 
Fluidics Station 400 (Affymetrix), and scanned in the Hewlett Packard GeneArray Scanner 
using Microarray Suite 5.0 (Affymetrix).  cRNA quality was assessed by examining the 
intensity ratio of 5’:3’ probe pair binding of control genes. 
 
Microarray Analysis 
    The rat genome RG_U34 GeneChip® set (Affymetrix) containing probe sets representing 
over 26,000 genes and expressed sequence tags (ESTs) was used for all hybridization 
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reactions.  Three independent hybridizations were performed with the RG_U34A array for 
cells that had been allowed to differentiate for 1 day (immature OLs [iOLs]), 5 days (mature 
OLs [mOLs]), and 3 days + 2 days with IFN-γ (IFN-γ-treated mature OLs [IFN-γ-mOLs]).  
Two independent hybridizations were completed with the RG_U34A array for cells that had 
been allowed to differentiate for 1 day in the presence of IFN-γ (IFN-γ-treated immature OLs 
[IFN-γ-iOLs]).  On the RG_U34B and RG_U34C arrays, two hybridizations were carried out 
for the IFN-γ-treated immature OLs, and one hybridization was conducted for each of the 
remaining samples.  Hybridization intensities were summarized using Robust MultiArray 
Analysis (RMA) (Irizarry et al., 2003) to generate an expression estimate for each probe set 
(gene).  Expression estimates were normalized using GeneSpring® software (Agilent 
Technologies) as follows:  1) negative expression estimates were floored to 0.01, 2) the top 
90% of expression estimates was used to calculate the 50th percentile for each array, and 3) 
expression estimates were normalized to the 50th percentile value of the corresponding array.  
Normalized expression estimates were averaged across replicate samples and significance of 
difference between treatment groups was determined by Student’s t-test (p-value<0.1).  We 
report here differential mRNA expression as the fold change between IFN-γ-treated and non-
treated cell populations.  Gene function information and probe set annotations were obtained 
from GeneSpring GX (Agilent Technologies), NetaffxTM (Affymetrix; www.affymetrix.com), 
the National Center for Biotechnology Information (NCBI; www.nbci.nlm.nih.gov) and 
literature review.  ESTs were identified, when possible, by BLAST search of the nucleotide 
database (www.ncbi.nlm.nih.gov/BLAST).  Pathway information was obtained from the 
Gene Map Annotator and Pathway Profiler (GenMAPP; Gladstone Institutes, University of 
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California at San Francisco; www.genmapp.org), PathArt© (Jubilent Biosys), NetAffxTM, and 
primary literature. 
 
Quantitative Real-Time Reverse Transcription-Polymerase Chain Reaction  
    RNA was treated with DNAse I and column purified (QIAGEN).  cDNA was then 
synthesized with random hexomers and Superscript II (Invitrogen).  Amplification was 
carried out by combining 4ng or 20ng of cDNA with the following reagents (in final 
concentrations):  0.2mM dATP, 0.2mM dGTP, 0.2mM dCTP, 0.4mM dUTP, 200mM 
forward primer, and 200mM reverse primer (Invitrogen), 3mM MgCl2, 0.02U/µl UNG, 
0.01U/µl AmpliTaq DNA polymerase, and 1X SYBR Green Dye in buffer (Applied 
Biosystems).  Real-time PCR amplification reactions were performed in triplicate wells for 
each gene per starting amount of cDNA on the Applied Biosystems 7700 Real Time PCR 
System (1 cycle at 50°C for 2 min, 1 cycle at 95°C for 10 min, 40 cycles at 95°C for 15 sec, 1 
cycle 60°C for 1 min).  GAPDH was used as an internal and normalization control, and the 
amplified transcripts were quantified by relative threshold cycle (CT) comparison.  Primers 
were designed with Primer Express software (Applied Biosystems) to amplify the following 
sequences:   
Accession#    Gene         Fwd Primer Rev Primer     
AA850495 EST CGCCCATGGCGTTCAT CAGAGGCCAAACGATCAAAAC 
AA899109  EST ACTCTATCACCCACCTCTAGTTCCAA  ATACTCACTGAGAACACCTGGACAGAGA   
AA997015 EST TGAATGAATGATAACAAGTAACATTGAGA CAACCCCTTCCCCTGCTT  
AA997255 EST CCAGGGTGGCCTTAAATTCA GTGGCTGGCACAGGACATT 
AA998964 EST CCGCCAATGGAAAATCCTAG AAAATCACAATACCAATTAAACCCACT 
AI073001 EST CATGGTCCAAAAATACAGCTTCAG GCCTACCTGTCGTATCACCAGAA 
AI112362 EST CTACTTGGGAGTGCATAATGAGGAT TGGAAAACTTTGTAAGACAGGGAATATA 
AI175346 EST CAGCTAGGGTGACGGCAAA TATGGAAGGCTTAAGTACGTTCAAAA 
AI232326 EST  CCCTCGGTCAGCTCAACAAT CACCCCCAGCGCATACC 
AF106860 GAPDH GGCCTACATGGCCT CTCTCTTGCTCTCAGTATCCTTGCT 
M34253 IRF1 CCCAAGACTTGGAAGGCAAAC TGGTCCTTCACTTCCTCGATGT  
AI235890 MHC CI CACACCCCCAGCTCACAAA GGTTTCCAACAGTGTAACGCAGTA 
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X17053 SIGJE GAATCGCACCTTCATACAGTTCCT AACCAACCCAAGCCCTTCTTT 
AA999171 STAT1 GCTGCATTAAGGAACACGACTGT CGTATGGCATGGTTCAAAGTCA 
AA799569 STAT2 AACGCCCATAGTACAGGTTCTCA GCCAACTGCTGCTGCTCTAAG 
 
 
 
 
RESULTS AND DISCUSSION 
 
    Primary oligodendrocyte progenitor cells (OPCs) were expanded from PND2 Sprague-
Dawley rats (Fig. 2.1) and relative mRNA expression was measured after cells had 
differentiated for 1 day (iOLs), 1day with IFN-γ (IFN-γ-iOLs), 5 days (mOLs), or 3 days 
followed by 2 days with IFN-γ (IFN-γ-mOLs).  We report here differential mRNA expression 
as fold change between IFN-γ-treated and non-treated cell populations.  Out of 26,263 genes 
surveyed 2647 (10%) were significantly up- or downregulated in IFN-γ-iOLs and 1293 
(4.9%) were significantly up- or downregulated in IFN-γ-mOLs. 
    The hybridization cocktail contained poly-A (Trp, Thr, Phe, Lys, and Dap) and 
hybridization (B2, BioB, BioC, BioD, and Cre) control genes.  The ratios of 5’:3’ probe pair 
binding for the poly-A controls ranged from 1:1 to 1:1.2, indicating that the RNA was of 
excellent quality.  Expression estimates of the hybridization controls were also normal, 
demonstrating that the hybridization reactions worked properly.  Furthermore, relative 
expression for several genes showing differential expression on the arrays was measured by 
quantitative real-time polymerase chain reaction (qRT-PCR), and these data corroborated the 
array findings (data not shown). 
 
Differential Expression of Genes Involved in Myelin Formation 
(Figure 2.2 and Table 2.1) 
 
    2’,3’-cyclic nucleotide 3’-phosphodiesterase (CNP), myelin basic protein (MBP), and 
proteolipid protein (PLP) are structural components of the myelin sheath.  MBP and PLP aid 
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in stabilizing the compact lamellar domains and in forming the intraperiod- and major dense 
lines, while CNP is present in the cytoplasmic channels traversing the sheath (De Angelis 
and Braun, 1996).  CNP interacts with tubulin to promote microtubule assembly and 
facilitates F-actin and microtubule organization, suggesting that it may play a role in 
directing myelin process extension (Lee et al., 2005).  As shown in Fig. 2.2, CNP, MBP, and 
PLP were upregulated in response to IFN-γ treatment of iOLs, but remained unchanged in 
mature cells treated with the cytokine.  We also saw an increase in microtubule-associated 
tubulins TUBA6, TUBB2B and TUBB3 in IFN-γ-iOLs, and an increase in TUBB3 in IFN-γ-
mOLs.   
    Myelin-associated oligodendrocytic basic protein (MOBP) was downregulated in mOLs 
treated with IFN-γ.  While MOBP is not essential for myelin formation (Yool et al., 2002), it 
is thought to be involved in myelin sheath compaction (Holz and Schwab, 1997) and 
evidence suggests it may be necessary for controlling axonal diameter and establishing 
proper arrangement of the radial component of the intraperiod line (Yoshikawa, 2001).    
    Claudin11 (CLDN11, OSP) is a major element of CNS myelin forming the tight junctions 
within myelin sheaths that create a paracellular barrier and avenue of signal transduction, 
which may regulate processes such as cell growth and differentiation (Gow et al., 1999; 
Morita et al., 1999; Tiwari-Woodruff et al., 2001).  CLDN11 is expressed in the O2-A line of 
OLs from the early progenitor to mature OL stage (Bronstein et al., 2000), and 
overexpression induces proliferation and migration in these cells (Tiwari-Woodruff et al., 
2001).  In our experiments, CLDN11 was upregulated in IFN-γ-iOLs and downregulated in 
IFN-γ-mOLs.   
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    Protein tyrosine phosphatase, receptor type Z, polypeptide 1 (PTPRZ1) has been shown to 
be important for remyelination after immune-mediated demyelination, as mice deficient in 
PTPRZ1 recovered more slowly and less completely from MOG-induced EAE than PTPRZ1 
expressing controls (Harroch et al., 2002).  We found PTPRZ1 to be downregulated in IFN-γ-
iOLs and unchanged in IFN-γ-mOLs. 
    Taken together, it appears that immature OLs may react to IFN-γ exposure by 
transcriptional upregulation of genes encoding structural and tight junction components of 
myelin, and downregulation of a remyelination-promoting gene.  Mature OLs treated with 
IFN-γ were less responsive, downregulating genes that may affect myelin sheath compaction 
and tight junction signaling.  Given the deleterious effects observed previously by IFN-γ 
exposure to OLs and myelination, it was surprising to find an increase in myelin gene 
expression in the IFN-γ-iOLs.  The role of IFN-γ is controversial, however, and in low doses 
has had a protective effect against CNS demyelination (Gao et al., 2000), thus, the increase in 
certain myelin genes observed here could possibly be a result of such protection.   
 
Differential Expression of Genes Involved in Cholesterol Biosynthesis  
(Figure 2.3 and Table 2.2) 
 
    Cholesterol is a major component of myelin comprising approximately 30% of the total 
lipid in myelin, thus, we were interested in whether IFN-γ affected cholesterol biosynthesis.  
As shown in Fig. 2.3, several genes in the pathway were differentially regulated in response 
to IFN-γ exposure.  In particular, HMGCR, NSDHL and APOE were upregulated in IFN-γ-
iOLs.  HMGCR is the rate-limiting enzyme in cholesterol biosynthesis, and APOE is thought 
to help transport cholesterol from degraded myelin into storage cells where it can later be 
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recovered by new remyelinating OLs (Mauch et al., 2001; Mahley, 1998; Sullivan et al., 
1997; Venezie et al., 1995; Poirier et al., 1993; Page et al., 1993).  SQLE, which converts 
squalene to squalene 2,3 epoxide in the second half of the pathway was downregulated in 
IFN-γ-iOLs, perhaps reflecting feedback regulation in response to the increase in the rate-
limiting enzyme upstream.  In IFN-γ-mOLs, there was a decrease in HMGCS2 and SC5D, 
the latter possibly indicating a shift toward 24-dehydrocholesterol rather than   
7-dehydrocholesterol.  It would appear from these data that iOLs exposed to IFN-γ may 
exhibit an increase in cholesterol synthesis and the recycling of existing cholesterol; whereas, 
in mature cells, cholesterol synthesis seems to be reduced.  These data parallel the increase in 
structural and tight junction gene expression in IFN-γ-iOLs and the decrease in sheath 
compaction and tight junction gene expression in IFN-γ-mOLs, again suggesting a possible 
protective role for IFN-γ in early OL development. 
 
 
Differential Expression of Genes Involved in Lipid Metabolism  
(Figure 2.4 and Table 2.3) 
 
    Maturing oligodendrocytes send out branches of membrane that become myelin sheath, 
and this process requires the generation of a large amount of lipid in addition to cholesterol.  
In that connection, we found numerous genes involved in lipid metabolism to be 
differentially regulated in response to IFN-γ in both immature and mature OLs.  In particular, 
lysophospholipase 1 (LYPLA1), which hydrolyzes lipophosphotidylcholine, was expressed 
at very low levels in both iOLs and mOLs was most robustly upregulated in both IFN-γ-
treated populations.  In addition, the lipid transport gene APOL2, and fatty acid degradation 
gene CTE1 were also upregulated in both IFN-γ-iOLs and IFN-γ-mOLs.  In contrast, the 
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triglyceride hydrolases LPL and PNLIP were downregulated in IFN-γ-mOLs, and down- and 
upregulated in IFN-γ-iOLs, respectively.   
 
Differential Expression of Genes Involved in Complement Activation  
(Figure 2.5 and Table 2.4) 
 
    In the classical complement activation pathway, complement component 1 (C1) peptides 
join antigen-bound antibody on the cell membrane to form C1 complexes.  These complexes 
then initiate a cascade of activation steps through various complement components that 
eventually results in the formation of membrane attack complexes (MACs).  MAC formation 
has several consequences including the upregulation of c-JUN, c-FOS, PDGF, bFGF, 
cytokines, proto-oncogenes, diacylglycerol, and ceramide; and an increase in PKC activity, 
MBP hydrolysis, mitosis, cell proliferation, cytosolic calcium ions, and reactive oxygen 
species (ROS).   Differential expression of genes involved in the complement activation 
pathway in response to IFN-γ treatment of immature and mature OLs is significantly higher 
than every other group of genes with the exception of those involved in antigen processing 
and presentation.  As shown in Fig. 2.5, genes involved in complement activation were 
upregulated in both IFN-γ-iOLs and IFN-γ-mOLs, and the MAC formation inhibitor CD59 
was downregulated in IFN-γ-mOLs.  Given the number of downstream effects of MAC 
formation, perhaps complement activation is an early key factor and is, at least partially, 
driving the sundry of other cellular effects we observed in response to IFN-γ exposure.   
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Differential Expression of Genes Involved in Antigen Processing and Presentation, and 
ER Stress 
(Figure 2.6 and Table 2.5) 
 
    As evidenced by aforementioned data and our present study, IFN-γ clearly elicits a 
significant immune response via antigen processing and presentation.  As shown in Fig. 2.6, 
genes for several subtypes of MHC class I and II, the class I assembly protein β2-
microglobulin (β2M), the class II transactivator (CIITA), and several MHC assembly proteins 
were substantially upregulated in both immature and mature cells exposed to IFN-γ.   
    Consistent with an increase in antigen presenting genes, we also found several genes 
involved in the processing of antigen via peptide degradation by the 20S proteasome, 
ubiquination, and proteolysis to also be upregulated in response to IFN-γ exposure in both 
immature and mature OLs.  Specifically, PSMA and PSMB subunits of the 20S proteasome 
along with cytokine-responsive PA28 “immunoproteasome” genes PSME1/2 were strongly 
upregulated in both IFN-γ-treated cell populations.  Also upregulated, but less so, was 
PSMF1, an inhibitor of the PA28 immunoproteasome, which may indicate feedback 
regulation.  Peptides broken down by the proteasome are transported into the ER lumen 
through the transporter TAP, and both TAP1 and TAP2 were upregulated in IFN-γ-iOLs and 
IFN-γ-mOLs.  Inside the ER, peptide antigens bind MHC class I associated with β2M and the 
trimolecule complex is exported out of the ER via TAP.  The complex then travels to the cell 
surface where the antigen can be recognized by T cells.   
    Peptide antigens can also be degraded by targeted ubiquination and proteolysis by the 26S 
proteasome.  This process is not only used for antigen presentation; it is also used to break 
down mal-folded, surplus, or aggregated proteins.  Synthesis, processing, and release of 
secretory and membrane proteins takes place in the ER.  Among other events, an 
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accumulation of unfolded or mal-folded proteins in the ER can initiate a stress response 
(Rutkowski and Kaufman, 2004; Ma and Hendershot, 2001).   
    Developing OLs are generating copious amounts of membrane and extending numerous 
membrane processes destined to become multilamellar myelin sheath.  This process alone 
heavily employs the ER; the added demand for large amounts of MHC, antigen and 
accessory protein synthesis and folding that occurs in response to IFN-γ has great potential 
for initiating an ER stress response.  Recent work has demonstrated that IFN-γ exposure 
during myelination in vivo induces ER stress (Lin et al., 2005; Lin et al., 2006), and we find 
evidence of the same here as well (Figs. 2.7 and 2.8).   
    Cells respond to unfolded proteins by 1) upregulating ER chaperones that promote folding 
and help prevent protein aggregation, 2) removing mal-folded proteins from the ER via 
retrograde transport and subsequent degradation by the 26S proteasome, and 3) decreasing 
translation of additional proteins.  If these responses are not enough to relieve the ER, or if 
the cause of stress is sustained, cells eventually succumb to death (Rutkowski and Kaufman, 
2004; Rao et al., 2004; Ma and Hendershot, 2001).   
    In this work, we found genes involved in protein folding (HSPA9A, TOR3A, FKBP4, and 
HSPCA) to be upregulated in IFN-γ-iOLs.  Numerous genes involved in ubiquination and 
proteolytic degradation of proteins were also highly upregulated in IFN-γ-treated iOLs, and 
to a lesser extent also in IFN-γ-treated mOLs.  In particular, the cathepsin family of genes 
was upregulated in IFN-γ-iOLs, including CTSB and CTSS, which are involved in 
processing MHC class II antigen complexes.  Additionally, gene expression of the poly 
(ADP-ribose) polymerases 9 and 10 (PARP9/10), along with the E3 ligase and Notch 
signaling gene DELTEX3 were strongly upregulated in both IFN-γ-treated cell populations.  
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Phosphorylation of eIF2α has been shown to inhibit translation in response to ER stress 
(Harding et al., 1999; Okada et al., 2002); whereas, PPP1R15B (CReP) inhibits the stress 
response by dephosphorylating eIF2α (Jousse et al., 2003).  In these experiments, eIF2α 
message was increased in both IFN-γ-treated groups with higher expression in the immature 
population, and PPP1R15B was also upregulated in the immature cells.  Since eIF2α 
phosphorylation has been shown to increase in response to IFN-γ (Lin et al., 2005), the 
upregulation of PPP1R15B could be a competing or feedback response.  Other translation 
initiation factors, including eIF2C1, eIF4B1, eIF4E, and eIF4EBP2 were downregulated in 
IFN-γ-iOLs; and eIF2B1 expression was downregulated in IFN-γ-mOLs.  Together, these 
data further support an IFN-γ-driven response to ER stress, particularly in immature OLs. 
 
Differential Expression of Genes Involved in the Immune Response  
(Figure 2.7 and Table 2.6) 
 
    In addition to complement activation and antigen presentation, IFN-γ treatment resulted in 
a significant increase in other immune response genes.  Not surprisingly, expression levels of 
several genes for IFN-γ-inducible proteins, GTPases, transmembrane proteins, and binding 
proteins increased significantly in both IFN-γ-iOLs and IFN-γ-mOLs.  Also increased 
significantly were GBP2, MX1 and MX2, which respond to viral infections; and CXCL10 
and CXCL11, which have been shown to recruit CD4+ and CD8+ T cells in the CSF in other 
diseases and whose receptors are expressed on the surface of these cells (Lepej et al., 2005; 
Iijima et al., 2003).  The FcIgG receptors, particularly FCGRIII, were also upregulated in 
both IFN-γ-treated populations.  These pro-inflammatory receptors promote macrophage 
activation and cytokine release.  In response to IFN-γ signaling, Janus tyrosine kinases 
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(JAKs) bind the IFN-γ-receptor and become phosphorylated.  STAT1 molecules bind the 
phosphorylated JAKs, dissociate and translocate to the nucleus where they induce 
transcription of GAS element-containing genes.  STAT-1 and STAT-2 showed robust 
upregulation in both IFN-γ-treated cell populations.   
 
Differential Expression of Genes Involved in Oxidative Stress Response  
(Figure 2.8 and Table 2.7) 
 
    We observed an increase in several genes that respond to reactive oxygen species (ROS) in 
IFN-γ-treated iOLs.  Four transcription factor activators, NFE2L2, NFκB1, ATF-1 and 
TGM2 were all upregulated in IFN-γ-iOLs, and TGM2 was also unregulated in IFN-γ-mOLs.  
These transcription factors induce several antioxidant genes, including HMOX1, UGT1A6 
and SOD2, which, along with the oxidase inhibitor CYBA, were also upregulated in the 
immature but not mature cultures treated with IFN-γ.  GRP75 is a member of the heat shock 
protein family of chaperones and there is evidence to suggest that it may inhibit the 
accumulation of ROS (Liu et al., 2005).  We observed an increase in GRP75 in IFN-γ-iOLs, 
but not IFN-γ-mOLs.  In addition, FTL1, an iron transporter that is induced by oxidative 
stress and has a protective role against oxidative insults (Kim and Kim, 2002), was highly 
expressed in non-treated OLs at both stages of development, and more than doubled in 
cytokine-treated immature cells.  TXN1, PRDX1 and PRDX4 are ROS scavengers.  TXN1 
and PRDX1 were upregulated, and PRDX4 was downregulated in IFN-γ-iOLs.  None of 
these genes were differentially expressed in IFN-γ-mOLs.  Overall, immature OLs appear to 
mount a stronger oxidative stress response than mature OLs. 
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Differential Expression of Genes Involved in Apoptosis  
(Figure 2.9 and Table 2.8) 
 
    The events leading to and preventing programmed cell death, or apoptosis, are intricate.  
We have previously reported that developing OL cultures die by apoptosis after two days of 
IFN-γ exposure and that mature OLs withstand its effects for approximately four to seven 
days, at which point they die by necrosis (Baerwald and Popko, 1998).  Accordingly, we 
found several genes involved in programmed cell death, both pro-apoptotic and survival, to 
be differentially expressed in response to IFN-γ exposure.   
 
Pro-Apoptotic Gene Expression 
    Of the 34 genes involved in promoting apoptosis that were differentially regulated, two 
(IRAK and DAP) were slightly downregulated in IFN-γ-iOLs and two (NME3 and CIDEB) 
were slightly downregulated in IFN-γ-mOLs; all others were upregulated in response to   
IFN-γ.  Most significantly upregulated in both populations was the IFN-γ-induced 
transcription factor IRF1, which as been shown to induce apoptosis via TRAIL (Park et al. 
2004).  Many of the upregulated apoptosis genes are involved in the extrinsic signaling 
pathways of FAS, TNF-α and IL-1, which result in caspase activation and DNA 
fragmentation.  Intrinsic apoptosis-promoting molecules include ITM2, BTG1, DAPK3, 
CIDEB, PKCD and NDG2.  In IFN-γ-iOLs, ITM2, BTG1, DAPK3, CIDEB and PKCD were 
strongly upregulated.  ITM2 and NDG2 message was also increased in IFN-γ-mOLs, while 
CIDEB was decreased.   
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Survival Gene Expression    
    With the exception of IGF1, all survival genes with differential expression were 
upregulated in cytokine-treated immature OLs and seemed to stem largely from the induction 
of TRAF2BP, which activates NFκβ and PIM1, and PIM1 induces SOCS-1 (Fig 2.11(g-h)).  
The induction of SOCS-1 is interesting in that it is capable of binding phosphorylated JAKs 
interrupting JAK-STAT signaling and the subsequent transcription of IFN-γ-sensitive genes.  
In the mature cell population, IFN-γ again elicited a downregulation of IGF1, as well as an 
upregulation of PIM1, TRAF2BP, CCL2 and SOCS-1.   
    In agreement with previous observations, immature oligodendrocytes appeared more 
vulnerable to apoptosis by the overall greater upregulation of pro-apoptotic genes in response 
to IFN-γ.  There was also a greater overall increase in survival genes in the immature cells, 
which perhaps reflects a concomitant protective defense response. 
 
Differential Expression of Genes in Various Other Functional Groups 
(Table 2.9) 
 
    It is clear from our data that IFN-γ treatment of developing and mature OLs elicits a 
diverse and complex response at the transcriptional level.  Table 2.11 lists expression 
changes in genes involved in several cellular functions including cell adhesion; cell cycle; 
cell growth and metabolism; cell motility and cytoskeleton organization; protein synthesis, 
metabolism, and modification; development, differentiation, and proliferation; signal 
transduction; transcription, and translation regulation; and transport.  While it is clear that 
IFN-γ affects the expression level of genes involved in many different functions, the effects 
are quite varied within most functional groups, and underscore the complexity of cytokine 
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signaling.  Genes of particular interest based on degree of differential regulation and function 
are discussed below.   
    In IFN-γ-iOLs, certain cell adhesion genes that play a role in mediating T cell attachment 
to the endothelium were upregulated, including the integrins ITGA4 and ITGAL, which are 
necessary for T cell induction of EAE (Graesser et al., 2000).  ITGAL was also upregulated 
in IFN-γ-mOLs.  Neuropilin 1 (NRP1), which binds VEGF and mediates endothelium 
permeability, was upregulated in IFN-γ-iOLs. 
    A host of cell cycle regulating genes was differentially expressed in both immature and 
mature OLs treated with IFN-γ.  Most notably was the robust upregulation of PBEF1, a gene 
that has not only been implicated in cell cycle regulation (Kitani et al., 2003), but also as a 
suppressor of apoptosis in response to inflammatory stimuli via inhibition of caspase-3 and 
caspase-8 (Jia et al., 2004).   
    Another large group of genes with differential regulation was those involved in 
cytoskeleton organization.  There were moderate, varied responses from several genes, but 
most significantly upregulated were coronin actin-binding genes, microtubule-associated and 
neurofilament genes, myosin, pleckstrin, and especially matrix Gla protein (MGP).  MGP is 
generally associated with bone formation, but it is also upregulated by T3 and TGFβ (Sato et 
al., 2005; Bostrom et al., 2004).  The developing OL cultures used in these experiments were 
treated with T3 to facilitate differentiation, and in this study TGFβ expression did not change 
in IFN-γ-iOLs and decreased in IFN-γ-mOLs.  It would seem, therefore, that MGP is also 
upregulated by IFN-γ and perhaps plays a role in the cytoskeletal changes necessary for 
process extension by maturing OLs.   
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    The development-associated gene TNFAIP2 displayed robust upregulation in both IFN-γ-
treated groups.  Additionally, estrogen-responsive finger protein (EFP, TRIM25) was 
strongly upregulated in IFN-γ-mOLs, and its expression was nearly twice as high in IFN-γ-
iOLs.  EFP responds to estrogen and has been implicated in cell proliferation associated with 
breast cancer (Suzuki et al., 2005).  Another gene product, VDUP1, inhibits proliferation by 
arresting cell cycle progression, and its expression was downregulated in both IFN-γ-iOLs 
and IFN-γ-mOLs. 
    Numerous signal transduction genes were differentially regulated in both IFN-γ-treated 
cell populations.  The most significant change was the upregulation of a sequence similar to 
interferon-inducible GTPase designated RGD1309362.  Lymphocyte cytosolic protein 2 
(LCP2, SLP-76), which plays a role in mediating T cell function (Kumar et al., 2005), 
increased substantially in cytokine-treated immature, but not mature OLs.   
    Equally abundant were differentially expressed transcription regulation genes.  In 
particular, STAT-1 and STAT-2 message (discussed in the immune response section) was 
greatly increased in IFN-γ-mOLs, and even more so in IFN-γ-iOLs.  Likewise, there was an 
upregulation of the interferon stimulated gene factor ISGF3G in both IFN-γ-treated groups.  
Upon stimulation by Type I or Type II interferon, STAT-1, STAT-2 and ISGF3G form a 
complex and translocate to the nucleus.  STAT molecules are dephosphorylated once inside 
the nucleus, then shuttled back out into the cytoplasm via nucleoporins 153 and 214 
(NUP153, NUP214) as well as exportin 1 (XPO1) (Zimmerman et al., 2005; Marg et al., 
2004).  Neither of the nucleoporins was represented on the arrays, but XPO1 showed a slight 
decrease at both time points. 
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    Numerous ESTs were also differentially regulated in both immature and mature OLs 
treated with IFN-γ.  For reference, these sequences along with their fold change values are 
listed in Table 2.10. 
 
CONCLUSION 
    Rat primary immature and mature oligodendrocyte cultures were treated with the pro-
inflammatory cytokine IFN-γ, and the transcriptional response was quantitated using 
microarray analysis.  It is clear from our data that IFN-γ elicits a dramatic immune response.    
The most significant differential regulation in both cytokine-treated immature and mature 
oligodendrocytes was seen in antigen processing and presenting genes, followed by genes 
that activate complement via the classical pathway.  We also observed significant differential 
expression of genes involved in consequential events of MHC induction and complement 
activation, including response to ER stress, ROS accumulation, and apoptosis.  Moreover, 
there was an overall greater response from immature than mature OLs exposed to IFN-γ, 
possibly rendering immature OLs more vulnerable to the detrimental effects of this cytokine. 
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Figure 2.1  Expression of lineage-specific markers in oligodendrocyte cultures.  Panels a-b: 
oligodendrocyte progenitor cells; panels c-d: mature oligodendrocytes.  OPCs isolated from 
neonatal rat forebrain were maintained in defined medium containing OPC mitogens   
PDGF-α and FGF2, while mature oligodendrocytes were derived from OPCs by culturing 
cells for 72 hrs in defined medium containing T3 and insulin (see Materials and Methods).  
Panel e: the numbers (percent) of cells expressing either progenitor or mature 
oligodendrocyte markers under either condition.  OPC cultures (orange bars) contained >80% 
A2B5, 97% NG2-progenitors with 7% O1-oligodendrocytes and <2% GFAP-astrocytes 
(n=624 cells counted).  OL cultures contained >90% O1-oligodendrocytes with <10% O4, 
GFAP-astrocytes (n=368 cells counted). Coverslips for immune cytochemistry were 
harvested from the same culture plates used to generate RNA for microarray analysis. 
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Figure 2.2  Expression Estimates of Genes Involved in Myelin Formation.  a-b) Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values for genes in a-b) are 
listed in Table 2.1.             
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Table 2.1  Differential Expression of Genes Involved in Myelin Formation.  Replicate RNA 
samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figure 2.2.  Positive fold change values 
indicate an increase, and negative values indicate a decrease in gene expression in the IFNγ-
treated groups.  The dagger indicates the Student’s t-test p-value was greater than 0.1; the 
asterisk indicates there was one sample for each treatment. 
 
 
 
  
 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AA901342 CLDN11 claudin 11  1.56  -1.68* 
L16532 CNP 2’,3’-cyclic nucleotide 3’-phosphodiesterase  2.38   1.03† 
K00512 MBP myelin basic protein  3.43   1.12† 
D28111 MOBP myelin-associated oligodendrocytic basic protein  1.02  -1.50  
M25888 PLP proteolipid protein  2.14  -1.34† 
AI013024 PTPRZ1 protein tyrosine phosphatase, receptor type Z, polypeptide 1 -2.57   1.05* 
U77931 PTPRZ1 protein tyrosine phosphatase, receptor type Z, polypeptide 1 -1.70   1.08
† 
AA892333 TUBA6 tubulin, alpha 6  1.55  -1.17† 
AA899219 TUBB2B tubulin, beta 2b  1.84  -1.14* 
AI229029 TUBB3 tubulin, beta 3  1.83   2.37* 
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Figure 2.3  Expression Estimates of Genes Involved in Cholesterol Biosynthesis.  a) 
Cholesterol biosynthetic pathway:  Genes highlighted in yellow are upregulated and genes 
highlighted in green are downregulated in one or both IFN-γ-treated cultures.  b) Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene was represented on the microarray 
set more than once by different accession numbers.  Multiple accession numbers for a single 
gene have been graphed separately to provide replicate information for fold change values 
with a Student’s t-test p-value greater than 0.1 or only one sample for each treatment group.  
Fold change values for genes in b) are listed in Table 2.2.       
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Figure 2.3  Expression Estimates of Genes Involved in Cholesterol Biosynthesis.   
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Table 2.2  Differential Expression of Genes Involved in Cholesterol Biosynthesis.  Replicate 
RNA samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figure 2.3.  Positive fold change values 
indicate an increase, and negative values indicate a decrease in gene expression in the IFNγ-
treated groups.  The dagger indicates the Student’s t-test p-value was greater than 0.1; the 
asterisk indicates there was one sample for each treatment. 
 
 
  
 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
D13921 ACAT1 acetyl-CoA acetyltransferase 1  1.92† -1.09† 
X04979 APOE apolipoprotein E  2.13  1.09 
M95591 FDFT1 farnesyl diphosphate farnesyl transferase 1  1.69† -1.14† 
M89945 FDPS farnesyl diphosphate synthase  1.84† -1.06† 
X55286 HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase  1.54  1.18† 
M33648 HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2  1.05† -2.07 
U31352 LSS lanosterol synthase  1.32 -1.02† 
U53706 MVD mevalonate (diphospho) decarboxylase  1.48† -1.03† 
M29472 MVK mevalonate kinase  1.40† -1.21 
AA893032 NSDHL NAD(P) dependent steroid dehydrogenase-like  1.91  1.31
† 
AA859330 SC5D sterol-C5-desaturase -1.53† -2.37* 
AA819300 SQLE squalene epoxidase -2.30 -1.03* 
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Figure 2.4  Expression Estimates of Genes Involved in Lipid Metabolism.  a-f) Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values for genes in a-f) are 
listed in Table 2.3.    
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Figure 2.4  Expression Estimates of Genes Involved in Lipid Metabolism.   
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Figure 2.4  Expression Estimates of Genes Involved in Lipid Metabolism.   
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Table 2.3  Differential Expression of Genes Involved in Lipid Metabolism.  Replicate RNA 
samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figure 2.4.  Positive fold change values 
indicate an increase, and negative values indicate a decrease in gene expression in the IFNγ-
treated groups.  The dagger indicates the Student’s t-test p-value was greater than 0.1; the 
asterisk indicates there was one sample for each treatment. 
 
 
  
 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
J02791 ACADM acetyl-CoA dehydrogenase, medium  2.85  1.13† 
J05210 ACLY ATP citrate lyase  1.15† -1.55 
J05210 ACLY ATP citrate lyase  1.77† -1.67 
AB012933 ACSL5 acyl-CoA synthetase long-chain family member 5  2.54  2.48 
X55572 APOD apolipoprotein D  2.50  1.02† 
AI070325 APOL2 apolipoprotein L2  4.30  5.13* 
AB009999 CDS1 CDP-diacylglycerol synthase 1  1.79  1.12† 
AA892325 CEPT1 choline/ethanolaminephosphotransferase 1  2.84  1.21† 
AB010428 CTE1 acyl-CoA hydrolase, cytosolic  5.18  3.33 
AI170568 DCI dodecenoyl-coenzyme A delta isomerase  1.69  1.43† 
AI145640 ELOVL6 elongation of long chain fatty acids, member 6 -1.90 -1.14* 
S69874 FABP5 fatty acid binding protein 5  2.72  1.63 
AI232047 GPAM glycerol-3-phosphate acyltransferase, mitochondrial -1.56 -1.58* 
X62322 GRN granulin  3.05  2.29 
AI013834 HSD17B4 17-beta hydroxysteroid dehydrogenase 4  1.80 -1.03† 
S81497 LIPA lipase A, lysosomal acid  1.89 -1.09† 
L03294 LPL lipoprotein lipase -3.10† -2.25 
L03294 LPL lipoprotein lipase -2.61† -2.08 
AA901350 LYPLA1 lysophospholipase  42.6  40.8* 
AF016047 PAFAH1B3 platelet-activating factor acetylhydrolase, isoform 1b, alpha1 subunit  1.62  1.12
† 
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 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI172143 PHYH phytanoyl-CoA hydroxylase -1.89 -1.76* 
AI029057 PHYH phytanoyl-CoA hydroxylase -1.20 -1.53* 
AA849518 PLA2G12A phospholipase A2, group XIIA  1.64  1.36* 
D88534 PNLIP pancreatic triglyceride lipase  1.88 -2.21 
M58369 PNLIP pancreatic triglyceride lipase  1.61 -2.55 
M19936 PSAP prosaposin  2.91  1.47† 
AA875233 PSAP prosaposin  1.95  1.16† 
J02585 SCD1 stearoyl-Coenzyme A desaturase 1  1.83 -1.10† 
AI011483 SCD2 stearoyl-Coenzyme A desaturase 2 -1.77  1.00* 
AI012418 SOAT1 sterol O-acyltransferase 1  1.41  1.83* 
AA957535 SOAT1 sterol O-acyltransferase 1  1.29  2.35* 
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Figure 2.5  Expression Estimates of Genes Involved in Complement Activation.  a) Genes 
highlighted in yellow are upregulated and genes highlighted in green are downregulated in 
one or both IFN-γ-treated cultures.  b-c) Gene symbols and Accession numbers are plotted on 
the x-axis; the average of replicate normalized expression values for each treatment group (as 
described in Materials and Methods) is plotted on the y-axis.  In some cases, a gene was 
represented on the microarray set more than once by different accession numbers.  Multiple 
accession numbers for a single gene have been graphed separately to provide replicate 
information for fold change values with a Student’s t-test p-value greater than 0.1 or only one 
sample for each treatment group.  Fold change values for genes in b-c) are listed in Table 2.4.         
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Figure 2.5  Expression Estimates of Genes Involved in Complement Activation.   
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Table 2.4  Differential Expression of Genes Involved in Complement Activation.  Replicate 
RNA samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figure 2.5.  Positive fold change values 
indicate an increase, and negative values indicate a decrease in gene expression in the IFNγ-
treated groups.  The dagger indicates the Student’s t-test p-value was greater than 0.1; the 
asterisk indicates there was one sample for each treatment. 
 
 
  
 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AA996499 C1QA complement component 1, q subcomponent, alpha polypeptide  5.27  1.64* 
X71127 C1QB complement component 1, q subcomponent, beta polypeptide  8.65  3.20
† 
AI177119 C1QG complement component 1, q subcomponent, gamma polypeptide  7.31  1.26* 
AA799803 C1R complement component 1, r subcomponent  5.39  6.47 
D88250 C1S complement component 1, s subcomponent  2.79  9.03† 
AI072392 C2 complement component 2  2.85  3.03* 
M29866 C3 complement component 3  3.04  1.73† 
X52477 C3 complement component 3  4.74†  2.15† 
U42719 C4A C4 complement protein, palmitoyl-protein thioesterase 2 -1.28
†  2.60 
Z50051 C4BPA complement component 4 binding protein, alpha  1.60 -1.02
† 
AA818025 CD59 CD59 antigen -1.15† -1.59 
AA800318 SERPING1 serine (or cysteine) proteinase inhibitor, clade G (C1 inhibitor), member 1  4.44  7.09 
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Figure 2.6  Expression Estimates of Genes Involved in Antigen Processing and Presentation.  
a-o) Antigen processing and presentation genes and representative Accession numbers are 
plotted on the x-axis; the average of replicate normalized expression values for each 
treatment group (as described in Materials and Methods) is plotted on the y-axis.  In some 
cases, a gene is represented on the microarray set more than once by different accession 
numbers.  Multiple accession numbers for a single gene have been graphed separately to 
provide replicate information for fold change values with a Student’s t-test p-value greater 
than 0.1 or only one sample for each treatment group.  Fold change values for genes in a-o) 
are listed in Table 2.5.       
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Figure 2.6  Expression Estimates of Genes Involved in Antigen Processing and Presentation.   
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Figure 2.6  Expression Estimates of Genes Involved in Antigen Processing and Presentation.  
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Figure 2.6  Expression Estimates of Genes Involved in Antigen Processing and Presentation.  
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Figure 2.6  Expression Estimates of Genes Involved in Antigen Processing and Presentation.  
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Figure 2.6  Expression Estimates of Genes Involved in Antigen Processing and Presentation.  
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Figure 2.6  Expression Estimates of Genes Involved in Antigen Processing and Presentation.  
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Figure 2.6  Expression Estimates of Genes Involved in Antigen Processing and Presentation.  
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Table 2.5  Differential Expression of Genes Involved in Antigen Processing and 
Presentation.  Replicate RNA samples from each treatment group were hybridized to separate 
arrays.  The average of replicate normalized expression estimates for each sample group was 
used to calculate the fold change difference in expression for each gene in Figure 2.6.  
Positive fold change values indicate an increase, and negative values indicate a decrease in 
gene expression in the IFNγ-treated groups.  The dagger indicates the Student’s t-test p-value 
was greater than 0.1; the asterisk indicates there was one sample for each treatment. 
 
 
  
 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
MHC class I presentation     
AI172570 B2M beta-2 microglobulin  8.18  10.7* 
AA848811 B2M beta-2 microglobulin  7.05  15.3* 
AA848811 B2M beta-2 microglobulin  5.64  8.40* 
AA819629 H28 histocompatibility 28   2.54  4.29* 
AI176358 RT1-149 RT1 class I,  type 149  6.62  12.1* 
L40364 RT1-149 RT1 class I,  type 149  4.98  6.66 
AF074609 RT1-A3 RT1 class Ib, locus A3  6.62  6.96 
M64795 RT1-Aw2 RT1 class Ib, locus Aw2  3.51  5.53 
M10094 RT1-Aw2 RT1 class Ib, locus Aw2  4.84  7.53 
AF074608 RT1-Aw2 RT1 class Ib, locus Aw2  7.31  7.40 
L40362 RT1-Aw2 RT1 class Ib, locus Aw2  7.11  6.71 
AI103500 RT1-Aw2 RT1 class Ib, locus Aw2  4.78  12.0* 
H33922 RT1-Aw2 RT1 class Ib, locus Aw2  8.31  17.1* 
M24324 RT1-Aw2 RT1 class Ib, locus Aw2  3.91  5.09 
M31018 RT1-Aw2 RT1 class Ib, locus Aw2  7.36  6.11 
AI235223 RT1-Aw2 RT1 class Ib, locus Aw2  12.2  21.1* 
M11071 RT1-Aw2 RT1 class Ib, locus Aw2  6.56  5.51 
M24026 RT1-CE12 RT1 class Ib, locus CE12  7.38  6.89 
AA858651 RT1-CE12 RT1 class Ib, locus CE12  5.14  8.53* 
 54
  
 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AF025308 RT1-CI RT1 class Ib, locus Cl  4.47  5.76 
U16025 RT1-M3 RT1 class Ib, locus M3  3.36†  3.84 
U16025 RT1-M3 RT1 class Ib, locus M3  2.52  2.18 
AA818887 RT1-N2 RT1 class Ib, H2-TL-like, grc region (N2)   2.63  2.57* 
L23128 RT1-N3 RT1 class Ib, H2-TL-like, grc region (N3)   3.83  6.78 
AF029240 RT1-S3 RT1 class Ib, locus S3  8.72†  7.76 
AI235890 RT1-S3 RT1 class Ib, locus S3  12.6†  16.0 
AF029240 RT1-S3 RT1 class Ib, locus S3  4.15  4.85 
X57523 TAP1 transporter 1, ATP-binding cassette, sub-family B   4.79  6.73 
X57523 TAP1 transporter 1, ATP-binding cassette, sub-family B  26.5
†  36.3 
X63854 TAP2 transporter 2, ATP-binding cassette, sub-family B  2.67  4.03 
MHC class II presentation     
AI045321 C2TA MHC class II transactivator  8.11  3.49* 
X13044 CD74 
CD74 antigen (invariant polpypeptide of 
major histocompatibility class II antigen-
associated) 
 25.9  20.1† 
X13044 CD74 
CD74 antigen (invariant polpypeptide of 
major histocompatibility class II antigen-
associated) 
 24.5†  23.1† 
X82396 CTSB cathepsin B  2.76  1.25† 
L03201 CTSS cathepsin S  3.51  2.37† 
M22366 RT1-Ba RT1 class II, locus Ba  2.29†  1.82 
K02815 RT1-Ba RT1 class II, locus Ba  5.14†  3.20 
AI236175 RT1-Ba RT1 class II, locus Ba  9.76  3.73* 
M36151 RT1-Bb RT1 class II, locus Bb  2.37  2.35† 
AI228153 RT1-Bb RT1 class II, locus Bb  11.5  5.38* 
M15562 RT1-Da RT1 class II, locus Da  10.3  10.5 
M15562 RT1-Da RT1 class II, locus Da  49.4  42.8 
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 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI111537 RT1-Db1 RT1 class II, locus Db1  3.73  2.56* 
U31598 RT1-DMa RT1 class II, locus DMa  1.86  1.71 
Z49761 RT1-DMa RT1 class II, locus DMa  2.24  2.38 
U31599 RT1-DMb RT1 class II, locus DMb  1.94†  1.76 
AI171966 RT1-DMb RT1 class II, locus DMb  4.31  3.57† 
20S proteasome      
E03358 PSMA2 proteasome (prosome, macropain) subunit, alpha type 2  2.31  1.23
† 
E03358 PSMA2 proteasome (prosome, macropain) subunit, alpha type 2  2.44  1.27
† 
D90258 PSMA3 proteasome (prosome, macropain) subunit, alpha type 3  2.87  1.45
† 
D21799 PSMB2 proteasome (prosome, macropain) subunit, beta type 2  2.27  1.93 
L17127 PSMB4 proteasome (prosome, macropain) subunit, beta type 4  2.55  1.30 
D10729 PSMB8 proteasome (prosome, macropain) subunit, beta type 8  10.5  13.7 
D10757 PSMB9 proteasome (prosome, macropain) subunit, beta type 9  25.5  30.5 
AI009427 PSMB10 proteasome (prosome, macropain) subunit, beta type 10   10.2  12.2
* 
AA848487 PSME1 proteasome (prosome, macropain) 28 subunit, alpha   6.39  7.55
* 
D45249 PSME1 proteasome (prosome, macropain) 28 subunit, alpha   5.90  4.88 
D45250 PSME2 proteasome (prosome, macropain) 28 subunit, beta   5.71  4.40 
AA851169 PSME2 proteasome (prosome, macropain) 28 subunit, beta   5.27  5.81
* 
AI011981 PSME2 proteasome (prosome, macropain) 28 subunit, beta   7.45  6.97
* 
AI045972 PSMF1 proteasome (prosome, macropain) inhibitor subunit 1  2.87  3.11
* 
Ubiquitin Pathway      
AI179248 APG3L autophagy 3-like   1.84 -1.02* 
AI180444 APG7L autophagy 7-like  -1.53  1.30* 
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 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI010435 CD2AP CD2-associated protein   1.70  1.02* 
AI073001 FBXO39 F-box protein 39   10.3  16.2* 
AA943147 HERC6 hect domain and RLD 6 ubiquitin ligase  4.22  7.01* 
AI231778 MARCH8 membrane-associated ring finger (C3HC4) 8  2.32  1.12† 
AA893199 NAT5 N-acetyltransferase 5   2.75 -1.09† 
AI232313 NUB1 NEDD8 ultimate buster-1  2.14  2.36* 
AA924532 NUB1 NEDD8 ultimate buster-1  2.33  2.24* 
AI044672 RNF19 ring finger protein (C3HC4 type) 19   1.61  2.14* 
AI236444 TOPORS topoisomerase I binding, arginine/serine-rich   -1.60 -1.30* 
AA955684 TRAIP TRAF-interacting protein   -1.88 -1.27* 
AI030354 UBD ubiquitin D  14.9  33.9* 
AI177396 UBE1L ubiquitin-activating enzyme E1-like  2.05  3.01* 
AI103150 UBE2C ubiquitin-conjugating enzyme E2C -2.92 -1.74* 
AI178800 UBE2L6 ubiquitin-conjugating enzyme E2L 6  2.22  2.78* 
AI178271 UBE2V2 ubiquitin-conjugating enzyme E2 variant 2 -1.92 -1.40* 
AI176509 UBLE1B ubiquitin-like 1 (sentrin) activating enzyme E1B   -1.69 -1.17
* 
AI101492 UBQLN1 ubiquilin 1 -1.50  1.01* 
AI071606 USP1 ubiquitin specific protease 1 -1.87 -1.32* 
AA851237 USP18 ubiquitin specific peptidase 18   6.02  6.60* 
AI171345 USP48 ubiquitin specific protease 48 -1.71 -1.08* 
AI059254 ZFP313 zinc finger protein 313  1.59  2.18* 
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Figure 2.7  Expression Estimates of Genes Involved in Proteolysis.  a-e) Gene symbols and 
Accession numbers are plotted on the x-axis; the average of replicate normalized expression 
values for each treatment group (as described in Materials and Methods) is plotted on the y-
axis.  In some cases, a gene is represented on the microarray set more than once by different 
accession numbers.  Fold change values for genes in a-e) are listed in Table 2.6.         
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Figure 2.7  Expression Estimates of Genes Involved in Proteolysis.   
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Figure 2.7  Expression Estimates of Genes Involved in Proteolysis.   
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Table 2.6  Differential Expression of Genes Involved in Proteolysis.  Replicate RNA 
samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figure 2.7.  Positive fold change values 
indicate an increase, and negative values indicate a decrease in gene expression in the IFNγ-
treated groups.  The dagger indicates the Student’s t-test p-value was greater than 0.1; the 
asterisk indicates there was one sample for each treatment. 
 
 
  
 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
U75404 AKAP12 A kinase (PRKA) anchor protein (gravin) 12   3.18  2.10 
AI044567 ARTS1 type 1 tumor necrosis factor receptor shedding aminopeptidase regulator   3.13  2.77* 
AA963204 ATAD1 ATPase family, AAA domain containing 1    1.49  2.07* 
AI639117 BF B-factor, properdin -1.18†  1.82 
AI231438 CNDP1  carnosine dipeptidase 1 -1.73 -1.27* 
AI008888 CSTB cystatin B  2.84 -1.06 
D90404 CTSC cathepsin C  2.97  1.36† 
AA926360 CTSC cathepsin C  2.82  1.57* 
M38135 CTSH cathepsin H  1.77 -1.10† 
AA851184 CTSY cathepsin Y  8.36  1.44* 
AA818798 CTSZ cathepsin Z  4.15  1.64* 
AA945915 DTX3 deltex3  9.21  10.2* 
L08505 DNCH1 dynein, cytoplasmic, heavy chain 1  1.80 -1.05† 
AA893353 DNPEP aspartyl aminopeptidase  2.07  1.51† 
D89340 DPP3 dipeptidylpeptidase 3  1.54 -1.02† 
AI101484 DPP6 dipeptidylpeptidase 6 -1.73 -1.29* 
AI013743 EPS8 epidermal growth factor receptor pathway substrate 8   -1.63  1.37* 
AA924598 MGLL monoglyceride lipase -1.02† -1.68* 
AA899964 MGLL monoglyceride lipase -1.23 -1.65* 
AI070584 MMP14 matrix metalloproteinase 14  -1.59 -1.27* 
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 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
X87157 NLN neurolysin  2.20  1.73 
AI045789 PARP10 poly (ADP-ribose) polymerase family, member 10  3.70  5.24* 
AA819679 PARP9 poly (ADP-ribose) polymerase family, member 9  11.3  13.4* 
AI177099 PRSS23 protease, serine, 23 -2.01 -1.30* 
AA891810 RNF130 ring finger protein 130, goliath  1.78 -1.32† 
L11319 SPC18 signal peptidase complex 18kD  1.64  1.04† 
AI030968 ST14 suppression of tumorigenicity 14  1.92  1.01* 
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Figure 2.8  Expression Estimates of Genes Involved in the Stress Response.  a-c) Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values for genes in a-c) are 
listed in Table 2.7.         
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Figure 2.8  Expression Estimates of Genes Involved in the Stress Response.   
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Table 2.7  Differential Expression of Genes Involved in the Stress Response.  Replicate 
RNA samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figure 2.8.  Positive fold change values 
indicate an increase, and negative values indicate a decrease in gene expression in the IFNγ-
treated groups.  The dagger indicates the Student’s t-test p-value was greater than 0.1; the 
asterisk indicates there was one sample for each treatment. 
 
 
  
 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI010618 CRYAC crystallin, alpha C  1.37  3.70* 
AI007985 EGLN1 EGL nine homolog 1   1.50 -1.02* 
AI008629 EXOSC9 exosome component 9 -2.02 -2.19* 
AI136977 FKBP4 FK506 binding protein 4  1.80  1.20† 
AI231547 FKBP4 FK506 binding protein 4  1.56  1.55† 
AI236601 HSP105 heat shock protein 105 kDa alpha   2.20  1.05† 
AI030338 HSP65 heat shock protein 65  1.01†  2.17* 
AI234604 HSP8 heat shock protein 8  2.76  1.29† 
S45392 HSP90 heat shock protein 90  2.57  1.07† 
S78556 HSPA9A  heat shock protein, A    3.17  1.14† 
AA899814 HSPCA heat shock protein 1a  2.62  1.74* 
AF017437 IAP integrin-associated protein form 4  1.44†  2.03 
L13619 INSIG1 insulin induced gene 1  1.76 -1.03† 
U09870 MVP major vault protein   3.28†  3.48 
AI237580 PPP1R15B  protein phosphatase 1, regulatory (inhibitor) subunit 15b    1.64 -1.29* 
AA997288 PARP12 poly (ADP-ribose) polymerase family  member 12  6.45  5.22* 
AI045780 RPS6KA6 ribosomal protein S6 kinase, polypeptide 5   1.18 -2.33* 
AI012832 SNN stannin  1.66 -1.19* 
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 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
Y08355 SQSTM1 sequestosome 1  1.85  1.37† 
AI010354 TGFBR2 transforming growth factor, beta receptor II  1.56  2.00* 
AI137038 TOR3A  torsin family 3, member A    1.59  1.58* 
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Figure 2.8  Expression Estimates of Genes Involved in Immune Response.  a-j) Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values for genes in a-j) are 
listed in Table 2.7.         
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Figure 2.8  Expression Estimates of Genes Involved in Immune Response.   
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Figure 2.8  Expression Estimates of Genes Involved in Immune Response.   
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Figure 2.8  Expression Estimates of Genes Involved in Immune Response.   
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Figure 2.8  Expression Estimates of Genes Involved in Immune Response.   
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Table 2.7  Differential Expression of Genes Involved in the Immune Response.  Replicate 
RNA samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figure 2.8.  Positive fold change values 
indicate an increase, and negative values indicate a decrease in gene expression in the IFNγ-
treated groups.  The dagger indicates the Student’s t-test p-value was greater than 0.1; the 
asterisk indicates there was one sample for each treatment. 
 
 
  
 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI145884 ATRN attractin -1.65 -1.18* 
Y07704 BEST5 Best5   12.4  25.7 
AI009658 CCL5 chemokine (C-C motif) ligand 5  1.05†  1.61 
AA924105 CCL6 chemokine (C-C motif) ligand 6 -1.44 -2.45* 
X13016 CD48 CD48 antigen  2.74  1.15† 
AI137672 CD69 CD69 antigen  2.11  1.13* 
AI172606 CKLFSF4 chemokine-like factor superfamily 4  -2.93 -1.52* 
AI100875 CKLFSF5 chemokine-like factor super family 5   -1.59  1.29* 
AA892557 CKLFSF6 chemokine-like factor super family 6    2.55  1.46† 
AA892557 CKLFSF6 chemokine-like factor superfamily 6  3.44  1.72† 
AI012222 CLEC2I c-type lectin 1  3.02  4.43* 
AI102438 CNIH cornichon homolog (Drosophila)   -1.79 -1.39* 
AI233311 CRLF1 cytokine receptor-like factor 1    1.99 -1.12* 
AA942770 CSF2RB colony stimulating factor 2 receptor beta 1  2.37  1.13* 
AF030358 CX3CL1 chemokine (C-X3-C motif) ligand 1  1.79†  2.15 
AI044222 CXCL9 chemokine (C-X-C motif) ligand 9  1.99  1.47* 
AA946476 CXCL9 chemokine (C-X-C motif) ligand 9 3.07  4.00* 
U17035 CXCL10 chemokine (C-X-C motif) ligand 10   20.7  17.7 
AI012235 CXCL11 chemokine (C-X-C motif) ligand 11  21.6  3.03* 
AI233696 CXCL16 chemokine (C-X-C motif) ligand 16  2.05  1.38* 
 72
  
 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AA945737 CXCR4 chemokine (C-X-C motif) receptor 4  1.66  1.17 
AA899612 EBI3 Epstein-Barr virus induced gene 3   2.02 -1.01* 
AA848930 FCGR1 Fc IgG receptor I  2.04 -1.12* 
X73371 FCGR2B Fc IgG receptor II  1.95  1.14† 
AI011757 FCGR3A Fc IgG receptor III  7.25  1.47* 
M32062 FCGR3A Fc IgG receptor III  5.62  2.75† 
AA891944 GBP2 guanylate nucleotide binding protein 2  42.1  29.0 
M80367 GBP2 guanylate nucleotide binding protein 2  24.4  30.8 
AI169249 GRAIL ring finger protein 128 GRAIL  2.69  6.10* 
AI237828 HPSE heparanase  1.80  1.49* 
AA848868 HPSE heparanase  2.90  1.84* 
D00913 ICAM intercellular adhesion molecule-1  3.02  1.80 
AA892259 IFCSBP interferon consensus sequence binding protein  8.84  5.58 
AA955246 IFGIP interferon-gamma inducible protein  25.8  61.7* 
AA852018 IFGIP30 interferon-gamma inducible protein 30   2.75  1.25* 
AA945204 IFI27L interferon-alpha inducible protein 27  5.21  9.79* 
AA955213 IFIG interferon inducible GTPase   17.0  37.6* 
X61381 IFIP  interferon induced protein  3.97  3.67† 
AI073106 IFIP1 interferon inducible protein 1   9.52†  15.9* 
AA799298 IFIT2 interferon-induced protein with tetratricopeptide repeats 2   1.84  4.35* 
AI237586 IFITM1  interferon induced transmembrane protein 1    1.50  1.41* 
AI169751 IFITM3 interferon induced transmembrane protein 3  1.83  2.59* 
AI010584 IFITM3 interferon induced transmembrane protein 3  4.74  5.81* 
AA925116 IGIFBP interferon-gamma inducing factor binding protein  10.3  17.1* 
AA900326 IGLC Ig light chain  1.10  2.96* 
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 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AA925676 IL12RB interleukin-12 receptor beta   1.11  3.34* 
U69272 IL15 interleukin-15  1.38  2.29 
AA925116 IL18BP interferon gamma inducing factor binding protein  3.13  4.36* 
AI010262 IL4R interleukin-4 receptor  2.24  1.16* 
AA819034 ISG12(B) putative ISG12(b) protein  3.89  8.38* 
AA945172 LAP3 leucine aminopeptidase 3   3.77  2.45 
AF065438 LGALS3BP lectin, galactoside-binding, soluble, 3 binding protein   4.42  3.72 
AA819853 LTB lymphotoxin B  1.85  1.93* 
AI233210 LY6E lymphocyte antigen 6 complex, locus E  2.67  4.31* 
AA874924 LY86 lymphocyte antigen 86  2.87  1.47† 
AA998506 MGC108823  interferon-inducible GTPase   60.7  101* 
X52711 MX1 myxovirus (influenza virus) resistance 1  14.1  26.0 
X52713 MX2 myxovirus (influenza virus) resistance 2  6.42  7.30 
AI639447 NFKBAK nuclear factor kappa B activating kinase  2.17  1.21† 
AI103032 NMI N-myc (and STAT) interactor   3.26  4.03* 
AA944463 NRP2 neuropilin 2  2.38  1.08* 
Z18877 OAS1 2'-5' oligoadenylate synthetase  3.48  5.01 
J04563 PDE4B phosphodiesterase 4B  1.62  1.59 
AA799729 PDE4B phosphodiesterase 4b, cAMP-specific  2.53  1.68 
U61729 PROL2 proline-rich protein 2  2.44  1.17† 
AI180292 SAA3 serum amyloid A3   3.29  1.02* 
U02983 SCG3 secretogranin III  1.69  1.06† 
AA851682 SELL selectin, lymphocyte  1.50  1.10* 
AA818796 SERPINB9 serine (or cysteine) peptidase inhibitor, clade B, member 9, SPI6  3.10  7.72 
X17053 SIGJE small inducible cytokine A2, JE product  2.89†  10.9 
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 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AA892921 SRI sorcin  2.76  1.26† 
AA892553 STAT1 signal transducer and activator of transcription 1  19.7  17.3 
AF057025 TLR4 toll-like receptor 4  1.52  1.13† 
M34043 TMSB4X thymosin, beta 4  1.68  1.15† 
AI169601 TNFRSF14 tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator)  1.81 -1.05* 
AA997077 TREX1 3'-5' exonuclease TREX1  3.80  3.00* 
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Figure 2.9  Expression Estimates of Genes Involved in Oxidative Stress Response.  a) Genes 
highlighted in yellow are upregulated in one or both IFN-γ-treated cultures.  b-d) Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values for genes in b-d) are 
listed in Table 2.8.         
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Figure 2.9  Expression Estimates of Genes Involved in Oxidative Stress Response. 
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Figure 2.9  Expression Estimates of Genes Involved in Oxidative Stress Response. 
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Table 2.8  Differential Expression of Genes Involved in the Oxidative Stress Response.  
Replicate RNA samples from each treatment group were hybridized to separate arrays.  The 
average of replicate normalized expression estimates for each sample group was used to 
calculate the fold change difference in expression for each gene in Figure 2.9.  Positive fold 
change values indicate an increase, and negative values indicate a decrease in gene 
expression in the IFNγ-treated groups.  The dagger indicates the Student’s t-test p-value was 
greater than 0.1; the asterisk indicates there was one sample for each treatment. 
 
 
  
 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AA849092 ATF1 activating transcription factor 1, cyclic-AMP-dependent   2.58  1.13* 
U18729 CYBA cytochrome b558 alpha-subunit   5.26  1.44† 
AI231807 FTL1 ferritin light chain 1  2.28 -1.06† 
AI231807 FTL1 ferritin light chain 1  2.42 -1.03† 
S78556 GRP75 75-kDa glucose regulated protein  2.28  1.04† 
J02722 HMOX1 heme oxygenase  1  1.92  1.92† 
AI179610 HMOX1 heme oxygenase  1  2.22  1.38† 
AI177161 NFE2L2 NF-E2-related factor 2  3.58  1.32† 
L26267 NFKB1 nuclear factor kappa B p105 subunit , 3' end  2.53  1.35† 
AI010083 PRDX1 peroxiredoxin 1  1.69  1.08† 
AI232900 PRDX4 peroxiredoxin 4 -1.59 -1.04* 
AI235842 SOD2 superoxide dismutase 2, mitochondrial  1.65  1.13* 
AA926129 SOD2 superoxide dismutase 2, manganese-containing  3.28
†  1.44† 
AI009426 TGM2 tissue-type transglutaminase  4.23  4.65* 
AA944316 TXN1 thioredoxin 1  2.25  1.67* 
J02612 UGT1A6 UDP glycosyltransferase 1 family, polypeptide A6  1.70 -1.10
† 
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Figure 2.11  Expression Estimates of Genes Involved in Apoptosis.  a) Genes highlighted in 
yellow are upregulated and genes highlighted in green are downregulated in IFN-γ-treated 
immature and b) mature OL cultures.  Gene symbols and Accession numbers for pro-
apoptotic genes c-g) and survival genes h-i) are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values for genes in c-i) are 
listed in Table 2.10.         
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Figure 2.11  Expression Estimates of Genes Involved in Apoptosis.   
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Figure 2.11  Expression Estimates of Genes Involved in Apoptosis.   
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Figure 2.11  Expression Estimates of Genes Involved in Apoptosis.   
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Figure 2.11  Expression Estimates of Genes Involved in Apoptosis.   
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Figure 2.11  Expression Estimates of Genes Involved in Apoptosis.   
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Figure 2.11  Expression Estimates of Genes Involved in Apoptosis.   
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Figure 2.11  Expression Estimates of Genes Involved in Apoptosis.   
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Figure 2.11  Expression Estimates of Genes Involved in Apoptosis.   
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Table 2.10  Differential Expression of Genes Involved in Apoptosis.  Replicate RNA 
samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figure 2.11.  Positive fold change 
values indicate an increase, and negative values indicate a decrease in gene expression in the 
IFNγ-treated groups.  The dagger indicates the Student’s t-test p-value was greater than 0.1; 
the asterisk indicates there was one sample for each treatment. 
 
 
  
 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
Pro-Apoptotic Genes    
AA800808 BID BH3 interacting domain death agonist  1.60  1.64 
L26268 BTG1 B-cell translocation gene 1  2.46  1.30† 
L26268 BTG1 B-cell translocation gene 1  3.14  1.37† 
U14647 CASP1  caspase 1  2.17†  1.44† 
AA946088 CASP7 caspase 7  1.94  3.13* 
AI146119 CASP11 caspase 11  1.81†  2.38* 
AI058382 CIDE-B cell death-inducing DNA fragmentation factor, alpha subunit-like effector B   2.85 -1.54* 
AA851650 DAP death-associated protein -1.51  1.21* 
AJ006971 DAPK3 death-associated protein kinase 3  2.41  1.30† 
AI030681 IKBKE inhibitor of kappaB kinase epsilon   2.04  1.17* 
D00403 IL-1A interleukin-1 alpha  1.82  1.05† 
M98820 IL-1B interleukin-1 beta  2.93  1.21† 
AI073247 IRAK interleukin-1 receptor-associated kinase 1 binding protein 1 -1.57 -1.33* 
M34253 IRF1 interferon regulatory factor 1  24.1  17.9 
AA998071 IRF5 interferon regulatory factor 5  1.83 -1.06* 
AA799861 IRF7 interferon regulatory factor 7  2.10  1.86† 
AA799861 IRF7 interferon regulatory factor 7   3.52†  2.80 
AI043702 ITM2B integral membrane protein 2b  2.09  1.26* 
AA799520 ITM2B integral membrane protein 2b  3.25  1.74† 
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 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI236097 ITM2B integral membrane protein 2B  1.50  1.63* 
U53184 LITAF LPS-induced TNF-alpha factor  12.2†  2.36 
U48596 MAP3K1 mitogen activated protein kinase kinase kinase 1  2.55  1.12
† 
U48596 MAP3K1 mitogen activated protein kinase kinase kinase 1  3.27 -1.15
† 
AA899681 NDG2 Nur77 downstream protein 2  1.18  2.00* 
X63594 NFKBIA nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, alpha   1.22
†  1.52 
X63594 NFKBIA nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, alpha   2.24
†  1.68 
AA956170 NME3 non-metastatic cells 3 -1.44 -1.52* 
AI009756 PDCD6IP programmed cell death 6 interacting protein  1.68  1.21* 
M18330 PKCD protein kinase C, delta  2.07  1.09† 
AA851245 PYCARD  apoptosis-associated speck-like protein containing a CARD  1.28  3.92* 
AI007920 RIPK1 receptor (TNFRSF)-interacting serine-threonine kinase 1   2.38  2.43* 
AF036537 RIPK3  homocysteine respondent protein HCYP2; receptor-interacting serine-threonine kinase 3  3.29
†  1.67 
AI231531 TNFRSF6  tumor necrosis factor receptor superfamily, member 6 (Fas)  1.31  2.73* 
    
Survival Genes    
AA799664 AKT1 RAC protein kinase alpha; v-akt murine thymoma viral oncogene homolog 1  1.73 -1.08
† 
X75856 BI-1  Bax inhibitor 1  2.21  1.26† 
X17053 CCL2 chemokine (C-C motif) ligand 2  2.33  7.33 
AA955871 IGF1 insulin-like growth factor I, exon 6 -4.10 -2.14* 
AA945615 IGF1 insulin-like growth factor I, exon 6 -3.04 -1.85* 
AI071236 IGF2 insulin-like growth factor 2  1.55 -1.16* 
AI010407 MAEA macrophage erythroblast attacher (predicted)  1.65  1.06* 
AA849796 MDM2 transformed mouse 3T3 cell double minute 2    1.68  1.25* 
L26267 NFKB1 nuclear factor kappa B  2.53  1.35† 
 90
  
 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AA944209 PIM1 proviral integration site 1  4.94  1.60* 
AA818996 QARS glutaminyl-tRNA synthetase  3.02 -1.03* 
L01624 SGK serine/threonine protein kinase; serum/glucocorticoid regulated kinase  2.38 -1.48
† 
AA849015 SOCS-1 suppressor of cytokine signaling-1  1.75  2.15* 
AI236947 TRAF2BP TRAF2 binding protein   3.15  2.56* 
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Table 2.11  Differential Expression of Genes Involved in various cell functions important for 
cell growth, development and membrane synthesis.  Replicate RNA samples from each 
treatment group were hybridized to separate arrays.  The average of replicate normalized 
expression estimates (not shown) for each sample group was used to calculate the fold 
change difference in expression for each gene in the table.  Positive fold change values 
indicate an increase, and negative values indicate a decrease in gene expression in the IFNγ-
treated groups.  The dagger indicates the Student’s t-test p-value was greater than 0.1; the 
asterisk indicates there was one sample for each treatment group. 
 
 
   Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
     
Cell Adhesion    
AI044792 CD47 CD47 antigen   1.67  2.21* 
AI230037 CDA08 T-cell immunomodulatory protein -2.01 -1.40* 
AI101443 COL1A2 procollagen, type I, alpha 2 -1.12†  2.43* 
AA955974 COL9A1 collagen alpha 1(IX) chain, long form  -2.67 -1.93* 
AA997447 ITGA4 integrin alpha 4  2.05  1.69* 
AA858880 ITGAL integrin alpha L  2.14  1.11* 
L21711 LGALS5 galectin-5   2.51  3.75 
AA859350 MCAM melanoma cell adhesion molecule   1.20  2.26* 
AI009843 NRP1 neuropilin 1  2.26  1.49* 
AI059481 NRXN3 neurexin 3 -1.46 -3.06* 
AA997710 PCDH19 protocadherin 19  -2.14 -1.14* 
AA874848 THY1 thy-1 cell-surface glycoprotein -1.32† -2.42 
     
Cell Cycle    
M80633 ADCY4 adenylyl cyclase type (IV)   2.75  1.11† 
X13933 CALM1 calmodulin 1  1.59  1.03† 
AA894330 CAMK2D calcium/calmodulin-dependent protein kinase II, delta  1.83  1.35
† 
AA998516 CCNA2 cyclin A2 -2.22 -1.60* 
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   Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI008203 CCNB2  cyclin B2   -1.22 -2.27* 
AI111344 CCNH cyclin H -1.70  1.05* 
AI176278 CCNI  cyclin I    2.82 -1.19* 
AI009652 CDC10 cell division cycle 10  1.94 -1.24* 
AI009002 CDC25B cell division cycle 25B -2.00 -1.69* 
AA956688 CDCA3 cell division cycle associated 3 -2.80 -2.21* 
AI177871 CDK2AP1 cyclin-dependent kinase 2-associated protein 1  -1.53 -1.64* 
AI230798 CDKN3  cyclin-dependent kinase inhibitor 3 -2.14 -2.31* 
AI058854 CENPJ centromere protein J  2.92  3.29* 
U66471 CGR19 cell growth regulatory with ring finger domain  2.09 -1.01† 
AI059345 CIT citron -1.51 -1.64* 
AI103556 CKS1B CDC28 protein kinase 1b  -1.72 -1.54* 
AA944180 CKS2 CDC28 protein kinase 2 -3.36 -2.19* 
AA943028 CSF1R colony stimulating factor 1 receptor  1.89 -1.04* 
AI010362 CUL1 cullin 1  1.92 -1.08* 
AI072269 DNAJA2 DnaJ (Hsp40) homolog, subfamily A, member 2 -1.54 -1.15* 
AA891884 ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3   1.13
† -1.51 
AA893235 G0S2 G0/G1 switch gene 2 -1.39† -2.37 
L32591 GADD45A growth arrest and DNA-damage-inducible 45 alpha  2.05  1.23 
AI070068 GADD45B  growth arrest and DNA-damage-inducible 45 beta    1.59  1.84* 
D38560 GAK cyclin G-associated kinase  1.69 -1.09† 
AA925012 GMNN geminin  -2.04 -1.66* 
AI177968 HIRA histone cell cycle regulation defective homolog A isoform 1 -2.18 -1.15* 
AI060200 KIF2C kinesin family member 2C -1.95 -1.54* 
AI229508 MCM2 minichromosome maintenance deficient 2 mitotin  -1.65 -1.12* 
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   Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI178465 MDC1 mediator of DNA damage checkpoint 1 -1.54 -1.14* 
AI178622 MDM1 transformed mouse 3T3 cell double minute 1 -1.81 -2.69* 
AI227852 MGC112830 similar to transcription factor -1.65 -1.44* 
AI044253 MYBL1  myeloblastosis oncogene-like 1   -1.77 -1.36* 
AI136733 NUCKS nuclear ubiquitous casein kinase and cyclin-dependent kinase substrate -1.68 -1.17* 
AA964152 NUSAP1 nucleolar and spindle associated protein 1  -2.07 -1.69* 
AI177755 PBEF1 pre-B-cell colony enhancing factor 1  6.99  6.33* 
AI103682 POLA1 polymerase (DNA directed), alpha 1 -1.66 -1.22* 
AA944231 POLD2 polymerase (DNA directed), delta 2 -1.56 -1.09* 
AI070935 POLE2 polymerase (DNA directed), epsilon 2 -1.70 -1.21* 
AI137747 POLG polymerase (DNA directed), gamma -1.52 -1.30* 
AI233712 PPM1D  protein phosphatase 1D magnesium-dependent, delta  -1.57 -1.04* 
AI043878 PPP6C protein phosphatase V  1.56 -1.17* 
AI113104 PRC1 protein regulator of cytokinesis 1  -1.82 -1.91* 
AI177134 PRIM2 DNA primase, p58 subunit -1.62 -1.48* 
AI170807 RABGAP1 RAB GTPase activating protein 1 -1.62 -1.18* 
M15427 RAF1 v-raf-1 murine leukemia viral oncogene homolog 1  1.85  1.12 
U11681 RAFT1 rapamycin and FKBP12 target-1 protein  1.58  1.08† 
AI236669 REV3L REV3-like, catalytic subunit of DNA polymerase zeta RAD54 like  -1.75 -1.76* 
AA899195 RFC2 replication factor C (activator 1) 2 -1.51  1.13* 
AI103093 RFC3 replication factor C (activator 1) 3  -1.82 -1.16* 
AI233728 RFC5 replication factor C (activator 1) 5  -1.71 -1.23* 
AI011991 RHOG  ras homolog gene family, member G    1.83  1.27* 
AI112987 RIS2 retroviral integration site 2  -1.75 -1.40* 
AA899590 RRM2 ribonucleotide reductase M2 -3.05 -1.85* 
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   Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI008106 S100A6 S100 calcium binding protein A6   1.11  2.89* 
AI137579 SESN1 sestrin 1  -1.57 -1.07* 
AA924839 SKP2 S-phase kinase-associated protein 2 , isoform 2 -1.80 -1.67* 
AA945656 SMC2L1 SMC2 structural maintenance of chromosomes 2-like 1 -2.35 -1.77* 
U89282 TEP1 telomerase associated protein 1  1.78  1.50† 
AA942706 TLK1 tousled-like kinase 1  1.62  1.14* 
AA851739 TLK2 tousled-like kinase 2   2.10  1.03* 
AI011321 XAB2 XPA binding protein 2  1.67  1.05* 
     
Cell Growth    
AA901152 18S 18S ribosomal RNA -1.48†  2.27* 
AI146189 ANXA3 annexin A3  3.02  1.18* 
AA925375 B3GAT1 beta-1,3-glucuronyltransferase 1  -1.52 -2.15* 
AI230113 BZW2 basic leucine zipper and W2 domains 2 -1.60 -1.17* 
M57276 CD53 CD53 antigen, leukocyte antigen MRC-OX44  4.52  1.34† 
AI230215 CDCA8 cell division cycle associated 8 -2.70 -2.32* 
AI233361 CHD6 chromodomain helicase DNA binding protein 6  -2.09 -2.56* 
X59737 CKMT1 creatine kinase, mitochondrial 1, ubiquitous -1.69 -1.32† 
AA893683 CPSF3 cleavage and polyadenylation specificity factor 3    2.08 -1.11
† 
AI070318 CTGF connective tissue growth factor  1.10†  1.68* 
AA848813 DP1 deleted in polyposis 1   1.34  1.79* 
AA848813 DP1 deleted in polyposis 1  1.23  1.90* 
AI070336 EMP1 epithelial membrane protein 1  1.34  3.93* 
AA818807 EMP2 epithelial membrane protein 2  1.06  2.12* 
AA851618 EMP3 epithelial membrane protein 3 -1.24  2.88* 
AA924460 EXOSC8 exosome component 8 -1.51 -1.29* 
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   Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
X08056 GAMT guanidinoacetate methyltransferase  1.12† -1.52 
J03588 GAMT guanidinoacetate methyltransferase  1.10† -1.64 
U07971 GATM glycine amidinotransferase  1.09† -1.88 
AI177583 GLT glycosyltransferase AD-017 -1.55  1.00* 
AI180266 HGDF hepatoma-derived growth factor -2.57 -1.09* 
AI137820 IGFBP10 insulin-like growth factor binding protein 10 -1.09†  4.66* 
AI029920 IGFBP5 insulin-like growth factor binding protein 5 -2.28 -2.46† 
AI176584 IGFBP5 insulin-like growth factor binding protein 5 -1.77 -3.61* 
AI175647 KARS lysyl-tRNA synthetase  1.43  1.93* 
AA892250 KARS lysyl-tRNA synthetase  3.22  1.96 
AA800787 LAMP2 lysosomal membrane glycoprotein 2  2.18 -1.18† 
AI177967 LTBP4 latent transforming growth factor beta binding protein 4   -2.31 -1.58* 
AI230642 NUP160 nucleoporin 160   -1.53  1.00* 
AA900364 ODF2 GLE1 RNA export mediator-like (yeast   -1.53 -1.22* 
AI044795 OGFR opioid growth factor receptor  1.75  1.35* 
AI104536 PCBP2 poly(rC) binding protein 2   -1.53 -1.31* 
AA819103 PFKL phosphofructokinase, liver  -2.77 -1.92* 
L25387 PFKP phosphofructokinase, platelet  2.83  2.78 
AI103465 POP4 processing of precursor 4 -1.79  1.11* 
AA850679 PRPF39 PRP39 pre-mRNA processing factor 39 homolog  1.91 -1.14* 
AI177921 PTDSS1 phosphatidylserine synthase 1   -1.50 -1.34* 
AA875286 PTOV1 prostate tumor over expressed gene 1    1.74 -1.19† 
AI060096 RASL11B RAS-like family 11 member B  1.67 -1.55* 
AI013541 RNASE T2 ribonuclease T2   2.56  1.44* 
AI012859 RNASEL ribonuclease L   1.94  1.43* 
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   Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
X62528 RNH ribonuclease/angiogenin inhibitor  2.32  1.64† 
AA800016 RNMT RNA (guanine-7-) methyltransferase    1.82  1.17† 
AI058889 RRS1 RRS1 ribosome biogenesis regulator homolog   -2.00 -1.38* 
AI177256 SLFN5 schlafen 5   2.26  2.93† 
AA899491 WARS tryptophanyl-tRNA synthetase   2.69  3.41* 
     
Electron Transport    
AA926200 AOX1 aldehyde oxidase 1 -1.20  2.60* 
X54081 COX4A cytochrome c oxidase 4a  2.24 -1.01† 
AI170570 ENTPD5 ectonucleoside triphosphate diphosphohydrolase 5 -1.50 -1.23* 
X12355 GRP58 glucose regulated protein 58 kDa  2.34  1.86† 
AA925747 MCF2L Mcf2 transforming sequence-like -1.56 -1.40* 
AA899520 RACGAP1 Rac GTPase-activating protein 1 -1.56 -1.13* 
AA893860 TARS threonyl-tRNA synthetase  1.64 -1.12† 
AI171837 TXNL2 thioredoxin-like 2 -2.27 -1.03* 
     
Nuclear mRNA Splicing    
AA819828 CUGBP1 CUG triplet repeat, RNA binding protein 1  -2.01 -1.62* 
AI178706 CUGBP2 CUG triplet repeat,RNA-binding protein 2 -1.72 -1.12* 
AI136376 HNRNPH1 heterogeneous nuclear ribonucleoprotein H1 -1.66 -1.01* 
AI111877 HNRPC  heterogeneous nuclear ribonucleoprotein C   -2.06 -1.14* 
AA945952 HNRPD heterogeneous nuclear ribonucleoprotein D  1.59  1.03* 
AI177016 LSM8  LSM8 homolog, U6 small nuclear RNA associated -1.72 -1.05* 
AI176497 MYEF2  myelin basic protein expression factor 2, repressor   -1.55 -1.65* 
AI171535 PABPC4  poly A binding protein, cytoplasmic 4   -1.90 -1.58* 
 97
   Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI233870 PABPC4  poly A binding protein, cytoplasmic 4   -1.52 -1.21* 
AA956626 RBMS3 RNA binding motif, single stranded interacting protein 3  1.02  2.58* 
AI171267 SFRS7  splicing factor, arginine/serine-rich 7   -1.81 -1.29* 
AI059437 SRRM1  serine/arginine repetitive matrix 1   -1.53  1.02* 
AA851909 SYNCRIP  synaptotagmin binding, cytoplasmic RNA interacting protein    2.31 -1.14* 
AI232957 TARDBP  TAR DNA binding protein   -1.83 -1.07* 
     
Cell Metabolism    
AI009194 AK2 adenylate kinase 2  1.79  1.42* 
AA799466 AK2 adenylate kinase 2  1.70  1.66† 
J03190 ALAS1 aminolevulinic acid synthase 1  1.72 -1.12† 
J03190 ALAS1 aminolevulinic acid synthase 1  1.50 -1.23† 
M12919 ALDOA aldolase A  2.58  1.10† 
AI233343 ASRGL1 asparaginase-like sperm autoantigen -1.71 -1.33* 
AI145601 CAR14  carbonic anhydrase 14    1.08† -2.55* 
AI100768 CAR8  carbonic anhydrase 8   -1.75 -1.92* 
AI177443 CERK ceramide kinase   -1.21† -2.05* 
AI234151 CHST2  carbohydrate sulfotransferase 2   -1.59  1.20* 
U52102 CRMP1 collapsin response mediator protein 1  1.52  1.06† 
M64755 CSAD cysteine sulfinic acid decarboxylase -1.02† -1.59 
M95768 CTBS chitobiase, di-N-acetyl-  1.60  1.00† 
M38566 CYP27 cytochrome P450 27a1  2.17  2.35 
U40004 CYP2J3 cytochrome P450 monooxygenase  1.84  3.24† 
AA946300 CYP4F1 cytochrome P450-like protein  1.33  3.48* 
AA848834 DHDDS  dehydrodolichyl diphosphate synthase    1.89  1.05* 
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   Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI030907 DHRS1 dehydrogenase/reductase (SDR family) member 1 -1.89 -1.13* 
AI170606 DNASEX deoxyribonuclease I-like 1  1.29†  2.01* 
AA851921 ECHDC1  enoyl Coenzyme A hydratase domain containing 1  1.55 -1.15* 
X16145 FUCA fucosidase, alpha-L- 1, tissue  1.93 -1.04† 
AI172253 GCSH glycine cleavage system protein H -1.81 -1.79* 
AI103550 GCSH glycine cleavage system protein H  -1.68 -1.70* 
AA892086 GNS glucosamine (N-acetyl)-6-sulfatase    2.32  1.21† 
AA957007 GSTM5 glutathione S-transferase, mu 5 -1.51  1.00* 
M13962 GUSB glucuronidase, beta  1.22† -1.57 
AA848820 HPGD NAD-dependent 15-hydroxyprostaglandin dehydrogenase  3.01  2.86* 
AA891524 ISOC2 isochorismatase domain containing 2   1.43†  1.54 
AI170294 MAN2A2 mannosidase 2 alpha 2  -2.28 -1.25* 
AA891670 MAN2B1 mannosidase 2, alpha B1  1.52 -1.10† 
Y09333 MTE1 mitochondrial very-long-chain acyl-CoA thioesterase  2.84
†  2.32 
AA945601 NADK inorganic polyphosphate/ATP-NAD kinase  2.08  1.42* 
AA945601 NADK inorganic polyphosphate/ATP-NAD kinase  2.05  1.26* 
AI059352 NT5 5 nucleotidase  1.40 -2.15* 
D10706 OAZ1 ornithine decarboxylase antizyme 1  2.78  1.09† 
D10706 OAZ1 ornithine decarboxylase antizyme 1  2.14  1.11† 
AA893184 PDHX pyruvate dehydrogenase complex, component X  1.74  1.19
† 
AA851370 PIP5K1A phosphatidylinositol-4-phosphate 5-kinase, type 1 alpha    2.85  1.50* 
AA891891 POLS  polymerase (DNA directed) sigma    1.64  1.03† 
AI179986 PSPH  phosphoserine phosphatase   -1.60 -1.36* 
AA851273 RARRES2 retinoic acid receptor responder 2  -1.04†  2.27* 
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   Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
M19257 RBP1 retinol binding protein 1  2.04 -1.32† 
AI045256 RECQL  RecQ protein-like   -1.50 -1.26* 
D10233 RENBP renin binding protein  1.87  1.15† 
AI236332 SAT spermidine/spermine N1-acetyl transferase  2.22  1.28* 
AI105184 SHMT1  serine hydroxymethyl transferase 1 (soluble)   -1.71 -1.48* 
AA998234 SLC25A15  solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15   -1.78 -1.03* 
AA850579 SUCLG2  succinate-Coenzyme A ligase, GDP-forming, beta subunit    2.11 -1.05* 
AI011510 TAS1R2 aldehyde dehydrogenase 4 family member A1   1.83  3.60* 
AI229638 TK1 thymidine kinase 1 -1.50 -1.43* 
AI014130 TYKI thymidylate kinase family LPS-inducible member    4.04  4.43* 
AI111492 TYKI thymidylate kinase family LPS-inducible member   5.09  8.63* 
AI170679 UGP2  UDP-glucose pyrophosphorylase 2   -1.86 -1.18* 
     
Protein Biosynthesis    
AI169284 ARL6IP1 ADP-ribosylation factor-like 6 interacting protein 1 -1.59 -1.18* 
AA901245 BOLL  boule-like    -1.39 -1.53* 
AI175100 BOLL  boule-like   -1.71 -1.66* 
AA818804 BOLL  boule-like   -1.60 -1.33* 
AA998690 ITGB4BP integrin beta 4 binding protein    1.79  1.11* 
AI175221 MRPL16 mitochondrial ribosomal protein L16 -1.68 -1.14* 
AI104369 MRPL42  mitochondrial ribosomal protein L42   -1.72 -1.03* 
AI178900 MRPS15 mitochondrial ribosomal protein S15 -1.52 -1.42* 
AA945611 RPL10 ribosomal protein L10  2.04  1.03† 
AI228624 RPL23 ribosomal protein L23 -1.77 -1.35* 
AA686461 RPL30  ribosomal protein L30 -1.55 -1.32* 
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(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI030000 RPL35 ribosomal protein L35  1.49  3.38* 
AA850115 SARS2 seryl-tRNA synthetase 2    1.65 -1.04* 
    
Protein Metabolism    
AA946474 CAST calpastatin  1.56  2.48* 
AI233209 CRYM crystallin, mu -1.81 -2.12* 
S74141 HCTK tyrosine kinase; hemopoietic cell kinase  2.53  1.42† 
AI177543 PTPLA protein tyrosine phosphatase-like, member a -2.35 -2.69* 
AI045021 TTC10 tetratricopeptide repeat domain 10  -1.44 -2.19* 
AA963073 TTK Ttk protein kinase  -2.20 -1.87* 
D30740 YWHAZ 
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta 
polypeptide 
 2.47  1.06† 
     
Protein Modification    
AI104393 ART3  ADP-ribosyltransferase 3    1.16  4.66* 
AI177962 AXL AXL receptor tyrosine kinase    1.29†  4.31* 
AI177841 AXL AXL receptor tyrosine kinase    1.35†  2.61* 
M63333 CAMK4 calcium/calmodulin-dependent protein kinase IV -1.58  1.02
† 
AA819816 CSNK1A1 casein kinase 1, alpha 1 -1.55 -1.25* 
AI179878 GALNT10 
UDP-N-acetyl-alpha-D-galactosamine: 
polypeptide N-
acetylgalactosaminyltransferase 10 
-1.50 -1.04* 
AA924000 JAK1 janus kinase 1  1.52  1.35* 
AA943886 PLK2 polo-like kinase 2   1.64  1.70* 
AI170309 PPP3CB protein phosphatase 3, catalytic subunit, beta -1.71 -1.08* 
AA964661 PPP4R2  protein phosphatase 4, regulatory subunit 2    1.50 -1.09* 
L34262 PPT palmitoyl-protein thioesterase  1.83  1.02† 
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(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI102009 PRKRA  protein kinase, interferon inducible double stranded RNA dependent activator   -1.52 -1.17* 
AI177910 PTPN18  protein tyrosine phosphatase, non-receptor type 18    1.82  1.10* 
X58828 PTPN2 protein tyrosine phosphatase, non-receptor type 2  1.55  1.11
† 
S49400 PTPN5 protein tyrosine phosphatase, non-receptor type 5  1.28  2.26 
U28938 PTPRO protein tyrosine phosphatase, receptor type, O  1.92 -1.86 
AI113338 PTPRT protein tyrosine phosphatase, receptor type, T  -1.86 -1.84* 
AI030254 RPS6KC1  ribosomal protein S6 kinase, polypeptide 1   -1.68  1.08* 
AI011832 SNRK SNF related kinase  1.98  1.24* 
AI059722 SRPK2  serine/arginine-rich protein specific kinase 2   -1.98 -1.48* 
AI102055 SRPK2  serine/arginine-rich protein specific kinase 2   -1.54 -1.22* 
     
Cell Motility    
AI112954 ABI3 ABI gene family, member 3   1.55 -1.13* 
AI070848 ACTB actin, beta  1.62  1.12† 
AF083269 ARPC1B actin related protein 2/3 complex, subunit 1B  2.64  1.15† 
AF083269 ARPC1B actin related protein 2/3 complex, subunit 1B  2.19  1.18† 
X76489 CD9 CD9 antigen  2.16 -1.59 
AI229547 MARCKS myristoylated alanine-rich C-kinase substrate  -1.99  1.01* 
AI229547 MARCKS myristoylated alanine-rich C-kinase substrate -1.69  1.34* 
AI010104 MSN moesin  1.57  2.63* 
     
Cytoskeletal    
AI014072 ADAMTS6 ADAMTS-6 precursor -2.19 -1.02* 
AA892332 ARPC4 actin related protein 2/3 complex, subunit 4    1.56  1.04† 
H32978 ARPC5L actin related protein 2/3 complex, subunit 5-like   -1.58 -1.24* 
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   Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AA891724 BICD2 bicaudal D homolog 2   1.09† -1.51 
AA850040 CAP1 CAP, adenylate cyclase-associated protein 1  1.59  1.10* 
AA894004 CAPG capping protein (actin filament), gelsolin-like    3.02  1.17† 
AA944422 CNN3 calponin 3, acidic  1.83  1.68 
AA819207 COL1A2 procollagen, type I, alpha 2 -1.33  1.82* 
AA859284 COL1A2 procollagen, type I, alpha 2 -1.44  1.82* 
X70369 COL3A1 collagen, type III, alpha 1  1.85 -1.48† 
AA892506 CORO1A coronin, actin binding protein 1A  2.14  1.27† 
AJ006064 CORO1B coronin, actin-binding protein 1B  2.85  1.18† 
AJ006064 CORO1B coronin, actin-binding protein 1B  2.40  1.01† 
AI232408 DAAM1 dishevelled associated activator of morphogenesis 1 -1.05
†  1.82* 
AA800743 DBNL drebrin-like  2.03  1.88† 
AI071800 DBNL drebrin-like  1.45  2.27* 
AI177125 DLC2 dynein light chain-2 -1.53 -1.77* 
AI103774 DLC2 dynein light chain-2 -1.47 -1.58* 
AI103370 FATH fat tumor suppressor homolog -1.86 -1.49* 
AI176380 KIF2 kinesin heavy chain member 2 -1.69 -1.20* 
AA851392 KIF22  kinesin family member 22   -1.83 -1.60* 
AA851392 KIF22  kinesin family member 22   -1.78 -1.67* 
AA892369 KIFC3  kinesin family member C3    1.20† -1.70 
AI030156 KLHL5 kelch-like 5  -1.78 -1.27* 
AI111561 KRT9 keratin 9, type I, cytoskeletal -1.03†  2.32* 
U30938 MAP2 microtubule-associated protein 2   1.14† -1.59 
AI176721 MAPEB1 microtubule-associated protein EB1  (weakly similar)  1.87  2.84 
AI227608 MAPT microtubule-associated protein tau  1.84 -1.52† 
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(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI012030 MGP matrix Gla protein  5.19  6.26 
AA944935 MIG12 MID1 interacting G12-like protein  1.58  1.72* 
AA924763 MIG12 MID1 interacting G12-like protein -1.06†  1.86* 
AA946377 MYH10 myosin heavy chain 10, non-muscle -1.66 -1.13* 
AI172178 MYH4 myosin, heavy polypeptide 4, skeletal muscle   -1.75 -1.17* 
S77858 MYL6 myosin, light polypeptide 6, alkali, smooth muscle and non-muscle    2.39  1.10
† 
AI030684 NFL neurofilament, light polypeptide  2.12  3.85* 
AA964535 PARVA parvin, alpha  1.02  1.52* 
AA799323 PLEK pleckstrin   3.36  1.36† 
AA964601 PLEKHC1  pleckstrin homology domain containing, family C (with FERM domain) member 1   -1.56  1.37* 
AI236227 PLS3 plastin 3 (T-isoform) -1.05†  1.67* 
AI012428 PSCDBP pleckstrin homology, Sec7 and coiled-coil domains, binding protein   2.73  1.23* 
AI144877 SSX2IP synovial sarcoma, X breakpoint 2 interacting protein -1.79 -1.23* 
AA899649 STMN3 stathmin-like 3  1.01† -2.42* 
AI045848 SVIL supervillin    1.25  1.67* 
AI013247 TAGLN2 transgelin 2; SM22-alpha homolog   1.08†  2.75* 
AI175566 TCTEX1 t-complex testis expressed 1 -1.40 -1.70* 
AB010119 TCTEX1 t-complex testis expressed 1  1.54† -1.69 
AI169615 VAPA vesicle-associated membrane protein, associated protein a -1.59 -1.17* 
AA956278 VASP vasodilator-stimulated phosphoprotein   2.18  1.36* 
AI176483 WASF2 WAS protein family, member 2    2.58 -1.01* 
     
Development    
AI235611 ANXA4 annexin A4  1.46†  2.15* 
U33553 CSPG5 chondroitin sulfate proteoglycan 5  2.02 -1.30† 
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(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI234146 CSRP1 cysteine and glycine-rich protein 1  1.54  1.56† 
AI229304 DSCR1L1 Down syndrome critical region gene 1-like 1 -1.07† -2.35* 
AI043809 GAS7 growth arrest specific 7  1.57  1.86* 
AA963891 GNAO guanine nucleotide binding protein, alpha o  1.12† -2.22* 
AA875659 INEXA internexin, alpha -1.44† -1.52 
AI072817 LRRN6A leucine rich repeat neuronal 6A  -2.05 -2.03* 
U03414 OLFM1 olfactomedin 1  1.19†  1.55 
AI030196 POGZ pogo transposable element with ZNF domain -1.56 -1.30* 
AI102497 SERPINE2 serine (or cysteine) proteinase inhibitor, clade E, member 2 -1.52 -1.08* 
AI229145 SERPINI1 serine (or cysteine) peptidase inhibitor, clade I, member 1  1.37
† -2.79* 
AA900057 SNX27 PDZ protein Mrt1 -2.08 -1.01* 
S72594 TIMP2 tissue inhibitor of metalloproteinase 2  1.75  1.06† 
AI102578 TNFAIP2 TNF-alpha induced protein 2  5.40  7.45* 
AI230716 TPM4 tropomyosin 4 -1.61  1.29* 
     
Differentiation    
AA944481 ANGPTL4 angiopoietin-like protein 4 -1.36  2.00* 
AI030028 CD34 CD34 antigen -2.39 -1.28* 
AA899893 DEPDC1B  DEP domain containing 1B  -2.19 -1.27* 
AA859837 GDA guanine deaminase  2.65  2.26 
AA817826 GPC6 Gpc6 protein -2.24 -1.18* 
AI011448 NOTCH2 notch 2  3.15 -1.32* 
AI177354 NUCB1 nucleobindin 1  3.11  4.07* 
AA899410 SHC1 Src homology 2 domain-containing transforming protein 1  2.66  1.50* 
AI231349 STMN2 stathmin-like 2  1.11† -1.55* 
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   Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI228231 TSPAN2 tetraspan 2 -1.35 -2.13* 
     
Proliferation    
AI013902 ANXA7 annexin A7  1.50  1.45* 
AI229206 APRIN androgen-induced proliferation inhibitor  -1.74 -1.24* 
AA893621 ATP13A ATPase type 13A   1.59  1.49 
AI231017 BUB3  budding uninhibited by benzimidazoles 3 homolog  -1.58  1.29* 
AI179620 CSNK2A1 casein kinase II, alpha 1 polypeptide -1.81 -1.38* 
AI030153 DDRF2 discoidin domain receptor family, member 2   1.27  2.72* 
AA859593 EFP estrogen-responsive finger protein  7.62  4.86 
AI229178 FGFR2 fibroblast growth factor receptor 2  1.01† -2.36* 
AI145424 FGFR3 fibroblast growth factor receptor 3 -2.18 -2.14* 
AI010226 FLI1 friend leukemia integration 1   2.02 -1.07* 
AA851814 GPNMB glycoprotein (transmembrane) nmb  1.65  2.59* 
AA925692 HCLS1 hematopoietic cell specific Lyn substrate 1  1.80  1.00* 
AI170366 HDGF hepatoma-derived growth factor -1.65 -1.20* 
AA997800 KI-67 antigen KI-67 -2.43 -2.08* 
AI103106 LMNB1 lamin B1 -3.02 -1.71* 
AI013222 PDGFA platelet derived growth factor alpha  1.46  3.47* 
D82071 PTGDS2 prostaglandin D2 synthase 2  1.86 -1.02† 
AI104090 RPS4X 40S ribosomal protein S4, X isoform  2.13  1.09* 
AI170353 S100A11  S100 calcium binding protein A11    -1.07†  4.00* 
AI010351 SCAP2 Src family associated phosphoprotein 2  2.57  1.14* 
AI137491 SSR1 signal sequence receptor, alpha   -1.53 -1.07* 
AA996959 VDUP1 vitamin D3 up-regulated protein 1 -2.35 -2.04* 
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   Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AA997302 ZFP36 zinc finger protein 36    2.22 -1.01* 
     
Signal Transduction    
AI072842 AKAP11 A-kinase anchor protein 11  -1.69 -1.33* 
AA926354 ARL11  ADP-ribosylation factor-like 11   -1.64 -1.66* 
AI228929 BAI3  brain-specific angiogenesis inhibitor 3   -1.84 -1.11* 
AI045319 BAIAP1  BAI1-associated protein 1   -1.82 -1.41* 
AI031002 CDC42EP4  CDC42 effector protein (Rho GTPase binding) 4   -1.78  1.18* 
AA851938 CDC42EP4  CDC42 effector protein (Rho GTPase binding) 4   -1.67 -1.29* 
AA892496 CHN2 chimerin 2  1.58† -1.62 
X55812 CNR1 cannabinoid receptor 1 (brain)  1.71 -1.13† 
AI146166 DLGAP1 PSD-95 binding protein -1.84 -1.10* 
AA943737 EDG1 endothelial differentiation sphingolipid G-protein-coupled receptor 1 -1.87  1.15* 
AI112149 EDG2 endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 2  1.02
†  2.26* 
AI112097 FGF13 fibroblast growth factor 13 -1.69 -2.69* 
AI179953 GJB2 gap junction membrane channel protein beta 2 -1.41 -3.25* 
AI059426 GJB6 gap junction membrane channel protein beta 6  1.76  1.00* 
AI228557 GNAI1 guanine nucleotide binding protein, alpha inhibiting 1 -1.10
† -2.76* 
AA817892 GNB2 guanine nucleotide binding protein, beta  2  2.03  1.01† 
AI232477 GNG5 guanine nucleotide binding protein, gamma 5  1.42† -1.54 
S61973 GRINA NMDA receptor glutamate-binding subunit  2.48  1.38† 
AI058957 HOMER2 homer homolog 2   1.27† -2.65* 
AI009602 IL13RA1 interleukin 13 receptor, alpha 1  2.19  1.88* 
AI010211 IQGAP3  IQ motif containing GTPase activating protein 3   -1.51 -1.35* 
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   Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI060017 LCP2 lymphocyte cytosolic protein 2   4.01 -1.22* 
M17412 LOC360721 growth and transformation-dependent protein  1.31† -1.68 
AA893357 MAGI1  membrane associated guanylate kinase interacting protein-like 1    1.55  1.35
† 
AI102732 MGC109340 microsomal signal peptidase, 23kDa  -2.47 -2.30* 
L09119 NRGN neurogranin -1.54 -1.01† 
AA998124 NUDT3  nudix (nucleotide diphosphate linked moiety X)-type motif 3   -1.84  1.09* 
AI030619 PAK4 P21 (CDKN1A)-activated kinase 4   -1.66 -1.04* 
AI168973 PDCL3 phosducin-like 3 -1.57 -1.12* 
AI102252 PHPT1  phosphohistidine phosphatase 1   -1.55 -1.11* 
D83538 PIK4CA phosphatidylinositol 4-kinase, catalytic, alpha  1.64  1.01† 
AI144586 PLEKHB1 evectin-1 -2.04 -1.43* 
AI044747 PPP1R14C protein phosphatase 1, regulatory (inhibitor) subunit 14c -1.58 -1.12* 
AI029941 PPP2R2D protein phosphatase 2, regulatory subunit B, delta isoform -1.53 -1.41* 
AA925328 RAB40B  Rab40b, member RAS oncogene family   -1.82 -1.41* 
AA946057 RAB7 Rab7, member RAS oncogene family  1.55  1.14* 
L07925 RALGDS ral guanine nucleotide dissociation stimulator  1.55 -1.04† 
AA944856 RAP1B Ras-related protein 1b  2.89  1.14† 
AI170661 RASA3 Ras p21 protein activator 3 -1.50  1.00* 
AA946457 RASGRP3 Ras, guanyl releasing protein 3 -2.07 -1.22* 
AI227769 RASSF4  Ras association (RalGDS/AF-6) domain family 4    1.59  4.27* 
AI010253 RGD1309362 similar to interferon-inducible GTPase    6.51  10.6* 
AA851185 SOCS2 suppressor of cytokine signaling 2  2.14  2.16* 
AA899068 TGFBR3 transforming growth factor, beta receptor 3  1.64 -1.09* 
AA850542 TRAF4 Tnf receptor associated factor 4  -2.03 -1.24* 
AI072698 TRAF4AF1 TRAF4 associated factor 1 -2.01 -2.08* 
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   Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI145007 TSPAN12 tetraspannin 12, transmembrane 4 superfamily member 12 -2.71 -1.55* 
     
Transcription Regulation    
AI171503 ARTS1 type 1 tumor necrosis factor receptor shedding aminopeptidase regulator  2.29  4.20* 
AI072945 CBX6  chromobox homolog 6   -1.51 -1.22* 
AI176486 CDKN2B cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) -1.58  1.03* 
AI169557 CDKN2C cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) -1.83 -1.31* 
AA893193 CHD2 chromodomain helicase DNA binding  protein 2    1.51  1.02
† 
AA891829 CIAO1  WD40 protein Ciao1    1.53  1.00† 
AI014091 CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2  1.40
†  1.54 
AI045762 CNOT6L CCR4-NOT transcription complex, subunit  6-like    1.57  1.12* 
AA944413 COPEB core promoter element binding protein  2.10  2.14* 
AI070020 CREB3L4 cAMP responsive element binding protein 3-like 4  2.36  1.19* 
AA946461 CREG  cellular repressor of E1A-stimulated genes    2.79  1.07* 
AI010116 CRSP6  cofactor required for Sp1 transcriptional activation, subunit 6    1.51  1.07* 
AI227592 CSEN calsenilin, presenilin binding protein, EF hand transcription factor -1.68  1.00* 
AI008205 DATF1 death associated transcription factor 1    2.17 -1.22* 
AA799481 EED  embryonic ectoderm development    1.75 -1.02† 
AA899415 ELF2 E74-like factor 2    2.34  1.30* 
AI101323 ETV5 ets variant gene 5  -2.35 -1.28* 
AI175569 FALZ fetal Alzheimer antigen  -2.11 -1.15* 
AI231201 FOXR1  forkhead box R1   -1.55 -1.06* 
AI178672 FUSIP1  FUS interacting protein  (serine-arginine rich) 1   -1.81 -1.27* 
AA892637 ELL3 elongation factor RNA polymerase II-like 3    1.80  1.31† 
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(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
X65948 GTF2B alpha initiation factor.; general transcription factor IIB  2.05  1.25
† 
U09551 HBP1 high mobility group box transcription factor 1  1.50 -1.39 
AI101116 HERC3 Hect domain and RLD 3   -1.58 -1.37* 
AI179857 HIP2  huntingtin interacting protein 2   -2.01 -1.20* 
X54250 HIVEP1 human immunodeficiency virus type I enhancer binding protein 1  1.62  1.36
† 
D37951 HIVEP2 human immunodeficiency virus type I enhancer binding protein 2  2.25  1.11
† 
AI179987 HMG17 high mobility group protein 17 -1.71 -2.18* 
AA996401 HMGB2  high mobility group box 2 -1.72 -1.39† 
AI072957 HMGB3 high mobility group box 3 -1.39† -2.03* 
AI178675 HMGN3 high mobility group nucleosomal binding domain 3 -2.12 -1.35* 
AI171983 HN1L HN1-like protein   -1.50 -1.15* 
AI178441 HNRPR heterogeneous nuclear ribonucleoprotein R -1.70 -1.67* 
AA925304 HNRPUL1  heterogeneous nuclear ribonucleoprotein U-like 1   -1.53 -1.10* 
AI102887 HOD homeobox only domain  1.53 -1.29* 
AI102739 HOD homeobox only domain  1.34† -2.14* 
AF000942 ID3 inhibitor of DNA binding 3  1.53  1.40† 
AA818860 IDB4 inhibitor of DNA binding 4  1.05†  2.05* 
AA819390 ING1  inhibitor of growth family, member 1   -1.59 -1.25* 
AI102643 ISGF3G interferon stimulated gene factor 3, gamma  2.53  3.42* 
AA799539 IVNS1ABP  influenza virus NS1A binding protein    1.14† -2.10 
AA858982 LMO4  LIM domain only 4   -1.10†  2.04* 
AI177103 MADH3 MAD homolog 3 -1.83 -1.07* 
AI231450 MEF2A myocyte enhancer factor 2C -1.51 -1.23* 
AI231313 MGC116373 similar to HR21spA -1.68 -1.27* 
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   Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI071279 MLL5  myeloid/lymphoid or mixed-lineage  leukemia 5   -1.63 -1.22* 
AI010147 MLLT1  myeloid/lymphoid or mixed lineage-leukemia translocation to 6   1.58  1.00* 
AI170291 MTPN myotrophin -1.71 -1.30* 
AI228667 MTPN myotrophin -1.63 -1.47* 
AI045608 NFIA nuclear factor I/A -1.59 -1.18* 
AI171842 NFIB nuclear factor I/B -2.36 -1.21* 
U14533 NR1H2 nuclear receptor subfamily 1, group H, member 2  1.76  1.14
† 
AA850038 NR2F2 nuclear receptor subfamily 2, group F, member 2  1.24
†  2.20* 
AF003926 NR2F6 nuclear receptor subfamily 2, group F, member 6  1.55  1.60
† 
AA998981 PEG3  paternally expressed 3   -1.71 -1.04* 
AI009219 PLEKHA5 pleckstrin homology domain containing, family A member 5  1.55  1.17* 
AA894282 PNRC2 proline-rich nuclear receptor coactivator 2  1.13† -1.52 
AA942959 PPP1R1B protein phosphatase 1, regulatory (inhibitor) subunit 1B -1.46 -3.21* 
AA924754 PRRX1 paired related homeobox 1 -1.53  1.00* 
AA851793 PURB pur-beta -2.42 -1.79* 
AI045231 RUNX1 runt related transcription factor 1  1.59  1.09* 
AI227638 SATB1  special AT-rich sequence binding protein 1   -1.97 -1.37* 
AA799614 SIRT2 sirtuin (silent mating type information regulation 2 homolog) 2   2.18 -1.35
† 
AA957591 SMARCA4 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily 
a, member 4 
-1.82 -1.23* 
AA957591 SMARCA4 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily 
a, member 4 
-1.71 -1.23* 
AI177058 SNAPC2  small nuclear RNA activating complex, polypeptide 2   -1.55 -1.08* 
U83883 SND1 staphylococcal nuclease domain containing 1  1.80  1.07† 
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(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AA900619 SNRPB similar to small nuclear ribonucleoprotein B  2.45 -1.07* 
AA963855 SOX11 SRY-box containing gene 11  1.66  1.71* 
AI137765 SOX4  SRY-box containing gene 4   -1.72 -1.09* 
AI073207 SOX6 SRY-box containing gene 6   -1.55 -1.03* 
AI070313 SP110 SP110 nuclear body protein    7.05  7.44* 
AI178187 SP140 SP140 nuclear body protein isoform 1  2.24  1.32* 
AA892553 STAT1 signal transducer and activator of  transcription 1  19.7  17.3 
AA799569 STAT2 signal transducer and activator of  transcription 2  7.77  5.03 
AI236828 STAT3 signal transducer and activator of  transcription 3  1.74  2.21* 
AI008865 STAT3 signal transducer and activator of  transcription 3  1.61  2.20* 
AI230912 TAF13  TAF13 RNA polymerase II, TATA box binding protein (Tbp)-associated factor   -1.52 -1.52* 
AI009780 TAF1A TATA box binding protein (Tbp)-associated factor, RNA polymerase I, A    2.28  3.55* 
AA964863 TAF4 Tbp-associated factor 4 -1.99 -2.26* 
AI231172 TCERG1 transcription elongation regulator 1  -1.55 -1.52* 
AI008415 TCF4 transcription factor 4 -1.79 -1.50* 
AA849929 TCF4 transcription factor 4 -1.52 -1.24* 
L25785 TGFB1I4 transforming growth factor beta 1 induced transcript 4  1.24
† -1.62 
AA850509 TRIP13 thyroid hormone receptor interactor 13 -2.01 -1.66* 
AA956638 UHRF1 ubiquitin-like, containing PHD and RING finger domains, 1 -1.79 -1.69* 
AA891717 USF1 upstream transcription factor 1  1.50  1.07† 
AA819367 VEZF1 vascular endothelial zinc finger 1   -1.58 -1.58* 
AI175794 XPO1 exportin 1, CRM1 homolog  -1.62 -1.58* 
AA924380 ZFP131  zinc finger protein 131   -1.55  1.01* 
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(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI010795 ZFP276  zinc finger protein 276    1.52  1.03* 
AI175753 ZFP307  zinc finger protein 307   -1.58  1.03* 
AI231074 ZNF541  zinc finger protein 541   -1.28 -2.29* 
     
Translation Initiation    
L29281 EIF2A eukaryotic translation initiation factor 2A  4.01  3.10 
AI031019 EIF2B1 eukaryotic translation initiation factor 2B, subunit 1 alpha  1.15
† -1.53 
AI031019 EIF2B1 eukaryotic translation initiation factor 2B, subunit 1 alpha  1.36
† -1.67 
AI175938 EIF2C1  eukaryotic translation initiation factor 2C, 1   -1.93 -1.13* 
AI172206 EIF4B  eukaryotic translation initiation factor 4B   -1.61 -1.28* 
AI178816 EIF4E eukaryotic translation initiation factor 4E -1.89 -1.37* 
AI101338 EIF4E3 eukaryotic translation initiation factor 4E member 3  1.11
†  2.32* 
AA926205 EIF4EBP2  eukaryotic translation initiation factor 4E binding protein 2   -2.36 -1.12* 
     
Transport    
AA848829 ABCA1 ATP-binding cassette, sub-family A member 1  2.53  1.36* 
M60322 ALDR1 aldose reductase   2.31  1.43† 
M60322 ALDR1 aldose reductase   1.56  1.30† 
U75917 AP2S1 adaptor-related protein complex 2, sigma 1 subunit  1.77  1.04
† 
U75917 AP2S1 adaptor-related protein complex 2, sigma 1 subunit  1.86 -1.02
† 
AI235942 AQP4 aquaporin 4 -1.63 -1.43* 
AA850290 ATP10D ATPase, class V, type 10D   4.17  1.10* 
AI176376 ATP1B1 ATPase Na+/K+ transporting beta 1  1.33 -2.34* 
AA817814 ATP1B2 ATPase, Na+/K+ transporting, beta 2  -1.61  1.08* 
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(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
Y12635 ATP6B2 ATPase, H+ transporting, lysosomal (vacuolar proton pump), beta 56/58 kDa, isoform 2  1.88  1.18
† 
AI013039 ATP6K vacuolar proton-ATPase subunit M9.2  1.88  1.44* 
AI172204 BCAP29 B-cell receptor-associated protein 29  -1.79 -1.09* 
AI175027 BET1 blocked early in transport 1 homolog  -1.59 -1.24* 
J05122 BZRP benzodiazepin receptor  1.66  1.31† 
M86621 CACNA2D1 calcium channel, voltage-dependent, alpha2/delta subunit 1 -1.53 -1.20
† 
AA956900 CBR3 NADPH-dependent carbonyl reductase, carbonyl reductase 3 -1.57  1.00* 
X66494 CHOT1 choline transporter -1.12† -2.15 
AI012221 CLIC1 chloride intracellular channel 1  1.43  2.72* 
AA851229 CLIC2 chloride intracellular channel 2   1.90  1.47* 
AI168975 CNDP2 cytosolic nonspecific dipeptidase (glutamate carboxypeptidase-like protein 1)   1.56  1.13* 
L33869 CP ceruloplasmin  2.69  1.98† 
AI010470 CP ceruloplasmin  2.36  5.65* 
AF007107 CYB5 soluble cytochrome b5  1.61 -1.19† 
D00568 CYP11B2 cytochrome P450, subfamily 11B,  polypeptide 2  1.60 -1.07
† 
J02852 CYP2A3A cytochrome P450, subfamily IIA   1.72 -1.08† 
AA945571 CYP2C6 cytochrome P450, subfamily IIC6  1.70 -1.09† 
D85035 DPYD dihydropyrimidine dehydrogenase  1.68  2.03† 
D63772 EAAC1 neuronal high affinity glutamate transporter; solute carrier family 1, member 1  1.16
† -1.75 
AA957585 EHD3 EH-domain containing 3  1.71  1.29* 
AI176596 ENTH enthoprotin -1.50 -1.17* 
AI059566 EPB4.1L4B  erythrocyte protein band 4.1-like 4b   -1.54  1.05* 
AI009344 FXYD1 FXYD domain-containing ion transport regulator 1  1.13  4.02* 
U38379 GGH gamma-glutamyl hydrolase precursor -1.08† -1.53 
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(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
X54656 GLURK3 glutamate receptor, ionotropic, AMPA3  (alpha 3) -1.76
† -1.72 
AA924630 GRHPR glyoxylate reductase/hydroxypyruvate reductase  -1.65 -1.02* 
D16478 HADHA 
mitochondrial long-chain enoyl-CoA 
hydratase/3-hydroxyacyl-CoA dehydrogenase 
alpha-subunit of mitochondrial trifunctional 
protein 
 1.61  1.26† 
AA851497 HBA-A1 hemoglobin alpha, adult chain 1   1.64  1.04* 
AA899367 HSD17B2 hydroxysteroid dehydrogenase 17 beta, type 2 -1.76  1.01* 
AI236145 HSD17B7 hydroxysteroid dehydrogenase 17 beta, type 7  1.30 -1.52 
AA891785 IDH2 isocitrate dehydrogenase 2 (NADP+), mitochondrial   1.68  1.12
† 
AI011824 IDH3B NAD+-specific isocitrate dehydrogenase  b subunit  1.53  1.01* 
AI111872 IMP9  importin 9   -1.81 -1.74* 
AA848315 IMPDH2 inosine monophosphate dehydrogenase 2 -1.57  1.04* 
AA849817 KCNAB1 potassium voltage-gated channel, shaker-related subfamily, beta member 1 -1.85 -1.69* 
AI007861 KCNAB3 potassium voltage gated channel, shaker related subfamily, beta member 3  1.70 -1.02* 
AA818016 KIF20A kinesin family member 20A , rabkinesin-6  -3.32 -2.24* 
AI231497 KPNA2 karyopherin (importin) alpha 2 -1.87 -1.39* 
AA851873 KPNB1 karyopherin (importin) beta 1 -1.52 -1.01* 
AA945166 MCFD2 multiple coagulation factor deficiency 2  1.62  1.06* 
AI009678 MYRIP myosin VIIA and Rab interacting protein -1.57  1.01* 
AA875268 NDUFS7 NADH dehydrogenase (ubiquinone) Fe-S protein 7  1.87  1.05
† 
AA799609 NUP98 nucleoporin 98  1.62 -1.18 
AA901035 OSBPL6  oxysterol binding protein-like 6   -1.52  1.05* 
U47031 P2RX4 purinergic receptor P2X, ligand-gated ion channel, 4  3.01  1.49
† 
X02918 P4HB prolyl 4-hydroxylase, beta polypeptide  2.04 -1.06† 
AI231465 PDK3 pyruvate dehydrogenase kinase, isoenzyme 3  -1.72 -1.48* 
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(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AA946250 PR voltage-dependent calcium channel gamma subunit-like protein  3.15  1.08* 
AI171526 PRICKLE1 prickle-like 1  -1.09 -2.05* 
AA799616 PTTG1IP  pituitary tumor-transforming 1 interacting protein    1.85 -1.09
† 
D79221 RA410 vesicle transport-related protein  1.73  1.19† 
AI179939 RAB2 Rab2, RAS oncogene family-like  6.67  9.12* 
M83678 RAB13 Rab13   1.95  2.84 
AI007905 RAB6B Rab6b, member RAS oncogene family   -1.56 -1.61* 
AA866460 RNP24 coated vesicle membrane protein  1.80 -1.23† 
AA956992 SCAMP3 secretory carrier membrane protein 3 -1.62  1.02* 
AI146177 SFXN5 sideroflexin 5 -1.66  1.08* 
AI104173 SLC11A1 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1   2.71 -1.05* 
AA892390 SLC11A2 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2  1.18
† -1.57 
AA925961 SLC12A2 solute carrier family 12, member -1.43 -2.28* 
U75395 SLC12A4  solute carrier family 12, member 4  2.05  1.49† 
AA799691 SLC12A7 solute carrier family 12 (potassium/chloride transporters), member 7  1.76  1.84
† 
AB000280 SLC15A4 peptide/histidine transporter  1.93 -1.56 
AI112459 SLC21A14 solute carrier family 21 (organic anion transporter), member 14 -1.99 -1.76* 
AA998949 SLC24A6   solute carrier family 24 (sodium/ potassium/calcium exchanger), member 6  2.84  1.43* 
AA925662 SLC32A2 solute carrier family 31, member 2    1.83  1.30* 
AA957643 SLC40A1 solute carrier family 39 (iron-regulated transporter), member 1 -1.08
†  1.56* 
AI229664 SLC40A1 solute carrier family 39 (iron-regulated transporter), member 1 -1.03
†  1.62* 
AA943700 SLC6A11 solute carrier family 6 (neurotransmitter transporter, GABA), member 11  1.51 -1.18* 
AA899235 SLC7A8 solute carrier family 8 (cationic amino acid transporter, Y+ system) member 7  1.76 -1.59* 
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(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AA999064 SMOX spermine oxidase   1.59 -1.02* 
AA892759 SNAP23 synaptosomal-associated protein 23  1.63 -1.02† 
AA943153 SNAP25 synaptosomal-associated protein 25  1.45† -3.73* 
AI030877 SNX10 sorting nexin 10    1.69  2.41* 
L20821 STX4A syntaxin 4   2.39  1.44† 
AI102079 STXBP1 syntaxin binding protein 1  1.53  1.49 
AA859088 SYT4 synaptotagmin 4 -1.09† -2.29* 
AI228125 SYT4 synaptotagmin 4  1.05† -2.09* 
AI237645 TFRC transferrin receptor -1.40† -2.27* 
AI146033 TIMM9 translocase of inner mitochondrial membrane 9 homolog  -1.56 -1.24* 
AI013157 TMED3 transmembrane emp24 domain containing 3   1.66  1.10* 
AI008536 TRAPPC4 trafficking protein particle complex 4  1.74  1.03* 
AA899079 TTYH1  tweety homolog 1     1.01† -1.50* 
AI227624 TTYH1  tweety homolog 1    -2.09 -1.51* 
AI012433 UA20 ATPase, class VI, type 11A    1.75 -1.26* 
AI007981 UCRC ubiquinol-cytochrome c reductase complex 7.2kDa protein isoform a   1.54 -1.12* 
AB013732 UGDH UDP-glucose dehydrogeanse  1.09† -1.57 
AI234533 UNC93B Unc93 homolog B   2.07  1.09* 
AI010239 UQCRC1 ubiquinol-cytochrome c reductase core  protein 1   1.75  1.00* 
AF054826 VAMP5 vesicle-associated membrane protein 5  1.79  3.43 
AA848348 VDAC1 voltage-dependent anion channel 1  1.83 -1.05* 
AI045409 XKR5 XK-related protein 5  -2.13 -1.78* 
AI233182 XPOT exportin, tRNA -1.64 -1.31* 
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Table 2.12  Differential expression of genes of unknown function.  Replicate RNA samples 
from each treatment group were hybridized to separate arrays.  The average of replicate 
normalized expression estimates (not shown) for each sample group was used to calculate the 
fold change difference in expression for each gene in the table.  Positive fold change values 
indicate an increase, and negative values indicate a decrease in gene expression in the IFNγ-
treated groups.  The dagger indicates the Student’s t-test p-value was greater than 0.1; the 
asterisk indicates there was one sample for each treatment group. 
 
 
  
 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Gene Symbol Gene Name Immature Mature 
AI136833 DUFD1 DUF729 domain containing 1   -2.49 -2.06* 
AI030494 KCTD2 potassium channel tetramerisation domain containing protein 2 -2.12 -1.19* 
AI237713 NS5ATP9 NS5A (hepatitis C virus) transactivated protein 9  -2.10 -1.92* 
AI137337 RGD1308877 similar to CGI-09 protein  -2.05 -1.25* 
AI012208 CAV caveolin -2.01 -1.47* 
AI029608 IBRDC3  IBR domain containing 3    4.93  4.27* 
AA850577 NCOR1 nuclear receptor co-repressor 1  2.55 -1.04* 
AI009752 LOC367314  similar to FLI-LRR associated protein-1  2.44  1.20* 
AI030755 FBXW17 F-box and WD-40 domain protein 17   2.36  3.08* 
AA850112 SURF4 surfeit protein 4  2.30 -1.05* 
AI010974 COMMD4  COMM domain containing 4    2.22  1.04* 
AI030921 LOC501065 similar to LNV  2.22  1.53* 
AI059844 FLN29  FLN29 gene product  2.09  1.84* 
AI058667 LOC289181 similar to IQ motif and WD repeats 1  2.00 -1.27* 
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Table 2.13  Differential Expression of ESTs.  ESTs were unidentifiable by BLAST 
algorithm against the Genbank database.  Replicate RNA samples from each treatment group 
were hybridized to separate arrays.  The average of replicate normalized expression estimates 
(not shown) for each sample group was used to calculate the fold change difference in 
expression for each gene in the table.  Positive fold change values indicate an increase, and 
negative values indicate a decrease in gene expression in the IFNγ-treated groups.  The 
dagger indicates the Student’s t-test p-value was greater than 0.1; the asterisk indicates there 
was one sample for each treatment group. 
 
 
 
 
Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
 
 
Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Immature Mature  Accession No. Immature Mature 
AA925743 -3.65 -1.51*  AI029480 2.24 1.74* 
AA925824 -3.29 -1.44*  AI058761 2.24 -1.09* 
AA849714 -3.18 -1.62*  AI233121 2.24 1.63* 
AI175283 -2.92 -1.24*  AI059875 2.23 -1.11* 
AI071227 -2.61 -1.63*  AI059735 2.19 -1.05* 
AI101818 -2.48 -1.20*  AI010719 2.19 -1.05* 
AI144771 -2.44 -2.03*  AA997460 2.18 -2.15* 
AI171307 -2.34 -1.21*  AA901178 2.12 1.02* 
AI104521 -2.33 -1.23*  AA800224 2.09 1.55 
AA945100 -2.28 1.02*  AI007721 2.09 -1.18* 
AI111551 -2.26 -1.72*  AI233164 2.09 -1.49* 
AA957836 -2.22 -1.34*  AI011183 2.08 1.24* 
AI136871 -2.21 -1.53*  AI045042 2.08 1.07* 
AI175590 -2.19 -1.52*  AA924764 2.07 2.82* 
AI144824 -2.19 -1.08*  AI043759 2.06 2.10* 
AI171367 -2.17 -1.36*  AI059740 2.05 -1.06* 
AI176490 -2.15 -1.27*  AI227669 2.03 2.68* 
AA946046 -2.14 -1.04*  AA800199 2.00 1.07† 
AI230370 -2.09 -1.75*  AI070107 1.95 2.96* 
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Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
 
 
Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Immature Mature  Accession No. Immature Mature 
AI229198 -2.04 -1.82*  AA998677 1.92 -2.21* 
AI176172 -2.03 -1.42*  AI009713 1.90 2.25* 
AI168940 -2.02 -1.67*  AA944289 1.87 2.13* 
AI008246 -2.01 -1.35*  AI029829 1.70 2.12* 
AI112043 -2.00 -1.58*  R46931 1.70 2.24* 
AA964426 -1.94 -2.14*  AA851040 1.70 2.54* 
AI043985 -1.92 2.06*  AA801255 1.63 -1.12* 
AI232128 -1.73 -2.31*  AI232924 1.62 2.94* 
AA997109 -1.73 -1.55*  AA964627 1.62 8.44* 
AI234914 -1.65 -2.15*  AI010179 1.51 2.19* 
AI011639 -1.63 -1.14*  AA925101 -1.18 -4.98* 
AA818158 -1.62 -2.98*  AA965107 1.20† -3.91* 
AI071973 -1.60 -2.11*  AI043990 -1.17† -3.35* 
AI070585 -1.57 -1.95*  AA925994 1.28 -3.07* 
AI171800 -1.50 -2.01*  AI070905 -1.37 -3.03* 
AA997015 41.4 49.7*  AI101500 -1.05† -2.89* 
AI044983 26.3 29.7*  AI045330 1.07† -2.76* 
AA819788 16.1 31.2*  AI101016 1.22† -2.64* 
AA998964 12.5 12.1*  AA998650 1.13 -2.60* 
AA899109 11.0 5.97*  AI102037 -1.49 -2.53* 
AI058707 8.40 1.46*  AI045116 -1.45 -2.49* 
AA818937 7.56 18.6*  AA998732 -1.20 -2.49* 
AA891220 7.47 5.00  AI071467 -1.04 -2.46* 
AA924350 5.34 6.07*  AA997945 1.08 -2.46* 
AI071166 5.32 3.79*  AI172541 -1.03† -2.39* 
AI060183 4.93 -1.02*  AI008647 1.05 -2.35* 
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Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
 
 
Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Immature Mature  Accession No. Immature Mature 
AA998576 4.92 6.72  AI235186 1.09† -2.26* 
AI012648 4.81 1.36*  AI059568 -1.03† -2.22* 
AI009770 4.50 3.54*  AI070118 -1.21† -2.16* 
AI234162 4.44 4.27*  AI071504 -1.19† -2.16* 
AI231805 4.10 1.67*  AA963228 -1.24 -2.16* 
AI059652 3.96 -1.10*  AI069939 1.27 -2.15* 
AI112362 3.95 5.09*  AI101009 -1.08† -2.11* 
AI012552 3.78 4.16*  AA944926 -1.38 -2.11* 
AA858505 3.77 5.41*  AI112807 1.32† -2.11* 
AA998169 3.58 -1.07*  AI175668 -1.18† -2.10* 
AA799804 3.48 -1.07†  AI233181 1.27† -2.08* 
AA963279 3.32 10.2*  AI009142 1.30 5.49* 
AI030026 3.29 2.64*  AI029264 1.30 3.90* 
AA849519 3.08 -1.14*  AI137286 1.17 3.89* 
AA851065 3.06 2.97*  AA944162 -1.08 3.46* 
H31418 2.85 1.42†  AI072476 -1.02† 3.44* 
AA924573 2.81 2.72*  AA818801 1.43 3.39* 
AI138040 2.66 2.28*  AA997849 1.46 3.11* 
AI029790 2.65 1.52*  AI071755 2.13† 3.08* 
AA849042 2.61 1.25*  AA850916 -1.08 2.92* 
AI059078 2.58 2.45*  AA925256 -1.02 2.77* 
AA851364 2.47 1.11*  AA924660 1.05† 2.64* 
AA849720 2.42 1.27*  AI043958 1.44 2.62* 
AA892284 2.40 -1.03†  AI175045 -1.04 2.55* 
AI176136 2.33 -1.82*  AA956304 1.35 2.51* 
AA801051 2.33 1.18*  AA926036 1.25 2.50* 
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Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
 
 
Fold Change 
(IFN-γ-tx OLs / Non-tx OLs) 
Accession No. Immature Mature  Accession No. Immature Mature 
AA893869 2.33 1.58  AI059241 1.30 2.49* 
AI177415 2.33 1.76*  AI102833 -1.35† 2.48* 
AA998356 2.31 1.64*  AI236053 1.10† 2.25* 
AA817708 2.31 1.03*  AI008019 -1.10 2.20* 
AI045343 2.30 -1.12*  AA944838 -1.32 2.17* 
AA851361 2.30 1.27*  AA925074 1.31 2.13* 
AA850686 2.29 -1.13*  AA963192 1.43 2.07* 
AI059095 2.28 4.23*  AI012475 -1.02 2.06* 
AI176599 2.25 1.04*  AI058995 1.44 2.04* 
AI013657 2.25 3.01*  AI144865 -1.05† 2.02* 
AI045577 2.25 -1.09*     
 
 
 
 
 
 
CHAPTER THREE 
EFFECTS OF INTERFERON-GAMMA ON DEMYELINATION AND 
REMYELINATION IN CUPRIZONE-TREATED MICE 
 
INTRODUCTION 
    Interferon-gamma (IFN-γ) is a pleiotropic cytokine secreted by activated T lymphocytes 
and natural killer cells with receptors on all cell types except erythrocytes.  This cytokine is 
an important modulator of the immune system and has been implicated in playing a 
deleterious role in immune-mediated diseases of the central nervous system (CNS) including 
multiple sclerosis (MS) in humans and experimental autoimmune encephalomyelitis (EAE) 
in rodents (reviewed in Popko et al., 1997; Baerwald et al., 1999; reviewed in Steinman, 
2001).  IFN-γ is not normally present in the CNS; however, it has been found in the cerebral 
spinal fluid and demyelinating lesions of MS patients (Panitch, 1992; Miller et al., 1995; 
reviewed in Roland and McFarland, 1995).  Furthermore, administration of the cytokine to 
MS patients exacerbated the disease (Panitch et al., 1987), and IFN-γ antibodies slowed its 
progression (Skurkovich et al., 2001).    
    In some types of EAE and in cuprizone-induced demyelination, there is a relapsing-
remitting cycle whereby demyelination is followed by periods of recovery (Franklin, 2002; 
Bruck et al., 2003).  A similar situation occurs in 85% of MS cases with exacerbations lasting 
several weeks followed by sometimes long periods of partial recovery.  Over time, the 
number of partially remyelinated and irreparable lesions increases to the point that patients 
enter a secondary progressive phase of the disease (Trapp et al., 1999). 
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    MS is the most common demyelinating disease of the CNS, affecting approximately 2.5 
million people world-wide, most often in the second to forth decade of life and with Northern 
American/Northern European and female bias (Compston and Coles, 2002; reviewed in 
Noseworthy, 1999).  The etiology and contributing factors of MS remain elusive, in part due 
to the extreme variability of symptoms and rate of progression, but it is now widely accepted 
that MS is an autoimmune inflammatory disorder with both environmental and genetic 
elements influencing its course (Raine, 1994; Noseworthy, 1999).   
    During exacerbations, demyelinated axons are unable to properly propagate electrical 
signals due to the loss of demarcated nodes of Ranvier, the short spaces between myelin 
sheath internodes at which sodium channels cluster and provide the depolarization/ 
repolarization necessary for rapid, salutatory conduction.  In periods of remission, 
oligodendrocyte progenitor cells (OPCs) migrate to lesion sites where they differentiate into 
mature oligodendrocytes (OLs) and extend membrane processes, which become sheaths of 
myelin that wrap bare axons and nearly fully restore signal conduction (Mason et al., 2000; 
Matsushima and Morell, 2001).  A single OL can extend up to ~50 myelin processes, which 
requires enormous amounts of plasma membrane lipid and protein synthesis (Smith, 1996). 
    While T cells and macrophages infiltrate the CNS and secrete cytokines in EAE, 
cuprizone-induced demyelination is largely non-immune-mediated, making it an excellent 
model for studying the effect of a single cytokine on demyelination and remyelination.  In 
this study, we have combined the cuprizone model of demyelination/remyelination 
(Matsushima and Morell, 2001) with a transgenic line of mice in which astrocytes, under the 
tetracycline-inducible system, ectopically express and secrete IFN-γ in the CNS (Lin et al., 
2004).  This system allows for both spatial and temporal control of IFN-γ expression.    
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MATERIALS AND METHODS 
 
Transgenic Animals and Cuprizone Treatment (Figures 3.1-3.3) 
    Two single transgenic lines of mice on the C57BL/6 background were exploited to create a 
double transgenic line expressing IFN-γ as previously described (Lin et al., 2004; Lin et al., 
2006).  Briefly, line 110 GFAP/tTA was crossed to line 184 TRE/IFN-γ to produce double 
transgenic GFAP/tTA x TRE/IFN-γ mice.  These animals express the tetracycline 
transactivator protein (tTA), which binds to a modified CMV/TRE promoter containing tTA 
binding sites to drive IFN-γ expression.  The transgene was suppressed from conception by 
adding 0.05mg/ml of doxycycline (dox) to the drinking water until either 6- or 8wks of age.  
Cuprizone treatment of male double transgenic mice receiving dox began at 6wks of age by 
incorporating 0.2% cuprizone (Sigma-Aldrich, St. Louis, MO) into milled chow.  Animals 
were returned to normal chow after 6wks of treatment (12wks of age).   
    All animal procedures were conducted in the laboratory of Brian Popko at the University 
of Chicago in complete compliance with the NIH Guide for the Care and Use of Laboratory 
Animals and were approved by the Institutional Animal Care and Use Committee of The 
University of Chicago. 
 
RNA Isolation, Amplification, and Microarray Hybridization 
    RNA was isolated according to previously-described methods (Lin et al., 2006).  Briefly, 
mice were perfused with ice-cold phosphate-buffered saline (PBS), and RNA was isolated 
from the corpus collosum (Jurevics et al., 2002) using Trizol Reagent (Invitrogen, Carlsbad, 
CA) followed by DNAseI (Invitrogen, Carlsbad, CA) treatment to eliminate genomic DNA.   
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    100ng of total RNA from each corpus collosum was used to synthesize cDNA according to 
the GeneChip® Eukaryotic Small Sample Target Labeling Protocol (Affymetrix).  Two 
rounds of amplification were conducted using T7-(dT)24 primer (Life Technologies).  
Biotinylated cRNA was then generated using the BioArray High Yield RNA Transcription 
Kit (Life Technologies), then subsequently fragmented in 5X fragmentation buffer (200mM 
Tris-acetate pH 8.1, 500mM KOAc and 150mM MgOAc) at 94°C for 35 min. 15µg of 
fragmented cRNA was added to hybridization cocktail (50pM control oligonucleotide [B2, 
BioB, BioC, BioD and Cre], 0.01mg/ml herring sperm DNA, 0.5mg/ml acetylated BSA, 
100mM MES, 1M [Na+], 20mM EDTA and 0.01% Tween 20).  10µg of cRNA in cocktail 
was hybridized to each array for 16 hours at 45°C in the GeneChip® Hybridization Oven 640 
(Affymetrix).  Microarrays were then washed, stained with R-phycoerythrin streptavidin in 
the GeneChip® Fluidics Station 400 (Affymetrix), and scanned in the Hewlett Packard 
GeneChip® Scanner 3000 7G 4C using GeneChip® Operating Software (Affymetrix).  cRNA 
quality was assessed by examining the intensity ratio of 5’:3’ probe pair binding of control 
genes. 
 
Microarray Analysis 
    The mouse genome MOE 430 2.0 GeneChip® (Affymetrix) containing probe sets 
representing over 45,000 genes and expressed sequence tags (ESTs) was used for all 
hybridization reactions, and three independent hybridizations were performed for each 
treatment group.  Hybridization intensities were summarized with the Robust MultiArray 
Analysis (RMA) algorithm (Irizarry et al., 2003) to generate an expression estimate for each 
probe set (gene).  Expression estimates were normalized using GeneSpring® software 
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(Agilent Technologies) as follows:  1) negative expression estimates were floored to 0.01, 2) 
the top 90% of expression estimates was used to calculate the 50th percentile for each array, 
and 3) expression estimates were normalized to the 50th percentile value of the corresponding 
array.  Normalized expression estimates were averaged across replicate samples and 
significance of difference between treatment groups was determined by Student’s t-test (p-
value<0.1).  We report here differential mRNA expression as the fold change between IFN-γ-
expressing and non-expressing sample groups.  Gene function information and probe set 
annotations were obtained from GeneSpring GX (Agilent Technologies), NetaffxTM 
(Affymetrix; www.affymetrix.com), the National Center for Biotechnology Information 
(NCBI; www.nbci.nlm.nih.gov) and literature review.  ESTs were identified, when possible, 
by BLAST search of the nucleotide database (www.ncbi.nlm.nih.gov/BLAST).  Pathway 
information was obtained from the Gene Map Annotator and Pathway Profiler (GenMAPP; 
Gladstone Institutes, University of California at San Francisco; www.genmapp.org), 
PathArt© (Jubilent Biosys), NetAffxTM (Affymetrix), and primary literature. 
 
RESULTS AND DISCUSSION 
 
    In order to examine the effects of a single cytokine, IFN-γ, on demyelination and 
remyelination, we used the tetracycline-inducible system to ectopically express IFN-γ in 
astrocytes at two different time points (Lin et al., 2004) and used the neurotoxicant cuprizone 
(bis-cyclohexanone oxaldihydrazone) to induce demyelination (Matsushima and Morell, 
2001).  The tetracycline transactivator protein (tTA) was under the transcriptional control of 
the astrocyte-specific glial fibrillary acidic protein (GFAP) promoter in one line of mice 
(110, GFAP/tTA), and in a second line, IFN-γ was under the control of the cytomegalovirus 
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(CMV) promoter than had been modified to contain tetracycline response element (TRE) 
sequences (184, TRE/IFN-γ).  These two lines were crossed to produce double transgenic 
animals (GFAP/tTA x TRE/IFN-γ) in which the tTA molecule binds the TRE sites on the 
CMV promoter allowing transcription of IFN-γ (Fig. 3.1).  Doxycycline (dox) is a 
tetracycline analog that binds tTA, preventing it from attaching to the CMV/TRE promoter, 
which effectively suppresses IFN-γ expression (Lin et al, 2004; Lin et al., 2006).  Cuprizone 
was incorporated at 0.2% into milled chow beginning at 6wks of age to induce demyelination 
in male double transgenic animals receiving dox.   
    There are considerable data that suggest IFN-γ both contributes to and protects against 
EAE and oligodendrocyte survival.  Given the controversial nature of this cytokine, IFN-γ 
was induced at two different time points to determine whether the timing of IFN-γ induction 
influences its effect on demyelination and/or remyelination.  One control group and two 
treatment groups were created, and the corpus collosa were harvested at either 11wks when 
demyelination was at maximum, or at 14wks when active remyelination was robust (Lin et 
al., 2006).  In all three groups, animals were given dox from conception, and cuprizone 
treatment began at 6wks of age and ended at 12wks of age.  In the control group, the animals 
remained on dox throughout the entire experiment.  In the first treatment group, dox was 
removed at the same time cuprizone treatment began (6wks of age) resulting in significant 
IFN-γ protein levels approximately two weeks later when demyelination was evident (Lin et 
al., 2004, 2005, 2006).  In the second treatment group, dox was removed two weeks after the 
initiation of cuprizone treatment (8wks of age), and measurable IFN-γ levels again occurred 
approximately two weeks later, when demyelination was at maximum.  Table 3.1 describes 
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the samples and comparisons used in this experiment, and the sample abbreviations in the 
table will be used throughout this paper.   
 
Table 3.1  Description of Samples, Abbreviations, and Expression Comparisons. 
 
Sample 
Abbreviation Sample Description 
Fold Change 
Comparison 
11wk-C Corpus collosum harvested at 11wks from control group. -------------- 
11wk-E Corpus collosum harvested at 11wks; IFN-γ induced at 6wks of age. 11wk-E / 11wk-C 
11wk-L Corpus collosum harvested at 11wks; IFN-γ induced at 8wks of age. 11wk-L / 11wk-C 
14wk-C Corpus collosum harvested at 14wks from control group. -------------- 
14wk-E Corpus collosum harvested at 14wks; IFN-γ induced at 6wks of age. 14wk-E / 14wk-C 
14wk-L Corpus collosum harvested at 14wks; IFN-γ induced at 8wks of age. 14wk-L / 14wk-C 
 
 
    Quantitative expression of 44,998 genes and ESTs plus 65 control genes from each of the 
sample groups described above was measured on MOE 430 2.0 GeneChips® (Affymetrix).   
We found 552 genes of interest based on significant difference (+/- 1.5-fold and Student’s t-
test p-value<0.1).  A statistical cutoff of p<0.1 was selected because of the natural variability 
that exists between animals, particularly for robustly expressed genes.  Using a lower p-value 
cutoff would likely result in too numerous false negatives.  Of the 552 significantly changing 
genes, 7 (1.2%) were upregulated and 117 (21%) were downregulated in the 11wk samples.  
At 14wks, 311 (56%) were upregulated and 124 (22%) were downregulated.   
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    The hybridization cocktail contained poly-A (Trp, Thr, Phe, Lys, and Dap) and 
hybridization (BioB, BioC, BioD, and Cre) control genes.  The ratios of 5’:3’ probe pair 
binding for the poly-A controls ranged from 1:1 to 1:1.8, indicating that the RNA was of 
excellent quality.  Expression estimates of the hybridization controls were also normal, 
demonstrating that the hybridization reactions worked properly.    
 
Differential Expression of Genes Involved in Myelin Formation  
(Figure 3.4; Table 3.2) 
 
    In 11-wk-old non-IFN-γ-expressing mice, the corpus collosum was severely demyelinated 
after 5 weeks of cuprizone treatment, and there were significantly fewer CC1+ mature 
oligodendrocytes than in non-treated mice (Lin et al., 2006).  At 14wks, after 2 weeks of 
recovery in the absence of cuprizone, there was considerable evidence of remyelination as 
measured by MBP immunostaining and EM analysis of remyelinated axons.  At 14wk-E, 
there was less remyelination (Lin et al., 2006); however, at 14wk-L remyelination was 
slightly enhanced (Lin and Popko, unpublished data).  There was no change in myelin gene 
expression at either 11wk-E or 11wk-L, but QK was upregulated at 14wk-E and TRFR, 
MAL, MBP, and QK were upregulated at 14wk-L.   
    The transferrin receptor (TRFR) has a high affinity for iron-bound transferrin (hTf) and 
administration of hTf has been shown to increase the rate of differentiation and myelination 
in cultured OLs (Paez et al., 2004; Garcia et al., 2003, 2004; Marta et al., 2003; Moos and 
Morgan 2000) as well as increase transcription of MBP, CNP, and several microtubule and 
actin genes (Marta et al., 2002).  Moreover, these actions are enhanced by IGF-1 (Espinosa-
Jeffrey et al., 2002).  In controls, TRFR was expressed at high levels (> 8 times the average 
expression on the array) and increased by 50% at 14wk-L.  Following a cuprizone-induced 
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demyelinating insult, OPCs repopulate the corpus collosum and differentiate into mature, 
myelinating OLs (Matsushima and Morell, 2001; Mason et al., 2000).  In the non-IFN-γ-
expressing animals, CC1+ oligodendrocytes began appearing in the corpus collosum after 
6wks of cuprizone treatment, and 2 weeks later their numbers had increased more than 5-fold 
(Lin et al., 2006; Lin and Popko, unpublished data).  At 14wk-E, however, there were 
significantly fewer CC1+ cells and more OPCs than at either 14wk-C or 14wk-L (Lin et al., 
2006; Lin and Popko, unpublished data) .  Perhaps, therefore, the upregulation of TRFR at 
14wk-L is a reflection of an increased number of mature, myelinating OLs, and thus a higher 
demand for iron. 
    Myelin and lymphocyte protein (MAL) is a component of myelin rafts and is found in the 
non-compact paranode regions of myelin where it is involved in maintaining proper axo-
paranode adhesion (Schaeren-Wiemers et al., 2004; Erne et al., 2002).  Myelin basic protein 
(MBP) is also a structural component of myelin, important for the stabilization of compact 
lamellar domains and for forming the intraperiod- and major dense lines.  The observed 
upregulation of MAL and MBP at 14wk-L may be indicative of increased paranode adhesion 
and myelin wrapping by mature OLs.   
    Quaking (QK) is an RNA-binding protein that regulates MAG splicing and stabilizes MBP 
mRNA (Wu et al., 2002; Lu et al., 2004).  In the control groups, QK expression was twice as 
robust during demyelination (11wk-C) than remyelination (14wk-C).  QK expression did not 
change in the presence of IFN-γ at 11wks, but increased more than 2-fold at 14wk-E and 
more then 3-fold at 14wk-L, further evidence for an effort to maintain myelin message levels 
during remyelination, particularly when IFN-γ is induced later.   
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    Several myelin-related genes, including MOBP, MAG, CNP, MOG, and PLP, did not 
show a difference in expression between the control and IFN-γ-expressing groups, but did 
show higher expression at 14wks than 11wks, which is consistent with a larger population of 
mature, myelinating OLs during the recovery phase.  Taken together, these data suggest that 
IFN-γ may promote myelin gene expression in remyelinating OLs, especially when induced 
at the peak of the demyelinating insult.   
 
Differential Expression of Genes Involved in Cholesterol and Lipid Biosynthesis and 
Metabolism  
(Figures 3.5 and 3.6; Table 3.3) 
 
    Cholesterol is synthesized locally in the brain and constitutes approximately 30% of the 
total lipid in myelin (Morell, 1996).  Cholesterol and fatty acid synthesis do not always 
correlate with the rate of myelination (Muse et al., 2001); however, they are necessary for 
generating plasma membrane and myelin sheath.  Few cholesterol and lipid synthesis genes 
were significantly differentially regulated.  At 11wk-E, SQLE, SC4MOL, HSD17B7 and 
VLDLR were moderately downregulated, but did not show significant difference in 
regulation at 11wk-L.  At 14wks there was a mixed response in both IFN-γ-expressing 
groups.  FDFT1, an enzyme involved in cholesterol synthesis, was modestly downregulated 
at 14wk-E and 14wk-L.  Other genes involved in fatty acid metabolism, peroxisomal 
organization and steroid synthesis were both up- and downregulated to some degree.  The 
most significant difference was a decrease in the peroxisomal biogenesis factor PEX6 
message at both 14wk-E and 14wk-L. 
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Differential Expression of Genes Involved in the Immune Response 
(Figures 3.7 and 3.8; Table 3.4) 
 
    We observed very little transcriptional change in immune response gene during the 
demyelination phase at 11wks, but saw a much greater response at 14wks that was dependent 
on the time of IFN-γ induction.  Strongly upregulated genes included PDE4B, which is 
induced by LPS stimulation and results in TNF-α upregulation (Jin and Conti, 2002); CD48 
and CD83, antigens involved in T cell and NK cell activation; interleukin receptors IL-6RA 
and IL-13RA1; and macrophage activation protein 2 (MPA2).  With few exceptions, immune 
response genes were more robustly upregulated at 14wk-E than 14wk-L.  Interestingly, JAK 
was upregulated in both 14wk-E and 14wk-L, but STAT-1 and STAT-2 were upregulated 
only in 14wk-E.  The JAK-STAT pathway is a major downstream event of IFN-γ signaling 
that elicits the upregulation of additional cytokine and immunoregulatory genes.  The 
difference in expression between 14wk-E and 14wk-L is suggestive of a protective role for 
IFN-γ during remyelination when induced at the peak of demyelination.    
 
 
Differential Expression of Genes Involved in Antigen Processing and Presentation, and 
ER Stress 
(Figures 3.9 - 3.14; Tables 3.5 - 3.8) 
 
    A hallmark of IFN-γ exposure to OLs is the robust upregulation of MHC class I and II 
(Baerwald et al., 1999; Benveniste and Benos, 1995).  Peptide antigens for MHC class I are 
cleaved by the proteasome, which is a conglomeration of many peptides that form a 26S or 
20S structure (Coux et al., 1996).  Alpha subunits encoded by PSMA genes and beta subunits 
encoded by PSMB genes make up the 20S proteasome.  The addition of RPN and RPT 
subunits encoded by PSMD and PSMC genes, respectively, constitutes the 26S proteasome.   
 133
    It is the 20S proteasome that degrades most peptides destined for antigen presentation; and 
in response to IFN-γ, TNF-α, and IFN-α, certain proteasome subunits are induced to form 
“immunoproteasomes” (Yamano et al., 2002).  Most of the antigens presented by MHC class 
I are processed in this manner.  Immunoproteasome subunits are encoded by PSMB8 
(LMP7), PSMB9 (LMP2), and PSME1/2 (PA28α/β), all of which were significantly 
upregulated at 14wk-E, but not 14wk-L, 11wk-E, or 11wk-L (Figs. 3.9b and 3.10g; Table 
3.5).  Peptides that have been broken down by the immunoproteasome are transferred to the 
endoplasmic reticulum (ER) via the transporter TAP1/2.  Inside the ER, MHC class I forms a 
dimer with β2 microglobulin (β2M) and associates with TAP until it binds a peptide antigen.  
The MHC-β2M-antigen complex is then released from the ER, processed through the Golgi, 
and transported to the cell surface where the antigen is presented to circulating T cells.  Like 
the proteasome genes, TAP1 and β2M were also upregulated at 14wk-E, but at no other time 
point (Fig. 3.10a,d; Table 3.5).  In addition, several MHC class I genes were robustly 
upregulated at 14wk-E, and to a lesser degree at 14wk-L (Figs. 3.9 and 3.10; Table 3.5).  
There was little change in transcriptional regulation of MHC class I at 11wks with only a few 
genes downregulated at 11wk-E (Fig. 3.9 and Table 3.5).  MHC class II antigen complexes 
are processed via endosomes by several accessory proteins including cathepsin S (CTSS) and 
CD74 invariant chain.  As observed with MHC class I expression, MHC class II genes, along 
with CTSS and CD74, were upregulated at 14wk-E, but not at any other time point (Figs. 
3.10e,f; Table 3.5).  These data are further evidence that when introduced late in the process 
of demyelination / early remyelination, IFN-γ results in a diminished immune response 
during the recovery period. 
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    Some peptides are targeted for degradation by ubiquination, then broken down by the 26S 
proteasome and transported into the ER for antigen presentation.  The process of 
ubiquination begins with the conjugation of ubiquitin to a ubiquitin-activating enzyme (E1), 
after which ubiquitin is transferred to a ubiquitin-conjugating enzyme (E2), and then 
ubiquitin ligase (E3) transfers the ubiquitin to a protein targeted for degradation (Hershko 
and Ciechanover, 1992; Ciechanover, 1994).  Data for these events are more difficult to 
interpret, as there was both increased and decreased expression of genes related to ubiquitin 
and 26S proteasome-mediated protein degradation.  Perhaps there are competing mechanisms 
for the degradation and preservation of proteins, or possibly the data represent a shift toward 
the use of certain ubiquitin genes over others. 
    At 11wk-L, the ubiquitin ligase UBE3A was slightly upregulated and the only ubiquitin 
gene differentially expressed at that time point (Fig. 3.9c, Table 3.5).  At 11wk-E, the 
ubiquitin-conjugating enzyme UBE2R2, the ubiquitin carboxy-terminal hydrolase UCHL1, 
and two deubiquinating enzymes, USP3 and USP11, were downregulated (Fig. 3.9c, Table 
3.5).  At 14wk-E and 14wk-L, the E2 enzyme UBE2D2 along with RNF122 and MARCH7 
were upregulated, while two E3 enzymes, NEDD4L and UBE3C, were downregulated Fig. 
3.10i; Table 3.5).  UBE3A was upregulated at 14wk-L; the E1-like enzyme UBE1L and 
deubiquinating enzyme USP18 were downregulated at 14wk-E and USP14 was 
downregulated at both 14wk-E and 14wk-L (Fig. 3.10h; Table 3.5).  Two 26S subunits were 
differentially regulated; PSMD10 was downregulated at 14wk-E and 14wk-L, and PSMD13 
was upregulated at 14wk-E (Fig. 3.10g; Table 3.5).   
    In addition to antigen processing, the 26S proteasome also degrades aggregated, mal-
folded or accumulated unfolded proteins.  Since the ER in OLs is already producing large 
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amounts of membrane components for myelination, the additional requirement for MHC 
antigen in response to IFN-γ could likely tax the ER such that unfolded proteins accumulate 
and a stress response is initiated (Lin et al., 2004, 2005).  Such a response involves the 
upregulation of protein folding chaperones, retrograde transport of mal-folded proteins out of 
the ER for degradation by the 26S proteasome, and decreased protein translation (Rutkowski 
and Kaufman, 2004; Rao et al., 2004; Ma and Hendershot, 2001).  Protein folding 
chaperones were slightly downregulated at 11wk-E, but not at any other time point (Fig. 
3.12; Table 3.7).  At both 14wk-E and 14wk-L there was upregulation of protein degradation 
genes, (Fig. 3.11; Table 3.6), and at 14wk-L there was an additional overall decrease in 
protein synthesis genes (Figs. 3.13 and 3.14; Table 3.8).  Together, these data provide some 
evidence of an ER stress response during remyelination, with the later-IFN-γ-expressers 
perhaps more able to mount a response.   
 
 
Differential Expression of Genes Involved in the Oxidative Stress Response 
(Figures 3.15 and 3.16; Table 3.9) 
 
    Cells initiate an oxidative stress response to combat damaging accumulation of reactive 
oxygen species (ROS), and evidence of such a response has been found in EAE and MS 
(Espejo et al., 2005; Gilgun-Sherki et al., 2004).   At 11wk-E there was a slight decrease in 
redox genes and at 11wk-L a slight increase.  At 14wk-E the oxidase inhibitor CYBA was 
upregulated, and at 14wk-L the antioxidant CAT was upregulated.  Other reducing genes had 
slight and varied regulation at both 14wk-E and 14wk-L.  It is unclear from these data 
exactly what role IFN-γ may play on oxidative stress during demyelination and remyelination 
in this system, but perhaps there is some increased response to ROS during the recovery 
phase.   
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Differential Expression of Genes Involved in Cell Death 
(Figures 3.17 and 3.18; Table 3.10) 
 
    Considerable evidence indicates developing OLs exposed to IFN-γ in culture undergo 
apoptosis (Baerwald and Popko, 1998; Agresti et al., 1996; Vartanian et al., 1995).  In our 
array analysis, we found only minor differential regulation of genes involved in cell death, 
and the timing of IFN-γ induction seemed to play a role in their expression.  Overall, there 
was a general decrease in apoptotic genes at 11wk-E, but not at 11wk-L.  The most 
significantly downregulated gene was TRB-3 at 11wk-E, which in addition to being pro-
apoptotic, also responds to ER stress (Corcoran et al., 2005).   
    At 14wks, differential regulation of minor cell death genes was varied in both 14wk-E and   
14wk-L.  Most notably, the pro-apoptotic DNA fragmentation gene CIDE-B was upregulated 
at 14wk-E, but downregulated at 14wk-L.  IGF-1, which has been shown to have a protective 
effect on OL survival (Ye et al., 1995; Mason et al., 2000; Gao et al., 2002), was robustly 
expressed in non-treated immature OLs, at ~10 times the average expression of the array and 
~ 6 times higher than non-treated mature OLs.  In both immature and mature populations, 
IFN-γ treatment resulted in a decrease in IGF-1; however, the decrease was considerably less 
in the mature cells, which may point to their resistance against the injurious effects of IFN-γ. 
 
 
Differential Expression of Genes Involved in Cell Cycle Regulation, Differentiation and 
Development 
(Figures 3.19 -3.23; Tables 3.11-3.13) 
 
    During peak demyelination, there was a decrease in expression of genes that promote 
withdrawal from proliferation, and this effect was more dramatic at 11wk-E than 11wk-L.  
Moreover, there was a decrease in differentiation-promoting genes at 11wk-E, but not 11wk-
L, and these genes were also increased at both 14wk-E and 14wk-L.  There was an 
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upregulation of cell cycle genes preferential to differentiation and these were more robustly 
upregulated at 14wk-L than 14wk-E.  Furthermore, development-associated genes were 
increased at 14wk-L and to a lesser extent at 14wk-E, but not in either 11-wk condition.  
Together, these data suggest that early IFN-γ expression may promote proliferation during 
demyelination, and that later IFN-γ expression may promote differentiation during 
remyelination.  Likewise, previous data have demonstrated a greater number of progenitor 
cells at 10wk-E than 10wk-C and fewer progenitors at 12wk-E and 12wk-L than 12wk-C 
(Lin et al., 2006; Lin and Popko, unpublished data).  Our measurements were taken between 
the time of the observed increase and decrease in OPCs; therefore, it is reasonable to presume 
that there would still be a number of proliferating OPCs at 11wks.  Lin et al. also reported 
that at 14wks there were fewer mature OLs in the early IFN-γ expressers (2005), but the 
same number in the late expressers (unpublished data) compared to controls.  Our data 
indicating some increased expression of differentiation and developmental genes at 14wk-L 
and less expression of the same at 14wk-E are consistent with these observations. 
 
 
Differential Expression of Genes Involved in Various Other Cell Functions 
(Figures 3.24 - 3.40 and Tables 3.14 - 3.22) 
 
    Clearly, IFN-γ expression during the beginning or peak of demyelination elicits diverse 
transcriptional responses.  Figures 3.24-3.40 and Tables 3.14-3.22 illustrate differential 
expression of genes involved in cell growth, cell metabolism, cytoskeleton organization, cell 
adhesion, protein modification, nucleic acid binding, transcription regulation, signal 
transduction, and transport.  Selected genes are discussed below. 
    Several myosin and kinesin motor proteins were upregulated in both 14wk-E and 14wk-L, 
and may play a role in extending membrane processes in mature OLs.  Contactin-1 
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(CNTN1), which takes part in axo-glial adhesion; the cell surface protein CD44, which may 
play a role in T cell attachment; and the cell-cell adhesion molecule cadherin-11 (CDN11) 
were also upregulated in both 14wk-E and 14wk-L.  Nucleic acid binding zinc finger proteins 
ZCCHC6 and ZDHHC2 were upregulated at 14wk-L and more so at 14wk-E.  In addition, 
numerous genes for mitochondrial ATPases, potassium channels, and solute carrier family 
transporters as well as several signal transduction genes were differentially regulated.       
    A number of genes of unknown function and many ESTs were differentially regulated in 
response to IFN-γ.  For reference, these genes and ESTs are listed in Tables 3.23 and 3.24, 
respectively. 
 
 
CONCLUSION 
    Transgenic mice expressing IFN-γ in astrocytes in a temporally-controlled system were 
treated with the demyelination-inducing toxicant cuprizone.  IFN-γ was induced either 
simultaneously with the start of cuprizone treatment or two weeks into treatment.  
Transcriptional regulation was measured from the corpus collosum either at the peak of 
demyelination or during robust remyelination and was quantitated using microarray analysis.  
Numerous genes were differentially regulated in response to IFN-γ, but interestingly, the 
degree of transcriptional regulation among several groups of genes was influenced by the 
timing of IFN-γ induction, particularly during active remyelination.   
    At 11wks, very few OLs still remain in the corpus collosum after cuprizone treatment (Lin 
et al., 2006; Matsushima and Morell, 2001; Mason et al., 2000).  The changes in gene 
expression measured here, therefore, may have occurred in the many infiltrating astrocytes 
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present in lesion sites and/or in new NG2+ progenitors, which begin to appear in the corpus 
collosum at 10wks (after 4wks of cuprizone treatment).   
    In the early expressers at 11wks, there was a greater induction of MHC and a decrease in 
protein synthesis and cell metabolism genes; whereas, in the late expressers, only MHC class 
I showed appreciable differential regulation.  Consistent with other work in our lab that 
measured an initial increase in progenitors at 10wk-E, but a decrease at 12wk-E (Lin et al., 
2006; Lin and Popko, unpublished data), the decrease in protein synthesis and metabolism 
genes may reflect a shut down of progenitor cells, and this also supports the observed 
decrease in remyelination in the early expressers (Lin et al., 2006). 
    After 6 weeks of cuprizone treatment followed by 2 weeks of recovery, non-IFN-γ-
expressing animals displayed an increase in myelin gene expression and the number of 
mature OLs, with a proportionate decrease in progenitor cells, as well as a ~48% recovery of 
remyelinated axons (Lin et al., 2006).  In contrast, the early IFN-γ expressers showed a 
decrease in myelin gene expression, fewer mature OLs, an increase in the number of 
astrocytes and macrophages, and only ~27% recovery of remyelinated axons (Lin et al., 
2006).   
    In the early expressers during remyelination, our analysis indicated an upregulation of both 
JAK and a STAT1, which are downstream modulators of IFN-γ signaling.  Concordantly, we 
observed robust upregulation of both MHC class I and class II along with their processing 
and assembly genes.  The processing of class I occurs in the ER, and several recent 
experiments have indicated that robust upregulation of MHC class I by IFN-γ in OLs, 
particularly actively myelinating OLs, leads to ER stress, which may contribute to OL cell 
death during remyelination (Lin et al, 2005, 2006; Lin and Popko, unpublished data).  In 
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addition to the large induction of MHC and protein processing genes, we also observed an 
increase in genes involved in protein ubiquination and degradation.  We did not, however, 
find appreciable upregulation of apoptotic genes.   
    In contrast to the early expressers, late expressers during remyelination showed an increase 
in myelin gene expression, fewer macrophages, and remarkably, an increase in the number of 
remyelinated axons compared even to control animals (55% vs. 48% in controls, p<0.05) 
(Lin and Popko, unpublished data).  Concordantly in our array experiments, we observed an 
increase in myelin gene expression, including MBP, MAL, and QK, and found only a slight 
upregulation in STAT1 with much weaker induction of downstream IFN-γ signaling genes. 
    Consistent with diminished IFN-γ intracellular signal transduction, we also observed 
reduced induction of MHC class I and II and very little upregulation of MHC processing and 
transport genes compared to early expressers.  Furthermore, there was no increase, or only a 
slight increase, in expression of IFN-γ-sensitive genes that were found to be upregulated in 
the early expressers, including interferon-inducible protein 1, interleukin 6 receptor alpha, 
interleukin 13 receptor alpha 1, macrophage activation 2, and IFN-γ-induced GTPase.          
    Taken together, these data strongly suggest that IFN-γ induction prior to the completion of 
demyelination results in decreased remyelination and fewer mature OLs, which may be due, 
at least in part, to ER stress induced by robust induction of MHC and protein processing 
genes.  When expressed later, however, our data point toward a possible beneficial role for 
IFN-γ in reparative remyelination.  
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Figure 3.1  Tetracycline-Inducible Expression of IFN-γ.  Two transgenic lines of mice were 
crossed to produce a double transgenic line expressing IFN-γ in the absence of doxycycline:  
a) the tetracycline operon repressor (tTA) and eukaryotic transcription activity domain fusion 
construct (VP16) are under the control of astrocyte-specific promoter for glial fibrillary 
acidic protein (GFAP); b) IFN-γ is driven by the CMV promoter modified to contain a 
binding site for tTA 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. 
b. 
c. 
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Figure 3.2  Cuprizone Model of Demyelination in C57BL/6J Wild-type Mice.  Six-week-old 
male mice were fed milled chow containing 0.02% Cuprizone for either 6wks or 16wks.  By 
the fifth week of treatment, nearly all axons were demyelinated.  Animals taken off 
Cuprizone after 6wks remyelinated nearly completely.  Animals treated with Cuprizone 
continuously for 16wks experienced partial remyelination in the sixth week followed by a 
second period of demyelination in weeks nine and ten.  Animals remyelinated only 
minimally in the twelfth week and were again nearly completely demyelinated from 14wks-
16wks (Matsushima and Morell, 2001). 
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Figure 3.3  Cuprizone Treatment and IFN-γ Induction in Male GFAP/tTA x TRE/IFN-γ 
Transgenic Mice.   
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Figure 3.4  Expression Estimates of Genes Involved in Myelin Formation at 14wks.  Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.2.      
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Table 3.2  Differential Expression of Genes Involved in Myelin Formation.  Replicate RNA 
samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figure 3.4.  Positive fold change values 
indicate an increase, and negative values indicate a decrease in gene expression in the IFNγ-
expressing groups.  Values in grey indicate the Student’s t-test p-value was greater than 0.1. 
 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
AK019046 MAL myelin and lymphocyte protein 1.27 1.38 1.58 1.61 
L07508 MBP myelin basic protein 1.49 1.28 1.49 1.73 
BB088198 QK quaking  1.17 1.15 2.14 3.13 
AK011596 TRFR transferrin receptor -1.21 1.06 1.48 1.52 
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Figure 3.5  Expression Estimates of Genes Involved in Cholesterol and Lipid Biosynthesis 
and Metabolism at 11wks.  Gene symbols and Accession numbers are plotted on the x-axis; 
the average of replicate normalized expression values for each treatment group (as described 
in Materials and Methods) is plotted on the y-axis.  In some cases, a gene is represented on 
the microarray set more than once by different accession numbers.  Fold change values are 
listed in Table 3.3.   
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Figure 3.6  Expression Estimates of Genes Involved in Cholesterol and Lipid Biosynthesis 
and Metabolism at 14wks.  a-c) Gene symbols and Accession numbers are plotted on the x-
axis; the average of replicate normalized expression values for each treatment group (as 
described in Materials and Methods) is plotted on the y-axis.  In some cases, a gene is 
represented on the microarray set more than once by different accession numbers.  Fold 
change values are listed in Table 3.3. 
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Figure 3.6  Expression Estimates of Genes Involved in Cholesterol and Lipid Biosynthesis 
and Metabolism at 14wks. 
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Table 3.3  Differential Expression of Genes Involved in Cholesterol and Lipid Biosynthesis 
and Metabolism.  Replicate RNA samples from each treatment group were hybridized to 
separate arrays.  The average of replicate normalized expression estimates for each sample 
group was used to calculate the fold change difference in expression for each gene in Figures 
3.5 and 3.6.  Positive fold change values indicate an increase, and negative values indicate a 
decrease in gene expression in the IFNγ-expressing groups.  Values in grey indicate the 
Student’s t-test p-value was greater than 0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
BB210491 ACADL acetyl-Coenzyme A dehydrogenase, long-chain 1.06 -1.19 -1.66 -1.77 
AW493391 DGKD diacylglycerol kinase, delta  -1.58 -1.06 1.53 1.19 
BB748075 ELOVL3 
elongation of very long chain fatty 
acids (FEN1/Elo2, SUR4/Elo3, 
yeast)-like 3 
1.16 -1.20 -1.39 -1.69 
BB028312 FDFT1 farnesyl diphosphate farnesyl transferase 1 -1.10 -1.12 -1.62 -1.88 
BB535261 HADHSC L-3-hydroxyacyl-Coenzyme A dehydrogenase, short chain 1.04 1.18 1.17 1.51 
NM_008253 HMGCL 3-hydroxy-3-methylglutaryl-Coenzyme A lyase -1.30 1.10 1.92 1.99 
AV362707 HMGCS1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 1.03 -1.01 -1.57 -1.55 
NM_016763 HSD17B7 hydroxysteroid (17-beta) dehydrogenase 7 -1.72 -1.21 1.57 1.38 
AV235735 HSD17B7 hydroxysteroid (17-beta) dehydrogenase 7 -1.12 1.06 1.41 1.55 
BB554029 HSD3B2 hydroxysteroid dehydrogenase-2, delta<5>-3-beta -1.01 -1.04 -1.48 -1.60 
NM_030680 PEX11A peroxisomal biogenesis factor 11a -1.18 -1.14 -1.44 -1.71 
BB315077 PEX5 peroxisome biogenesis factor 5 1.21 1.10 1.24 1.79 
BG971031 PEX6 peroxisomal biogenesis factor 6 1.00 -1.36 -2.03 -2.49 
AK005441 SC4MOL sterol-C4-methyl oxidase-like -1.84 -1.21 2.21 2.01 
BB224405 SCARB1 scavenger receptor class B, member 1 -1.03 -1.56 -1.37 -1.86 
BB138434 SCARB1 scavenger receptor class B, member 1 -1.10 -1.50 -1.48 -2.00 
NM_009270 SQLE squalene epoxidase -1.56 -1.19 1.76 1.87 
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   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
BF148627 STS steroid sulfatase -1.28 1.11 1.66 1.86 
BM239368 TDE1 tumor differentially expressed 1 -1.07 1.21 1.27 1.88 
AK005203 TDE1L tumor differentially expressed 1, like -1.28 1.21 1.64 1.81 
NM_013703 VLDLR very low density lipoprotein receptor -1.69 1.00 1.53 1.74 
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Figure 3.7  Expression Estimates of Genes Involved in the Immune Response at 11wks.  
Gene symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.4.      
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Figure 3.8  Expression Estimates of Genes Involved in the Immune Response at 14wks.   
a-e) Gene symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.4.  
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Figure 3.8  Expression Estimates of Genes Involved in the Immune Response at 14wks. 
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Figure 3.8  Expression Estimates of Genes Involved in the Immune Response at 14wks. 
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Figure 3.8  Expression Estimates of Genes Involved in the Immune Response at 14wks. 
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Table 3.4  Differential Expression of Genes Involved in the Immune Response.  Replicate 
RNA samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figures 3.7 and 3.8.  Positive fold 
change values indicate an increase, and negative values indicate a decrease in gene 
expression in the IFNγ-expressing groups.  Values in grey indicate the Student’s t-test p-
value was greater than 0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
AW227993 C1QB complement component 1, q subcomponent, beta polypeptide -1.07 -1.40 -1.11 -1.54 
NM_007573 C1QBP complement C1q binding protein -1.58 1.02 1.57 1.72 
K02782 C3 complement C3 -1.09 -1.18 2.05 1.75 
NM_009779 C3AR1 complement C3a receptor 1 -1.04 -1.14 1.67 1.43 
BB385581 CBLB casitas B-lineage lymphoma b -1.11 -1.09 1.92 2.40 
BE634960 CD48 CD48 antigen 1.09 -1.01 2.03 1.54 
NM_009856 CD83 CD83 antigen -1.12 -1.12 2.53 2.52 
NM_020008 CLECSF12 
C-type (calcium dependent, 
carbohydrate recognition domain) 
lectin, superfamily member 12 
1.20 -1.12 2.08 1.64 
AK018103 COL4A3BP collagen, type IV, alpha 3 binding protein 1.13 1.12 1.52 1.62 
NM_013499 CRRY complement receptor related protein -1.33 -1.13 1.53 1.29 
AV254798 CSF2RB  colony stimulating factor 2 receptor, beta 1, low-affinity -1.50 -1.04 1.72 1.97 
BB278992 CX3CR1 chemokine (C-X3-C) receptor 1 1.08 -1.08 -1.69 -1.96 
NM_021274 CXCL12 chemokine (C-X-C motif) ligand 12 -2.00 -2.15 1.71 1.01 
BC006640 CXCL5 chemokine (C-X-C motif) ligand 5 -1.56 -1.50 -1.22 -1.26 
NM_009141 CXCR3 chemokine (C-X-C motif) receptor 3 -2.12 -1.80 1.70 1.45 
NM_016874 DEFB2 defensin beta 2 1.07 1.05 1.81 1.68 
U03065 DEFCR15 defensin related cryptdin 15 1.15 1.26 1.69 2.04 
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   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-L 14wk-E 
AY035380 ELAVL2 ELAV (embryonic lethal, ab-normal vision, Drosophila)-like 2 1.09 1.07 1.53 1.61 
AK014133 ELAVL4 ELAV (embryonic lethal, ab- normal vision, Drosophila)-like 4 -1.05 1.20 1.31 1.53 
BF136544 FGL2 fibrinogen-like protein 2 -1.06 -1.15 2.54 1.31 
NM_008326 IFI1 interferon inducible protein 1 1.23 1.10 3.56 1.64 
NM_010499 IFI202B interferon activated gene 202B -1.18 -1.09 1.30 1.62 
NM_008330 IFI47 interferon gamma inducible protein 1.11 -1.08 4.94 1.58 
NM_008332 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 -1.21 -1.21 2.30 1.47 
NM_010501 IFITM3L interferon induced transmembrane protein 3-like -1.40 -1.62 2.94 1.53 
BE994488 IGH-VJ558  immunoglobulin heavy chain, (J558 family) -1.01 -1.02 1.63 1.59 
AV057155 IGK-V28 immunoglobulin kappa chain variable 8  1.30 1.14 1.92 1.50 
BB485297 IKBKAP 
inhibitor of kappa light 
polypeptide enhancer in B-cells, 
kinase complex-associated protein 
1.34 1.11 2.15 1.08 
BI081033 IL13RA1 interleukin 13 receptor, alpha 1 -1.23 -1.27 2.11 1.61 
L20048 IL6RA interleukin 6 receptor, alpha 1.06 -1.82 2.05 1.07 
NM_008407 ITK IL2-inducible T-cell kinase 1.83 1.63 1.37 1.36 
BF224937 JAK1 Janus kinase 1 1.06 -1.29 2.54 2.94 
BC022943 LCP2 lymphocyte cytosolic protein 2 -1.13 -1.36 1.62 1.38 
BC002070 LY6E lymphocyte antigen 6 complex, locus E 1.00 1.00 1.73 1.15 
AW546141 MARCO macrophage receptor with collagenous structure -1.12 -1.35 1.63 1.29 
NM_020048 MCMD5 mini chromosome maintenance deficient 5 -1.66 -1.21 1.98 1.88 
NM_023799 MGEA5 meningioma expressed antigen 5 (hyaluronidase) -2.08 -1.09 1.57 1.85 
BM241485 MPA2 macrophage activation 2 -1.45 -2.30 8.41 1.77 
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   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-L 14wk-E 
L20315 MPEG1 macrophage expressed gene 1 -1.05 -1.14 1.78 1.45 
BM124348 MRG2 myeloid ecotropic viral integration site-related gene 2 -1.71 -1.10 1.17 1.15 
AI844633 NCF1 neutrophil cytosolic factor 1 -1.06 -1.13 1.67 1.46 
BM205191 NOVA1 neurooncological ventral antigen 1 -1.07 1.07 1.73 1.67 
NM_021893 PDCD1LG1 programmed cell death 1 ligand 1 1.28 1.01 2.73 1.18 
BE950979 PDE4B phosphodiesterase 4B 1.28 1.05 2.25 2.63 
NM_011210 PTPRC protein tyrosine phosphatase, receptor type, C 1.15 -1.13 1.77 1.62 
NM_009283 STAT1 signal transducer and activator of transcription 1 1.09 -1.12 2.68 1.35 
BM239586 STAT1 signal transducer and activator of transcription 1 -1.21 -1.55 3.50 1.57 
AW214029 STAT1 signal transducer and activator of transcription 1 -1.04 -1.63 3.77 1.53 
BB229853 STAT2 signal transducer and activator of transcription 2 -1.01 -1.41 2.22 1.10 
AI325183 STAT6 signal transducer and activator of transcription 6 -1.48 -1.19 1.83 1.73 
AK014566 TAPBP TAP binding protein -1.23 -1.35 1.97 1.44 
BC010580 TRIM21 tripartite motif protein 21 -1.06 -1.17 1.68 1.21 
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Figure 3.9  Expression Estimates of Genes Involved in Antigen Processing and Presentation 
at 11wks.  Gene symbols and Accession numbers for genes involved in a) MHC class I 
presentation, b) the 20S proteasome, and c) the ubiquitin pathway are plotted on the x-axis; 
the average of replicate normalized expression values for each treatment group (as described 
in Materials and Methods) is plotted on the y-axis.  In some cases, a gene is represented on 
the microarray set more than once by different accession numbers.  Fold change values are 
listed in Table 3.5.  
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Figure 3.9  Expression Estimates of Genes Involved in Antigen Processing and Presentation 
at 11wks.   
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Figure 3.10  Expression Estimates of Genes Involved in Antigen Processing and 
Presentation at 14wks.  Gene symbols and Accession numbers for genes involved in a-d) 
MHC class I presentation, e-f) MHC class II presentation, g) the 20S and 26S proteasomes, 
and h-i) the ubiquitin pathway are plotted on the x-axis; the average of replicate normalized 
expression values for each treatment group (as described in Materials and Methods) is plotted 
on the y-axis.  In some cases, a gene is represented on the microarray set more than once by 
different accession numbers.  Fold change values are listed in Table 3.5.  
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Figure 3.10  Expression Estimates of Genes Involved in Antigen Processing and 
Presentation at 14wks. 
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Figure 3.10  Expression Estimates of Genes Involved in Antigen Processing and 
Presentation at 14wks. 
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Figure 3.10  Expression Estimates of Genes Involved in Antigen Processing and 
Presentation at 14wks. 
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Figure 3.10  Expression Estimates of Genes Involved in Antigen Processing and 
Presentation at 14wks. 
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Table 3.5  Differential Expression of Genes Involved in Antigen Processing and 
Presentation.  Replicate RNA samples from each treatment group were hybridized to separate 
arrays.  The average of replicate normalized expression estimates for each sample group was 
used to calculate the fold change difference in expression for each gene in Figures 3.9 and 
3.10.  Positive fold change values indicate an increase, and negative values indicate a 
decrease in gene expression in the IFNγ-expressing groups.  Values in grey indicate the 
Student’s t-test p-value was greater than 0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-L 14wk-E 
MHC Class I Presentation      
NM_030711 ARTS1  
type 1 tumor necrosis factor 
receptor shedding aminopeptidase 
regulator 
-1.30 -1.27 1.76 1.50 
AA170322 B2M beta-2 microglobulin 1.16 1.04 1.74 1.41 
NM_009735 B2M beta-2 microglobulin -1.24 -1.20 2.65 1.79 
AI099111 B2M beta-2 microglobulin -1.28 -1.15 3.59 2.51 
AF390178 BAT1A HLA-B-associated transcript 1A -1.89 -1.15 1.22 1.10 
BC011067 BAT1A HLA-B-associated transcript 1A -1.85 -1.12 1.63 1.46 
M69068 H2-D1 histocompatibility 2, D region locus 1 -1.14 -1.19 5.14 3.15 
L36068 H2-D1 histocompatibility 2, D region locus 1 -1.13 -1.14 5.18 3.02 
M86502 H2-D1 histocompatibility 2, D region locus 1 -1.16 -1.17 5.26 3.08 
M83244 H2-D1 histocompatibility 2, D region locus 1 9.42 3.07 31.7 12.7 
X00246 H2-D1 histocompatibility 2, D region locus 1 10.18 3.36 35.3 15.2 
J00406 H2-D1 histocompatibility 2, D region locus 1 13.22 4.44 51.0 21.9 
L23495 H2-K histocompatibility 2, K region -1.33 -1.38 2.94 1.93 
BC011306 H2-K histocompatibility 2, K region -1.44 -1.33 3.37 2.20 
S70184 H2-K histocompatibility 2, K region -1.29 -1.20 3.42 2.08 
NM_023422 H2-KE2 H2-K region expressed gene 2 -1.02 -1.17 -1.18 -1.56 
AV132191 H2-KE6 H2-K region expressed gene 6 -1.65 -1.16 1.40 1.21 
M33151 H2-L histocompatibility 2, D region locus 1 -1.20 -1.16 3.51 2.02 
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   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
M34962 H2-L histocompatibility 2, L region -1.13 -1.20 6.00 3.09 
NM_013819 H2-M3 histocompatibility 2, M region locus 3 1.03 1.01 1.99 1.54 
BC018402 H2-Q1 histocompatibility 2, Q region locus 1 1.71 1.29 1.29 1.18 
M29881 H2-Q8 histocompatibility 2, Q region locus 7 1.12 -1.20 3.38 1.77 
NM_010395 H2-T10 histocompatibility 2, T region locus 10 -1.12 -1.20 1.76 1.06 
NM_010398 H2-T23 histocompatibility 2, T region locus 23 1.05 -1.25 2.26 -1.03 
BB285733 H47 histocompatibility 47 -1.02 -1.10 -1.35 -1.53 
BC024897 TAP1 transporter 1, ATP-binding cassette, sub-family B, MDR/TAP 1.15 -1.16 1.98 -1.06 
MHC Class II Presentation      
BC003476 CD74 CD74 3.24 1.83 6.36 2.07 
AU019852 CTSB cathepsin B 1.02 -1.01 -1.51 -1.31 
NM_021281 CTSS cathepsin S 1.01 -1.07 1.79 1.50 
BE688749 H2-AA histocompatibility 2, class II antigen A, alpha 6.48 2.91 9.59 3.67 
NM_010379 H2-AB1 histocompatibility 2, class II antigen A, beta 1 3.04 1.52 6.84 2.39 
U13648 H2-EA histocompatibility 2, class II antigen E alpha 1.24 1.11 1.62 1.28 
AF119253 H2-EA histocompatibility 2, class II antigen E alpha 5.97 1.83 25.0 6.26 
U13648 H2-EA histocompatibility 2, class II antigen E alpha 10.83 1.19 53.9 12.6 
NM_010382 H2-EB1 histocompatibility 2, class II antigen E beta 3.13 1.78 7.34 2.49 
20S Proteasome       
BC014783 PSMB3 proteasome (prosome, macropain) subunit, beta type 3 -1.86 -1.05 2.00 1.76 
NM_011185 PSMB3 proteasome (prosome, macropain) subunit, beta type 3 -1.61 -1.13 1.55 1.33 
NM_011186 PSMB6 proteasome (prosome, macropain) subunit, beta type 6 -1.53 -1.08 1.34 1.27 
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   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
NM_010724 PSMB8 
proteosome (prosome, macropain) 
subunit, beta type 8 (large multi-
functional peptidase 7 - LMP7) 
-1.29 -1.43 4.07 1.84 
NM_013585 PSMB9 
proteosome (prosome, macropain) 
subunit, beta type 9 (large multi-
functional peptidase 2, LMP2) 
1.04 -1.18 4.62 1.57 
NM_011189 PSME1 proteasome (prosome, macropain) 28 subunit, alpha -1.43 -1.42 2.28 1.46 
NM_011190 PSME2 proteasome (prosome, macropain) 28 subunit, beta -1.35 -1.20 2.07 1.48 
BB310829 PSMF1 proteasome (prosome, macropain) inhibitor subunit 1 -1.57 -1.16 1.63 1.53 
BB310829 PSMF1 proteasome (prosome, macropain) inhibitor subunit 1 -1.50 -1.08 1.47 1.27 
26S Proteasome       
NM_011874 PSMD10 proteasome (prosome, macropain) 26S subunit, non-ATPase, 10 -1.23 -1.06 -1.49 -1.68 
BM730602 PSMD13 proteasome (prosome, macropain) 26S subunit, non-ATPase, 13 -1.64 -1.13 1.96 1.71 
Ubiquitin Pathway       
BB248730 MARCH7 membrane-associated RING-CH protein VII  1.18 1.02 1.61 2.11 
BB360028 NEDD4L  
developmentally down-regulated 
gene 4-like, neural precursor cell 
expressed 
-1.15 -1.27 -2.18 -2.40 
BI150320 RNF122 ring finger protein 122  -1.13 1.04 2.32 2.13 
BM232298 SQSTM1 sequestosome 1  -1.46 -1.04 2.10 2.26 
AK004894 UBE1L ubiquitin-activating enzyme E1-like -1.06 -1.18 1.51 -1.01 
AK010432 UBE2D2 ubiquitin-conjugating enzyme E2D 2 -1.23 1.11 2.17 2.42 
BE917478 UBE2R2 ubiquitin-conjugating enzyme E2R 2 -1.51 -1.13 1.33 1.11 
BB166188 UBE3A ubiquitin protein ligase E3A 1.58 1.55 1.51 1.80 
BE690666 UBE3C ubiquitin protein ligase E3C 1.21 -1.25 -2.17 -1.86 
NM_011670 UCHL1 ubiquitin carboxy-terminal hydrolase L1 -1.88 -1.07 1.57 1.34 
AI117611 USP11 ubiquitin specific protease 11 -1.96 -1.10 1.57 1.58 
BI690175 USP14 ubiquitin specific protease 14 -1.22 -1.18 2.18 1.92 
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   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
NM_011909 USP18 ubiquitin specific protease 18 -1.53 -1.96 2.34 1.25 
NM_021323 USP3 ubiquitin specific protease 3 -1.60 -1.18 1.28 1.20 
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Figure 3.11  Expression Estimates of Genes Involved in Proteolysis at 14wks.  Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.6. 
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Table 3.6  Differential Expression of Genes Involved in Proteolysis.  Replicate RNA 
samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figure 3.11.  Positive fold change 
values indicate an increase, and negative values indicate a decrease in gene expression in the 
IFNγ-expressing groups.  Values in grey indicate the Student’s t-test p-value was greater than 
0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
BE952331 APBA2BP 
amyloid beta (A4) precursor 
protein-binding, family A, member 
1 binding protein 
-2.18 -1.09 1.14 -1.02 
AF070066 CPB2 carboxypeptidase B2 (plasma) 1.00 1.10 -1.53 -1.33 
NM_007754 CPD carboxypeptidase D -1.28 -1.05 1.56 1.94 
NM_009982 CTSC cathepsin C -1.17 -1.39 2.15 1.66 
D87867 FOLH1 folate hydrolase -1.72 -1.21 2.04 1.85 
NM_015765 HSP14 heat shock protein 4 -1.43 -1.12 1.58 1.47 
AF282844 MMP16 matrix metalloproteinase 16 1.24 1.06 1.97 2.08 
NM_030253 PARP9 poly (ADP-ribose) polymerase family, member 9 -1.11 -1.28 2.06 1.48 
BB482313 RAD23B RAD23b homolog  1.03 -1.01 1.69 2.26 
NM_009112 S100A10 S100 calcium binding protein A10 (calpactin) -2.01 -1.66 1.06 1.68 
AV295650 S100A10 S100 calcium binding protein A10 (calpactin) -1.68 -1.81 -1.47 1.11 
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Figure 3.12  Expression Estimates of Genes Involved in the Stress Response at 11wks.  Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.7.  
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Table 3.7  Differential Expression of Genes Involved in the Stress Response.  Replicate 
RNA samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figure 3.12.  Positive fold change 
values indicate an increase, and negative values indicate a decrease in gene expression in the 
IFNγ-expressing groups.  Values in grey indicate the Student’s t-test p-value was greater than 
0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
AK006478 DNAJB4 DnaJ (Hsp40) homolog, subfamily B, member 4  -1.07 1.29 1.20 1.50 
AK007410 GADD45G growth arrest and DNA-damage-inducible 45 gamma -1.67 -1.36 1.02 -1.27 
AK010939 HSBP1 heat shock factor binding protein 1 -1.53 -1.13 1.34 1.05 
BC002153 HSBP1 heat shock factor binding protein 1 -1.58 -1.14 1.50 1.46 
NM_008303 HSPE1 heat shock protein 1 -1.59 -1.38 1.28 1.00 
BC027377 MAPKAP1 MAP kinase interacting protein 1 -1.63 -1.19 1.04 1.10 
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Figure 3.13  Expression Estimates of Genes Involved in Protein Biosynthesis at 11wks.  a-c) 
Gene symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.8.  
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Figure 3.13  Expression Estimates of Genes Involved in Protein Biosynthesis at 11wks.   
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Figure 3.14  Expression Estimates of Genes Involved in Protein Biosynthesis at 14wks.  a-c) 
Gene symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.8.  
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Figure 3.14  Expression Estimates of Genes Involved in Protein Biosynthesis at 14wks.   
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Table 3.8  Differential Expression of Genes Involved in Protein Biosynthesis.  Replicate 
RNA samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figures 3.13 and 3.14.  Positive fold 
change values indicate an increase, and negative values indicate a decrease in gene 
expression in the IFNγ-expressing groups.  Values in grey indicate the Student’s t-test p-
value was greater than 0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
BB736240 COX15 cytochrome c oxidase assembly protein  -1.08 -1.27 -1.81 -2.05 
BB379386 DDX16 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 16 1.05 -1.13 -1.55 -1.64 
BB229155 EIF2C3 eukaryotic translation initiation factor 2C, 3 1.20 -1.23 1.33 1.55 
AK002576 EIF3S6IP 
eukaryotic translation initiation 
factor 3, subunit 6 interacting 
protein 
-1.17 1.22 1.58 1.54 
BB858329 EIF3S8 eukaryotic translation initiation factor 3, subunit 8 -1.61 -1.34 -1.95 -1.71 
BM120823 EIF4E2 eukaryotic translation initiation factor 4E member 2 -1.12 -1.60 -1.52 -2.06 
AV216412 EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1 -2.47 -2.25 -1.12 -1.37 
NM_007918 EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1 -1.85 -1.53 -1.07 -1.22 
BB530332 FARS2 phenylalanine-tRNA synthetase 2, mitochondrial -1.02 -1.31 -1.84 -2.46 
AB049641 MRPL13 mitochondrial ribosomal protein L13 -1.30 -1.24 -1.28 -1.69 
AB049641 MRPL15 mitochondrial ribosomal protein L15 -1.53 -1.10 1.23 1.09 
BG519318 MRPL15 mitochondrial ribosomal protein L15 -1.53 -1.02 1.43 1.45 
AK004034 MRPL17 mitochondrial ribosomal protein L17 -1.50 -1.05 1.38 1.19 
BB041267 MRPL20 mitochondrial ribosomal protein L20 -1.76 1.00 1.49 1.65 
NM_053161 MRPL3 mitochondrial ribosomal protein L3 -1.81 -1.10 1.65 1.51 
AV021593 MRPL52 mitochondrial ribosomal protein L52 -1.52 -1.67 -1.23 -2.18 
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   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
AV021593 MRPL52 mitochondrial ribosomal protein L52 -1.47 -1.51 -1.21 -1.95 
BI246587 MRPS16 mitochondrial ribosomal protein S16 -1.74 -1.11 1.69 1.38 
BQ177137 RNU22 RNA, U22 small nucleolar -3.02 -1.78 1.66 1.16 
BQ177137 RNU22 RNA, U22 small nucleolar  -2.50 -1.59 1.56 1.31 
BB422726 RPL18 ribosomal protein L18 -1.24 -1.31 -1.32 -1.58 
NM_011289 RPL27 ribosomal protein L27 -1.32 -1.32 -1.26 -1.86 
AV111459 RPL27 ribosomal protein L27 -1.29 -1.26 -1.19 -1.63 
AV066335 RPL35 ribosomal protein L35 -1.28 -1.32 -1.14 -1.63 
NM_025592 RPL35 ribosomal protein L35 -1.41 -1.31 -1.10 -1.67 
AV172221 RPL35 ribosomal protein L35 -1.17 -1.29 -1.37 -2.06 
AV124739 RPL35 ribosomal protein L35 -1.10 -1.27 -1.42 -2.05 
AV124680 RPL35A ribosomal protein L35a -1.14 -1.23 -1.29 -1.83 
NM_018730 RPL37A ribosomal protein L37a -1.18 -1.38 -1.13 -1.63 
AV066985 RPL37A ribosomal protein L37a -1.09 -1.31 -1.12 -1.62 
AV151252 RPS21 ribosomal protein S21 -1.25 -1.50 -2.03 -2.72 
AK008386 RPS24 ribosomal protein S24 -1.37 -1.21 -1.25 -1.68 
AV111319 RPS24 ribosomal protein S24 -1.33 -1.20 -1.48 -1.96 
AV206764 RPS24 ribosomal protein S24 -1.29 -1.17 -1.11 -1.52 
BB836796 RPS27L ribosomal protein S27-like -1.81 -1.60 1.69 1.13 
BB836796 RPS27L ribosomal protein S27-like -1.71 -1.61 1.32 -1.11 
AV111399 RPS28 ribosomal protein S28 -1.77 -1.60 1.45 1.03 
AK004068 RPS4X ribosomal protein S4, X-linked -2.36 -1.23 1.23 1.11 
AI414989 RPS8 ribosomal protein S8 -1.71 -1.05 3.44 3.05 
AK009502 TIA1 cytotoxic granule-associated RNA binding protein 1 -1.70 1.05 1.12 1.13 
BB474913 TIAL1 Tial1 cytotoxic granule-associated RNA binding protein-like 1 -1.14 1.29 1.93 2.78 
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Figure 3.15  Expression Estimates of Genes Involved in the Oxidative Stress Response at 
11wks.  Gene symbols and Accession numbers are plotted on the x-axis; the average of 
replicate normalized expression values for each treatment group (as described in Materials 
and Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray 
set more than once by different accession numbers.  Fold change values are listed in Table 
3.9.  
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Figure 3.16  Expression Estimates of Genes Involved in the Oxidative Stress Response at 
14wks.  a-b) Gene symbols and Accession numbers are plotted on the x-axis; the average of 
replicate normalized expression values for each treatment group (as described in Materials 
and Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray 
set more than once by different accession numbers.  Fold change values are listed in Table 
3.9.  
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Table 3.9  Differential Expression of Genes Involved in the Oxidative Stress Response.  
Replicate RNA samples from each treatment group were hybridized to separate arrays.  The 
average of replicate normalized expression estimates for each sample group was used to 
calculate the fold change difference in expression for each gene in Figures 3.15 and 3.16.  
Positive fold change values indicate an increase, and negative values indicate a decrease in 
gene expression in the IFNγ-expressing groups.  Values in grey indicate the Student’s t-test 
p-value was greater than 0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
NM_009687 APEX1 apurinic/apyrimidinic endonuclease 1 -1.56 -1.10 1.43 1.27 
AI607603 CAT catalase -1.11 1.01 1.94 2.12 
AK018713 CYBA cytochrome b-245, alpha  -1.41 -1.45 2.01 1.41 
BC019374 GCLC glutamate-cysteine ligase, catalytic -1.03 1.13 1.49 1.54 
NM_008416 JUNB Jun-B oncogene 1.01 -1.11 1.43 1.68 
AV356118 MAOA monoamine oxidase A 1.05 1.06 1.75 1.92 
BG064061 MAPK10 mitogen activated protein kinase 10 1.09 -1.27 -1.73 -1.83 
AA175187 MT1A metallothionein-I activator -1.45 -1.22 -1.03 -1.50 
NM_016764 PRDX4 peroxiredoxin 4 -1.32 -1.33 -1.20 -1.65 
NM_007452 PRDX4 peroxiredoxin 4 -1.42 -1.06 1.81 1.59 
BB530180 SOD1 superoxide dismutase 1 1.14 1.02 1.61 1.49 
AI847438 SOD2 superoxide dismutase 2, mitochondrial 1.22 1.50 1.23 1.39 
BB550124 TGM2 transglutaminase 2, C polypeptide 1.24 -1.27 -1.28 -1.68 
AW321975 TGM2 transglutaminase 2, C polypeptide 1.22 -1.27 -1.24 -1.65 
M93954 TIMP2 tissue inhibitor of metalloproteinase 2 -1.04 -1.26 1.51 1.28 
AK002358 TXN2 thioredoxin 2 -1.54 -1.05 1.20 1.16 
AV300942 TXNL thioredoxin-like (32kD) 1.02 -1.08 -1.31 -1.52 
BI416051 TXNL2 thioredoxin-like 2 -1.54 1.04 1.70 1.79 
BB458835 TXNL2 thioredoxin-like 2 -1.29 -1.21 -1.41 -1.73 
BB030680 TXNRD3  thioredoxin reductase 3 -1.27 -1.18 -1.13 -1.52 
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Figure 3.17  Expression Estimates of Genes Involved in Cell Death at 11wks.  a-b) Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.10.  
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Figure 3.18  Expression Estimates of Genes Involved in Cell Death at 14wks.  a-c) Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.10. 
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Figure 3.18  Expression Estimates of Genes Involved in Cell Death at 14wks.   
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Table 3.10  Differential Expression of Genes Involved in Cell Death.  Replicate RNA 
samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figures 3.17 and 3.18.  Positive fold 
change values indicate an increase, and negative values indicate a decrease in gene 
expression in the IFNγ-expressing groups.  Values in grey indicate the Student’s t-test p-
value was greater than 0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
Pro-Apoptotic Genes      
L16846 BTG1 B-cell translocation gene 1, anti-proliferative -1.46 -1.21 2.11 1.79 
NM_007570 BTG2 B-cell translocation gene 2, anti-proliferative -1.44 1.09 1.36 1.81 
NM_007808 CYCT cytochrome c, testis -1.58 -1.03 1.23 1.10 
NM_030732 IRAK4 interleukin-1 receptor-associated kinase 4 -1.05 1.06 1.44 1.69 
BI966443 ITM2A integral membrane protein 2A -1.10 1.15 1.82 1.98 
U18310 MAP2K4 mitogen activated protein kinase kinase 4 -1.07 1.11 1.80 2.10 
BM227247 MYCBP c-myc binding protein -1.58 -1.27 1.06 1.05 
AW049660 NFKBIB 
nuclear factor of kappa light chain 
gene enhancer in B-cells inhibitor, 
beta 
1.12 -1.07 -1.69 -1.42 
AK003899 PDCD11 programmed cell death protein 11 -1.55 -1.39 -1.08 -1.08 
AI642124 PDCD4 programmed cell death 4 -1.23 1.06 -1.52 -1.42 
AF161074 PDCD5 programmed cell death 5 -1.14 -1.09 -1.19 -1.52 
AI323543 PEA15 phosphoprotein enriched in astrocytes 15 -1.60 -1.28 1.61 1.49 
AV216351 SIVA  Cd27 binding protein (Hindu God of destruction) 1.02 -1.15 -1.35 -1.62 
NM_013869 TNFRSF19 tumor necrosis factor receptor superfamily, member 19 -1.52 -1.22 2.21 1.96 
BC012955 TRB-3 Tribbles 3 homolog -4.00 -1.90 -1.15 -1.18 
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   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
Survival  Genes      
BB082119 BAG4 BCL2-associated athanogene 4 -1.24 1.09 1.85 2.01 
NM_007566 BIRC6 baculoviral IAP repeat-containing 6 1.06 -1.07 -1.45 -1.59 
AV296697 IKKG inhibitor of kappaB kinase gamma 1.10 -1.03 1.49 1.60 
BC005629 NME2 
expressed in non-metastatic cells 
2, protein (NM23B) (nucleoside 
diphosphate kinase) 
-1.59 -1.12 1.53 1.44 
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Figure 3.19  Expression Estimates of Genes Involved in Cell Cycle at 11wks.  Gene symbols 
and Accession numbers are plotted on the x-axis; the average of replicate normalized 
expression values for each treatment group (as described in Materials and Methods) is plotted 
on the y-axis.  In some cases, a gene is represented on the microarray set more than once by 
different accession numbers.  Fold change values are listed in Table 3.11.  
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Figure 3.20  Expression Estimates of Genes Involved in Cell Cycle at 14wks.  a-b) Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.11.  
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Table 3.11  Differential Expression of Genes Involved in Cell Cycle.  Replicate RNA 
samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figures 3.19 and 3.20.  Positive fold 
change values indicate an increase, and negative values indicate a decrease in gene 
expression in the IFNγ-expressing groups.  Values in grey indicate the Student’s t-test p-
value was greater than 0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
BC027328 BRD4 bromodomain containing 4 -2.41 -2.25 1.55 -1.10 
BB538325 CCND2 cyclin D2 1.07 -1.88 1.30 1.14 
NM_009829 CCNE2 cyclin E2 -1.52 -1.23 1.48 1.46 
NM_020006 CDC5L cell division cycle 5-like -1.10 -1.11 1.56 1.44 
NM_009870 CDK4 cyclin-dependent kinase 4 -2.31 -1.33 1.98 1.53 
NM_009870 CDK4 cyclin-dependent kinase 4 -1.85 -1.22 1.32 1.16 
NM_009870 CDK4 cyclin-dependent kinase 4 -1.80 -1.21 1.19 -1.10 
AK007630 CDKN1A cyclin-dependent kinase inhibitor 1A (P21) -2.31 -1.87 -1.35 -1.85 
NM_007669 CDKN1C cyclin-dependent kinase inhibitor 1C (P57) -2.81 -1.87 -1.44 -1.76 
AW012617 MALAT1 metastasis associated lung adenocarcinoma transcript 1 1.08 -1.17 2.18 2.47 
BB137599 SCHIP1 schwannomin interacting protein 1 1.16 1.12 1.36 2.18 
NM_013787 SKP2 S-phase kinase-associated protein 2 (p45) -1.06 1.00 1.46 1.86 
BQ174473 STAG1 stromal antigen 1 -1.07 1.05 1.78 1.92 
AK010925 TBRG4 cell cycle progression 2 protein -1.65 -1.09 1.37 1.22 
BC016606 TNFSF5IP1 tumor necrosis factor superfamily, member 5-induced protein 1 -1.71 -1.15 1.55 1.58 
BF608615 YWHAZ 
tyrosine 3-monooxygenase/ 
tryptophan 5-monooxygenase 
activation protein, zeta polypeptide 
-1.03 1.02 1.58 1.39 
AV027921 YWHAZ 
tyrosine 3-monooxygenase/ 
tryptophan 5-monooxygenase 
activation protein, zeta polypeptide 
-1.29 1.01 1.87 1.56 
AV027921 YWHAZ 
tyrosine 3-monooxygenase/ 
tryptophan 5-monooxygenase 
activation protein, zeta polypeptide 
-1.25 1.02 1.86 1.63 
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Figure 3.21  Expression Estimates of Genes Involved in Differentiation at 11wks.  Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.12.  
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Figure 3.22  Expression Estimates of Genes Involved in Differentiation at 14wks.  a-b) Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.12.  
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Table 3.12  Differential Expression of Genes Involved in Differentiation.  Replicate RNA 
samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figures 3.21 and 3.22.  Positive fold 
change values indicate an increase, and negative values indicate a decrease in gene 
expression in the IFNγ-expressing groups.  Values in grey indicate the Student’s t-test p-
value was greater than 0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
NM_007463 APEG1 aortic preferentially expressed gene 1 1.19 -1.10 -1.83 -2.13 
BB159263 ARPP-21 cyclic AMP-regulated phosphoprotein, 21  -1.48 1.09 2.00 1.53 
AF375476 ATF5 activating transcription factor 5 -2.60 -1.82 -1.08 -1.20 
BG064496 EDF1 endothelial differentiation-related factor 1 -1.50 -1.60 1.58 1.49 
BB550017 EDF1 endothelial differentiation-related factor 1 1.15 1.05 1.41 1.77 
BB133079 EDG2 
endothelial differentiation, 
lysophosphatidic acid G-protein-
coupled receptor, 2 
-1.27 1.03 1.51 1.66 
BB210623 EDG3  
endothelial differentiation, 
sphingolipid G-protein-coupled 
receptor, 3 
-1.29 -1.28 1.62 1.22 
NM_025380 EFNA1 ephrin A1 -1.64 -1.10 1.57 1.42 
BG066438 GMFB glia maturation factor, beta -1.08 -1.08 1.58 1.88 
AK013970 GMFB glia maturation factor, beta -1.33 -1.05 2.14 2.91 
AB030185 GNG13 guanine nucleotide binding protein 13, gamma -1.80 -1.20 1.11 -1.13 
U29539 LAPTM5 lysosomal-associated protein transmembrane 5 1.02 -1.32 1.69 1.38 
BI695636 LAPTM5 lysosomal-associated protein transmembrane 5 -1.38 -1.09 1.59 1.63 
BG076333 MTL5 metallothionein-like 5 -2.35 -1.48 1.06 1.11 
BE994433 PROX1 prospero-related homeobox 1 1.20 1.07 1.53 2.21 
BB271145 SEMA4F  
sema domain, immunoglobulin 
domain (Ig), TM domain, and 
short cytoplasmic domain 
-1.01 -1.07 -1.94 -1.97 
AW988981 ZFP313 zinc finger protein 313 -1.35 -1.33 -1.16 -1.61 
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Figure 3.23  Expression Estimates of Genes Involved in Development at 14wks.  a-b) Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.13.  
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Table 3.13  Differential Expression of Genes Involved in Development.  Replicate RNA 
samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figure 3.23.  Positive fold change 
values indicate an increase, and negative values indicate a decrease in gene expression in the 
IFNγ-expressing groups.  Values in grey indicate the Student’s t-test p-value was greater than 
0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
BM114293 AMD1 S-adenosylmethionine decarboxylase 1 1.09 1.12 2.60 2.43 
NM_018790 ARC activity regulated cytoskeletal-associated protein 1.47 1.11 1.63 2.40 
NM_015814 DKK3 dickkopf homolog 3 -1.06 1.18 2.08 2.41 
BB821609 DRBP1 developmentally regulated RNA binding protein 1 1.04 -1.12 -1.71 -2.27 
BG074577 NES nestin 1.14 1.06 1.37 1.59 
BB462688 SEMA6D 
sema domain, transmembrane 
domain (TM), and cytoplasmic 
domain, (semaphorin) 6D 
-1.29 -1.07 1.79 1.94 
BI738328 SFPQ 
splicing factor proline/glutamine 
rich (polypyrimidine tract binding 
protein associated) 
1.18 1.06 2.13 2.55 
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Figure 3.24  Expression Estimates of Genes Involved in Cell Growth at 11wks.  Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.14.  
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Figure 3.25  Expression Estimates of Genes Involved in Cell Growth at 14wks.  a-b) Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.14.  
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Table 3.14  Differential Expression of Genes Involved in Cell Growth.  Replicate RNA 
samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figures 3.24 and 3.25.  Positive fold 
change values indicate an increase, and negative values indicate a decrease in gene 
expression in the IFNγ-expressing groups.  Values in grey indicate the Student’s t-test p-
value was greater than 0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
NM_025389 ANAPC5 anaphase-promoting complex subunit 5 -1.89 -1.11 1.46 1.14 
BC003478 ARF6 ADP-ribosylation factor 6 -1.06 -1.28 -1.44 -1.63 
AW537237 ARL6IP ADP-ribosylation-like factor 6 interacting protein -1.17 -1.01 1.67 1.62 
NM_019812 CBX5 chromobox homolog 5 -1.03 1.09 1.47 1.78 
NM_016748 CTPS cytidine 5'-triphosphate synthase  -1.19 1.06 1.52 1.41 
BC010224 GHR growth hormone receptor -1.51 1.00 1.19 1.17 
NM_010284 GHR growth hormone receptor -1.11 -1.14 1.47 1.50 
AI324988 MCMD6 mini chromosome maintenance deficient 6  -1.22 -1.38 -1.55 -1.99 
NM_008568 MCMD7 mini chromosome maintenance deficient 7  -1.95 -1.33 -1.16 -1.23 
AA223007 NPR2 natriuretic peptide receptor 2 -1.10 1.27 1.79 2.62 
AB025413 NRG4 neuregulin 4 -1.62 -1.75 -1.43 -1.62 
BB208426 POLB DNA polymerase B1 1.19 1.19 1.34 2.08 
AK010400 RFC2 replication factor C (activator 1) 2 (40kD) -1.60 -1.34 -1.11 -1.40 
BF180212 SYCP3  synaptonemal complex protein 3 1.00 1.23 1.94 2.03 
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Figure 3.26  Expression Estimates of Genes Involved in Metabolism at 11wks.  Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.15.  
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Figure 3.27  Expression Estimates of Genes Involved in Metabolism at 14wks.  a-b) Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.15.  
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Table 3.15  Differential Expression of Genes Involved in Metabolism.  Replicate RNA 
samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figures 3.26 and 3.27.  Positive fold 
change values indicate an increase, and negative values indicate a decrease in gene 
expression in the IFNγ-expressing groups.  Values in grey indicate the Student’s t-test p-
value was greater than 0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
AA681807 AGL amylo-1,6-glucosidase, 4-alpha-glucanotransferase  1.34 1.53 2.66 2.64 
BB831090 AHCYL1  S-adenosylhomocysteine hydrolase-like 1 -1.03 1.16 2.31 2.45 
BM941201 ALDO3 aldolase 3, C isoform 1.58 2.08 1.17 1.25 
AV330806 AMPD2 adenosine monophosphate deaminase 2 (isoform L) -1.23 -1.70 -1.86 -1.99 
BC017606 CA10 carbonic anhydrase-related protein 10 -1.05 -1.11 -1.79 -1.74 
NM_019698 CHST2 carbohydrate sulfotransferase 2 -1.62 -1.20 1.34 1.22 
AB075019 EHD1 EH-domain containing 1 -1.08 1.06 1.55 1.33 
NM_010145 EPHX1 epoxide hydrolase 1, microsomal -1.20 -1.14 1.53 1.52 
BB071632 ERH enhancer of rudimentary  -2.03 -1.13 1.91 1.62 
BB041868 G2AN alpha glucosidase 2, alpha neutral subunit  1.31 1.03 1.57 2.10 
AV078914 HSD17B10 hydroxyacyl-CoA dehydrogenase type II -1.33 -1.22 -1.54 -2.09 
NM_008548 MAN1A mannosidase 1, alpha -1.10 -1.08 2.55 2.31 
BE948333 NTRK2 neurotrophic tyrosine kinase, receptor, type 2 1.24 -1.13 1.28 2.03 
L21027 PHGDH 3-phosphoglycerate dehydrogenase -2.25 -1.26 2.15 2.03 
BB650419 PHPT1  phosphohistidine phosphatase 1 -2.01 -1.05 2.25 1.56 
AK003844 PITPNC1 phosphatidylinositol transfer protein, cytoplasmic 1 1.21 -1.15 -2.01 -2.23 
BC003788 PNP purine-nucleoside phosphorylase -1.05 1.08 2.55 2.05 
BB095517 SPG21 spastic paraplegia 21 homolog (human) -1.77 -1.27 1.92 1.71 
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Figure 3.28  Expression Estimates of Genes Involved in Cytoskeleton Organization at 
11wks.  Gene symbols and Accession numbers are plotted on the x-axis; the average of 
replicate normalized expression values for each treatment group (as described in Materials 
and Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray 
set more than once by different accession numbers.  Fold change values are listed in Table 
3.16.  
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Figure 3.29  Expression Estimates of Genes Involved in Cytoskeleton Organization at 
14wks.  a-b) Gene symbols and Accession numbers are plotted on the x-axis; the average of 
replicate normalized expression values for each treatment group (as described in Materials 
and Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray 
set more than once by different accession numbers.  Fold change values are listed in Table 
3.16.  
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Figure 3.29  Expression Estimates of Genes Involved in Cytoskeleton Organization at 
14wks.  
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Table 3.16  Differential Expression of Genes Involved in Cytoskeleton Organization.  
Replicate RNA samples from each treatment group were hybridized to separate arrays.  The 
average of replicate normalized expression estimates for each sample group was used to 
calculate the fold change difference in expression for each gene in Figures 3.28 and 3.29.  
Positive fold change values indicate an increase, and negative values indicate a decrease in 
gene expression in the IFNγ-expressing groups.  Values in grey indicate the Student’s t-test 
p-value was greater than 0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
BC019435 CALD caldesmon, non-muscle -1.11 -1.43 2.92 2.55 
BF143638 CDC42EP3 CDC42 effector protein (Rho GTPase binding) 3 -1.43 1.05 1.97 1.84 
AW494443 CLMN calmin  1.26 1.14 -2.04 -1.62 
BC002136 CORO1A coronin, actin binding protein 1A -2.53 -1.24 1.57 1.20 
BB740218 CORO1C coronin, actin binding protein 1C -2.20 -1.27 1.01 -1.37 
AA170590 GPHN gephyrin 1.08 1.43 1.89 2.06 
AV340742 KIF17 kinesin family member 17 -1.53 -1.51 1.08 -1.01 
BQ175246 KIF1B kinesin family member 1B 1.11 1.08 1.92 2.31 
NM_016705 KIF21A kinesin family member 21A 1.01 1.22 1.85 2.30 
NM_008442 KIF3B kinesin family member 3B -1.02 1.01 1.75 1.66 
BB448784 KIF5B kinesin family member 5B -1.11 -1.12 1.52 1.56 
NM_008448 KIF5B kinesin family member 5B -1.06 1.11 1.48 1.99 
BI328541 KIF7 kinesin family member 7 -1.10 -1.33 -1.84 -1.22 
NM_010754 KIFC1 kinesin family member C1 -1.38 1.07 1.49 1.55 
BC026760 MYLN myosin light chain, alkali, nonmuscle -1.50 -1.07 2.22 1.96 
NM_019472 MYO10 myosin X -1.08 -1.29 1.64 1.60 
BB200233 MYO9B myosin IXb 1.13 1.20 1.35 1.63 
NM_009260 SPNB2 spectrin beta 2, non-erythrocytic 1.11 -1.03 2.04 2.33 
BB151477 TAOK1 TAO kinase 1 -1.05 -1.08 2.17 2.38 
BB559082 TBCA tubulin cofactor a -1.27 -1.29 -1.38 -1.88 
 206
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
NM_025284 TMSB10 thymosin, beta 10 -1.39 -1.33 -1.83 -2.26 
AK002271 TPM1 tropomyosin 1, alpha -1.89 -1.13 1.54 1.30 
BM232388 TPM1 tropomyosin 1, alpha 1.00 -1.16 1.40 1.56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 207
Figure 3.30  Expression Estimates of Genes Involved in Cell Adhesion at 11wks.  Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.17.  
 
 
0
1
2
3
4
CDH13 ITGB4BP
BB776961 NM_008403
A
ve
ra
ge
d 
N
or
m
al
iz
ed
 E
xp
re
ss
io
n 
Es
tim
at
e
11wk-C 11wk-E 11wk-L
 
 
  
 
 208
Figure 3.31  Expression Estimates of Genes Involved in Cell Adhesion at 14wks.  a-c) Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.27.  
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Figure 3.31  Expression Estimates of Genes Involved in Cell Adhesion at 14wks.   
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Table 3.17  Differential Expression of Genes Involved in Cell Adhesion.  Replicate RNA 
samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figures 3.30 and 3.31.  Positive fold 
change values indicate an increase, and negative values indicate a decrease in gene 
expression in the IFNγ-expressing groups.  Values in grey indicate the Student’s t-test p-
value was greater than 0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
AU016407 ADAM19 a disintegrin and metalloproteinase domain 19 1.03 -1.43 -1.40 -1.84 
BC005676 CD44 CD44 antigen -1.75 -1.84 1.82 1.72 
AK012880 CDH11 cadherin 11 1.94 1.71 2.06 3.29 
BE692399 CDH11 cadherin 11 1.33 1.02 1.21 1.60 
BB776961 CDH13 cadherin 13 -1.81 -1.21 1.28 1.20 
NM_009867 CDH4 cadherin 4 -1.15 -1.25 -1.51 -1.56 
NM_007727 CNTN1 contactin 1 1.07 1.03 1.70 1.55 
BB234940 DDR1 discoidin domain receptor family, member 1 1.36 1.00 -1.43 -1.66 
AI874681 DDR1 discoidin domain receptor family, member 1 1.28 -1.04 -1.37 -1.56 
BB378700 DDR1 discoidin domain receptor family, member 1 1.07 -1.14 -1.38 -1.53 
AF351196 DSCAML1 Down syndrome cell adhesion molecule-like 1 1.26 1.02 -1.73 -1.83 
NM_010327 GP1BB glycoprotein Ib, beta polypeptide 1.04 -1.15 -1.47 -1.64 
NM_008397 ITGA6 integrin alpha 6 1.07 -1.15 1.56 1.57 
BM935811 ITGA6 integrin alpha 6 -1.14 -1.14 1.46 1.60 
NM_021334 ITGB1BP1 integrin beta 1 binding protein 1 1.61 -1.07 1.63 1.59 
NM_008403 ITGB4BP integrin beta 4 binding protein -1.56 -1.07 1.52 1.20 
BB543979 ITGB5 integrin beta 5 1.14 -1.48 -1.51 -1.84 
BG924124 JCAM2 junction cell adhesion molecule 2 1.03 1.11 1.44 1.73 
NM_010708 LGALS9 lectin, galactose binding, soluble 9 -1.50 -1.48 1.59 1.03 
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   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
AK019497 SYMPK symplekin -1.05 -1.13 -1.40 -1.54 
AK015705 TM4SF9  transmembrane 4 superfamily member 9 1.03 -1.02 1.63 1.79 
NM_011693 VCAM1 vascular cell adhesion molecule 1 -1.57 -1.64 2.06 1.72 
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Figure 3.32  Expression Estimates of Genes Involved in Protein Modification at 14wks.  
Gene symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.18.  
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Table 3.18  Differential Expression of Genes Involved in Protein Modification.  Replicate 
RNA samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figure 3.32.  Positive fold change 
values indicate an increase, and negative values indicate a decrease in gene expression in the 
IFNγ-expressing groups.  Values in grey indicate the Student’s t-test p-value was greater than 
0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
NM_026268 DUSP6 dual specificity phosphatase 6 -1.24 -1.07 1.86 2.13 
AK013481 EPHA4 Eph receptor A4 -1.57 1.08 1.63 1.78 
BE951744 EPHA5 Eph receptor A5 -1.24 -1.04 1.83 1.90 
X79084 EPHA7 Eph receptor A7 -1.36 1.22 1.69 2.02 
NM_010243 FUT9 fucosyltransferase 9 1.14 1.53 1.58 2.04 
BB621969 GOSR2 golgi SNAP receptor complex member 2 -1.22 -1.16 -2.05 -1.44 
AU016501 LTBP3 latent TGF-beta binding protein 3 1.13 -1.12 -2.42 -2.87 
BB151391 PCMDT1 
protein-L-isoaspartate (D-
aspartate) O-methyltransferase 
domain containing 1 
-1.09 1.29 1.73 1.98 
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Figure 3.33  Expression Estimates of Genes Involved in Nucleic Acid Binding at 11wks.   
a-b) Gene symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.19.  
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Figure 3.34  Expression Estimates of Genes Involved in Nucleic Acid Binding at 14wks.   
a-c) Gene symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.19. 
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Figure 3.34  Expression Estimates of Genes Involved in Nucleic Acid Binding at 14wks.   
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Table 3.19  Differential Expression of Genes Involved in Nucleic Acid Binding.  Replicate 
RNA samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figures 3.33 and 3.34.  Positive fold 
change values indicate an increase, and negative values indicate a decrease in gene 
expression in the IFNγ-expressing groups.  Values in grey indicate the Student’s t-test p-
value was greater than 0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
BB152562 CUGBP2 CUG triplet repeat, RNA binding protein 2 1.22 -1.16 2.22 2.11 
BC003830 H1F2 histone 1, H1c -1.51 -1.19 1.66 1.58 
BB533903 H1F2 histone 1, H1c -1.50 -1.35 1.06 -1.35 
NM_008211 H3F3B H3 histone, family 3B -1.76 -1.21 1.62 1.63 
AV374669 H3F3B  H3 histone, family 3B -1.81 -1.18 1.47 1.67 
AI848909 HIST4 histone 1, H3a -1.18 -1.35 -1.25 -1.54 
NM_054043 MSI2H Musashi homolog 2 1.21 1.09 2.19 2.12 
AB003040 PEG3 paternally expressed 3 -1.01 1.19 1.59 2.11 
BB528672 R3HDM R3H domain  1.27 1.00 1.37 2.18 
AA138720 RBM10 RNA binding motif protein 10 1.04 -1.11 -2.07 -2.06 
AY052560 RBM3 RNA binding motif protein 3 -1.25 1.26 2.08 2.40 
BE446879 RBM5 RNA binding motif protein 5 2.08 -1.07 -1.29 -1.22 
BB821417 SRRM2 serine/arginine repetitive matrix 2 1.36 1.28 1.67 2.55 
AV325874 TTC14 tetratricopeptide repeat domain 14  1.10 1.13 1.50 2.12 
BM227980 ZCCHC6 zinc finger, CCHC domain containing 6 -1.62 -1.52 3.04 2.14 
BB224658 ZDHHC2 zinc finger, DHHC domain containing 2 1.07 1.05 3.58 2.99 
AI875447 ZFH4  zinc finger homeodomain 4 1.13 -1.15 -1.66 -1.88 
BB253117 ZFHX1A  zinc finger homeobox 1a 1.12 1.09 1.36 1.55 
X16493 ZFP106 zinc finger protein 106 -1.01 -1.05 -1.58 -1.78 
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   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
BB083438 ZFP13 zinc finger protein 13 -1.14 -1.16 -1.69 -1.74 
BB546771 ZFP179 zinc finger protein 179 1.34 1.03 -2.04 -2.05 
BQ176535 ZFP278 zinc finger protein 278 1.09 1.36 1.59 1.55 
BM208058 ZFP28 zinc finger protein 28 -1.50 -1.22 -1.01 -1.18 
BB031791 ZFP36L2 zinc finger protein 36 like 2 -1.05 1.07 2.11 3.03 
BB732439 ZFP536 zinc finger protein 536 1.12 -1.05 -2.06 -1.58 
BM115349 ZFP644 zinc finger protein 644 1.00 1.28 2.34 2.27 
BC005602 ZFP91 zinc finger protein 91 1.05 1.04 1.92 1.64 
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Figure 3.35  Expression Estimates of Genes Involved in Transcription Regulation at 11wks.  
Gene symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.20.  
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Figure 3.36  Expression Estimates of Genes Involved in Transcription Regulation at 14wks.  
a-h) Gene symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.20.  
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Figure 3.36  Expression Estimates of Genes Involved in Transcription Regulation at 14wks.   
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Figure 3.36  Expression Estimates of Genes Involved in Transcription Regulation at 14wks.   
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Figure 3.36  Expression Estimates of Genes Involved in Transcription Regulation at 14wks.   
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Table 3.20  Differential Expression of Genes Involved in Transcription Regulation.  
Replicate RNA samples from each treatment group were hybridized to separate arrays.  The 
average of replicate normalized expression estimates for each sample group was used to 
calculate the fold change difference in expression for each gene in Figures 3.35 and 3.36.  
Positive fold change values indicate an increase, and negative values indicate a decrease in 
gene expression in the IFNγ-expressing groups.  Values in grey indicate the Student’s t-test 
p-value was greater than 0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
NM_007471 APP amyloid beta (A4) precursor protein -1.12 1.18 2.14 2.55 
NM_023502 APP amyloid beta (A4) precursor protein -1.25 1.00 1.75 2.05 
BG242719 BCLAF1 Bcl2-associated transcription factor 1 -1.13 1.17 1.89 2.08 
NM_011498 BHLHB2 basic helix-loop-helix domain containing, class B2 -1.03 1.31 1.79 2.31 
AA967305 CNOT4 CCR4-NOT transcription complex, subunit 4 -1.02 -1.09 1.67 1.40 
BB821847 CNOT7 CCR4-NOT transcription complex, subunit 7 -1.46 1.15 1.44 1.66 
BB335087 CPSF6 cleavage and polyadenylation specific factor 6 1.34 1.14 2.57 2.46 
AF448508 CREBBP CREB binding protein  1.32 1.15 1.74 2.21 
BC003220 E2F5 E2F transcription factor 5 -1.77 -1.25 1.96 2.08 
X06746 EGR2 early growth response 2 -1.09 -1.41 1.92 2.65 
BC005486 ETV1 ets variant gene 1 -1.78 -1.13 1.69 1.89 
BI901633 ETV1 ets variant gene 1 -1.01 1.15 1.67 1.69 
BB168668 GTF2H4 general transcription factor II H, polypeptide 4 -1.14 -1.35 -1.71 -2.19 
NM_010364 GTF2IRD1 general transcription factor II I repeat domain-containing 1 -1.55 -1.33 -1.11 -1.20 
BB461532 HDAC7A histone deacetylase 7A 1.08 1.21 1.28 1.54 
BB825115 HOXA3 homeo box A3 1.28 1.08 1.69 2.09 
BB160544 IGHMBP2  immunoglobulin mu binding protein 2 1.09 1.06 -1.42 -1.55 
NM_030887 JUNDP2  Jun dimerization protein 2 1.12 -1.03 -1.30 -1.51 
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   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
NM_008452 KLF2 Kruppel-like factor 2 (lung) 1.05 1.11 1.16 1.51 
U20344 KLF4 Kruppel-like factor 4 (gut) -1.19 -1.31 1.32 2.19 
AV230488 KLF7 Kruppel-like factor 7 (ubiquitous) -1.36 -1.20 1.76 2.10 
BE851797 KLF7 Kruppel-like factor 7 1.00 -1.07 1.96 1.95 
BG868949 LAMB1-1 laminin B1 subunit 1 1.58 -1.03 -1.94 -2.11 
NM_019484 LSM4  U6 snRNA-associated SM-like protein 4 -1.55 -1.52 1.59 1.05 
NM_008539 MADH1 MAD homolog 1 -1.25 -1.17 1.71 1.97 
AI595932 MEF2C myocyte enhancer factor 2C -1.18 1.21 1.90 2.32 
AK019458 MLLT1 
myeloid/lymphoid or mixed 
lineage-leukemia translocation to 3 
homolog  
-1.11 1.01 1.72 1.75 
BB496038 MLLT6 
myeloid/lymphoid or mixed 
lineage-leukemia translocation to 6 
homolog  
-1.06 1.07 -2.21 -1.55 
AK013847 MYT1L myelin transcription factor 1-like 1.00 1.31 1.70 2.10 
NM_010909 NFX1 nuclear transcription factor, X-box binding 1 -1.02 -1.01 -1.26 -1.61 
BB389081 NLK nemo like kinase -1.04 1.05 -1.95 -2.07 
AV277444 NOD27 nucleotide-binding oligomerization domains 27 1.44 1.06 3.05 1.70 
AU066920 NR2C2 nuclear receptor subfamily 2, group C, member 2  1.02 1.08 2.05 2.25 
AV272221 NRIP1 nuclear receptor interacting protein 1 1.16 1.07 2.09 2.18 
BG920261 NSAP1L NS1-associated protein 1-like 1.20 1.06 1.98 2.46 
AV348246 NXF bHLH-PAS type transcription factor NXF -1.50 1.00 2.03 2.20 
BM230222 PAPOLA poly (A) polymerase alpha 1.01 1.03 1.92 2.05 
NM_011066 PER2 period homolog 2 1.18 1.22 1.85 3.83 
AK008143 PNPT1 polyribonucleotide nucleotidyltransferase 1  -1.20 1.05 3.37 2.69 
BB225012 PREB prolactin regulatory element binding 1.05 -1.15 -2.81 -3.17 
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   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
BB303415 RABL3 RAB, member of RAS oncogene family-like 3 -1.03 -1.26 1.74 1.70 
AI159652 RMB25 RNA binding motif protein 25  1.01 -1.14 1.49 1.88 
BB203348 RNPC2 
RNA-binding region containing 
protein 2, coactivator of AP-1 and 
estrogen receptors 
1.10 1.17 2.45 3.47 
BB306272 RORA RAR-related orphan receptor alpha 1.48 1.38 2.19 2.08 
BB751387 RORC RAR-related orphan receptor gamma 1.04 -1.28 1.95 2.20 
NM_015772 SALL2 sal-like 2 (Drosophila) -1.11 -1.02 1.63 1.60 
NM_009193 SART1 squamous cell carcinoma antigen recognized by T-cells 1 -1.12 1.18 1.63 1.64 
U31967 SOX21 DNA-binding protein SOX21 -1.28 -1.30 1.55 1.60 
BG069917 SSA2 Sjogren syndrome antigen A2 -1.07 1.30 1.88 2.21 
NM_013692 TIEG TGFB inducible early growth response 1.13 -1.16 2.35 2.33 
BM945528 TRIM24 tripartite motif protein 24 -1.42 1.27 2.11 2.95 
BG068242 TRIM30 tripartite motif protein 30 -1.12 -1.44 2.43 1.88 
C88269 XRN2 5'-3' exoribonuclease 2 -1.05 1.19 2.65 3.31 
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Figure 3.37  Expression Estimates of Genes Involved in Signal Transduction at 11wks.  a-b) 
Gene symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.21.  
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Figure 3.38  Expression Estimates of Genes Involved in Signal Transduction at 14wks.  a-g) 
Gene symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.21.  
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Figure 3.38  Expression Estimates of Genes Involved in Signal Transduction at 14wks.   
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Figure 3.38  Expression Estimates of Genes Involved in Signal Transduction at 14wks.   
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Figure 3.38  Expression Estimates of Genes Involved in Signal Transduction at 14wks.   
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Table 3.21  Differential Expression of Genes Involved in Signal Transduction.  Replicate 
RNA samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene in Figures 3.37 and 3.38.  Positive fold 
change values indicate an increase, and negative values indicate a decrease in gene 
expression in the IFNγ-expressing groups.  Values in grey indicate the Student’s t-test p-
value was greater than 0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. Gene Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
NM_133900 ARFRP1  ADP-ribosylation factor related protein 1 -1.89 -1.27 1.54 1.44 
AV028400 ARFRP1  ADP-ribosylation factor related protein 1 -1.17 -1.49 -1.90 -1.90 
BG072448 ARHGEF2 rho/rac guanine nucleotide exchange factor (GEF) 2 1.16 1.00 1.33 1.60 
BB292625 ATAD1 ATPase family, AAA domain containing 1 1.33 1.40 1.61 2.24 
BB385044 CD3Z  CD3 antigen, zeta polypeptide -1.55 -1.30 1.38 1.39 
BC021354 DCAMKL1 
double cortin and 
calcium/calmodulin-dependent 
protein kinase-like 1 
1.19 1.24 1.74 2.35 
NM_010828 DLL3 delta-like 3 (Drosophila) -1.06 1.02 -1.42 -1.61 
BB194720 DOCK3 dedicator of cytokinesis 3 -1.10 1.20 1.54 1.95 
BB045510 DOCK4 dedicator of cytokinesis 4 -1.13 -1.14 1.73 2.08 
BB451714 EDNRB endothelin receptor type B -1.13 1.03 1.81 2.14 
BB258560 FGF14 fibroblast growth factor 14  -1.28 1.21 1.68 2.24 
BF160931 GABARAPL2 GABA(A) receptor-associated protein-like 2 -1.77 -1.10 1.59 1.44 
AF156490 GABRG3 
gamma-aminobutyric acid 
(GABA-A) receptor, subunit 
gamma 3 
-1.04 -1.05 1.66 1.62 
AU015577 GPCR123 G protein-coupled receptor 123 -1.12 -1.08 -3.10 -2.39 
AV277640 GPR105 G protein-coupled receptor 105 1.00 1.12 1.42 1.52 
BB049642 GRIK1 glutamate receptor, ionotropic, kainate 1 -1.16 -1.11 1.42 1.51 
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   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. Gene Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
BQ174268 HTR2C 5-hydroxytryptamine receptor 2C 1.03 1.57 2.63 2.02 
NM_018738 IGTP interferon gamma induced GTPase  1.60 1.10 5.44 2.18 
BI102913 IL6ST IL-6 signal transducer 1.03 1.04 1.75 2.34 
BB283493 LPHN3 
latrophilin-3, Ca+2-independent 
alpha-latrotoxin receptor homolog 
3; lectomedin 3  
-1.04 1.00 -2.14 -1.92 
BF472806 MAGI-1 
membrane associated guanylate 
kinase, WW and PDZ domain 
containing 1 
-2.02 1.25 1.46 1.30 
NM_016693 MAP3K7 mitogen activated protein kinase kinase kinase 7 1.12 1.24 -1.45 -1.55 
NM_019579 MPP5 
membrane protein, palmitoylated 
3 (MAGUK p55 subfamily 
member 5) 
-1.16 1.06 2.28 2.40 
U10551 MRAS muscle and microspikes RAS 1.03 -1.20 1.59 2.05 
BB249447 PCTK1 PCTAIRE-motif protein kinase 1 1.10 -1.28 -2.09 -2.41 
NM_008845 PIP5K2A phosphatidylinositol-4-phosphate 5-kinase, type II, alpha -1.10 -1.20 1.88 2.15 
AV209892 PKIG protein kinase inhibitor, gamma -1.32 -1.59 -1.79 -2.06 
BB308836 PPM1L protein phosphatase 1 (formerly 2C)-like -1.12 1.22 1.84 2.11 
AV023830 PRKACA protein kinase, cAMP dependent, catalytic, alpha 1.04 -1.13 -1.54 -1.62 
NM_025980 PRKACA protein kinase, cAMP dependent, catalytic, alpha 1.18 -1.03 1.53 1.62 
AK005230 RAB2B RAB2B protein -2.23 -1.32 1.45 1.53 
AW124885 RAPGEF4 Rap guanine nucleotide exchange factor (GEF) 4 1.42 1.15 1.49 1.99 
BC011511 RASSF3 Ras association (RalGDS/AF-6) domain family 3 -1.03 1.00 2.09 2.03 
NM_026418 RGS18 regulator of G-protein signaling 18 -1.07 -1.07 1.70 1.43 
BB233670 RGS2 regulator of G-protein signaling 2 -1.09 -1.23 -1.49 -1.81 
BB025471 RGS9 regulator of G-protein signaling 9 -1.12 1.25 2.04 1.93 
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   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. Gene Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
AV047988 RHOBTB3 Rho-related BTB domain containing 3 1.06 1.58 1.57 2.45 
NM_053271 RIMS2 regulating synaptic membrane exocytosis 2 1.36 1.05 -1.88 -2.32 
BB014721 SEH1L SEH1-like  1.03 -1.23 -1.83 -2.04 
AV328280 SLC1A2 glutamate transporter 2.20 1.07 2.99 3.01 
AV069725 SOCS-7 suppressor of cytokine signaling 7 1.06 -1.10 -1.41 -1.88 
NM_010656 SSR4 signal sequence receptor, delta -1.08 1.23 1.89 2.45 
BM936504 SYN2 synapsin II -1.12 -1.20 2.05 2.06 
BB388293 SYT1 synaptotagmin 1 1.17 1.26 -2.03 -1.65 
AV138438 SYT7 synaptotagmin 7 1.16 -1.12 -2.17 -2.05 
NM_021297 TLR4 toll-like receptor 4 -1.05 -1.16 1.57 1.44 
NM_134131 TNFAIP8 TNF-alpha-induced protein 8 -1.21 -1.04 2.12 1.71 
BB268998 TULP4 tubby like protein 4 1.48 1.08 3.15 2.99 
M58566 TXK TXK tyrosine kinase 1.13 -1.20 1.28 1.65 
BB154367 YWHAQ 
tyrosine 3-monooxygenase/ 
tryptophan 5-monooxygenase 
activation protein, theta  
-1.05 1.05 1.49 1.64 
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Figure 3.39  Expression Estimates of Genes Involved in Transport at 11wks.  a-b) Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.22.  
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Figure 3.40  Expression Estimates of Genes Involved in Transport at 14wks.  a-h) Gene 
symbols and Accession numbers are plotted on the x-axis; the average of replicate 
normalized expression values for each treatment group (as described in Materials and 
Methods) is plotted on the y-axis.  In some cases, a gene is represented on the microarray set 
more than once by different accession numbers.  Fold change values are listed in Table 3.22.  
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Figure 3.40  Expression Estimates of Genes Involved in Transport at 14wks.   
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Figure 3.40  Expression Estimates of Genes Involved in Transport at 14wks.   
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Figure 3.40  Expression Estimates of Genes Involved in Transport at 14wks.   
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Table 3.22  Differential Expression of Genes Involved in Transport.  Replicate RNA samples 
from each treatment group were hybridized to separate arrays.  The average of replicate 
normalized expression estimates for each sample group was used to calculate the fold change 
difference in expression for each gene in Figures 3.39 and 3.40.  Positive fold change values 
indicate an increase, and negative values indicate a decrease in gene expression in the IFNγ-
expressing groups.  Values in grey indicate the Student’s t-test p-value was greater than 0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
BC026496 ABCA8B ATP-binding cassette, sub-family A (ABC1), member 8b 1.24 1.09 1.21 1.68 
AV309591 ABCF3 ATP-binding cassette, sub-family F (GCN20), member 3 -1.05 -1.03 -1.55 -1.37 
AI552141 ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1 -1.12 -1.28 -1.33 -1.55 
NM_019652 ASNA1 
arsA (bacterial) arsenite 
transporter, ATP-binding, homolog 
1 
-1.61 -1.10 1.31 1.12 
NM_009721 ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide -1.04 1.18 1.52 1.59 
NM_007506 ATP5G2 
ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit 
c (subunit 9), isoform 2 
-1.55 -1.07 1.70 1.52 
BE989344 ATP5G2 
ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit 
c (subunit 9), isoform 2 
1.51 1.08 -1.07 -1.05 
NM_020582 ATP5J2 
ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit 
f, isoform 2 
-1.51 -1.18 1.09 -1.53 
AV216686 ATP5L 
ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit 
g 
-1.07 -1.22 -1.41 -1.93 
NM_013795 ATP5O 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, O 
subunit 
-1.34 -1.16 -1.16 -1.64 
AW125445 ATP8A2 
ATPase, aminophospholipid 
transporter-like, class I, type 8A, 
member 2 
1.20 1.11 1.43 1.63 
BM941165 COX5A cytochrome c oxidase, subunit Va -1.20 -1.13 -1.52 -1.87 
AV111078 COX7A1 cytochrome c oxidase, subunit VIIa 1 -1.19 -1.15 -1.26 -1.54 
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   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
BG091932 CYBB cytochrome b-245, beta polypeptide 1.36 -1.09 2.43 1.77 
BC010528 CYP3A16 cytochrome P450, 3a16 1.13 1.21 1.57 1.81 
NM_019503 FXYD2 FXYD domain-containing ion transport regulator 2 -1.44 -1.05 2.05 1.76 
AV002675 FXYD3 FXYD domain-containing ion transport regulator 3 1.01 1.00 -1.23 -1.53 
BC027434 HBB-BH1 hemoglobin Z, beta-like embryonic chain  -1.14 -1.14 2.01 1.95 
AI788952 IDH1 isocitrate dehydrogenase 1 (NADP+), soluble -1.13 -1.01 2.59 1.97 
AV328356 KCNA7 
potassium voltage-gated channel, 
shaker-related subfamily, member 
7 
1.55 1.16 -1.47 -1.63 
BQ175822 KCNC1 potassium voltage gated channel, Shaw-related subfamily, member 1 1.11 1.32 1.22 1.55 
BB487239 KCNQ1 potassium voltage-gated channel, subfamily Q, member 1 1.50 1.03 1.79 2.28 
AB000497 KCNQ2 potassium voltage-gated channel, subfamily Q, member 2 -1.08 -1.17 -1.49 -1.60 
AV271979 MLXIP  Mlx interactor MIR -1.37 -1.40 2.04 2.50 
AK005233 MTX2 metaxin 2 -1.68 1.00 1.65 1.51 
BC025155 NDUFC1 
NADH dehydrogenase 
(ubiquinone) 1, subcomplex 
unknown, 1 
-1.63 -1.04 2.00 1.67 
NM_134104 NDUFS5 NADH dehydrogenase (ubiquinone) Fe-S protein 5 -1.32 1.01 -1.18 -1.50 
NM_134104 NDUFV2 NADH dehydrogenase (ubiquinone) flavoprotein 2 -1.48 -1.20 -1.24 -1.67 
U21209 NGB neuroglobin 1.02 1.15 1.93 2.40 
AW107754 RAB10 RAB10, member RAS oncogene family -1.15 1.02 1.39 1.60 
BB493265 RNUT1 RNA, U transporter 1 -2.11 -1.63 1.03 -1.34 
NM_021789 SBDN synbindin -1.90 -1.13 1.64 1.59 
BB357585 SLC1A3 solute carrier family 1, member 3 -1.28 -1.18 1.87 1.43 
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   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. 
Gene 
Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
BM220359 SLC1A3 solute carrier family 1, member 3 -1.43 -1.10 1.68 1.52 
NM_028122 SLC15A1 solute carrier family 15 (oligopeptide transporter), 1 -1.41 -1.40 1.83 1.54 
BB365275 SLC1A4 
solute carrier family 1 
(glutamate/neutral amino acid 
transporter), member 4 
-1.64 -1.23 2.07 1.84 
AI303435 SLC20A2 solute carrier family 20, member 2 -1.06 -1.20 -1.39 -1.52 
BM209618 SLC2A1 solute carrier family 2 (facilitated glucose transporter), member 1 1.22 -1.03 -1.40 -1.63 
BM207588 SLC2A10 solute carrier family 2 (facilitated glucose transporter), member 10 1.23 -1.08 -1.43 -1.59 
NM_134086 SLC39A1 solute carrier family 39 (iron-regulated transporter), member 1 -1.13 1.07 1.57 1.71 
U25708 SLC3A2 
solute carrier family 3 (activators 
of dibasic and neutral amino acid 
transport), member 2  
-1.94 -1.30 1.64 1.65 
AI315030 SLC4A4 solute carrier family 4 (anion exchanger), member 4 -1.02 1.03 1.53 1.79 
BB454531 SLC4A8 solute carrier family 4 (anion exchanger), member 8 -1.24 -1.21 1.51 1.85 
BB129409 SLC6A2 
solute carrier family 6 
(neurotransmitter transporter, 
noradrenalin), member 2 
-1.45 1.11 1.74 2.35 
NM_009320 SLC6A6 
solute carrier family 6 
(neurotransmitter transporter, 
taurine), member 6 
-1.29 1.00 1.83 2.19 
NM_007515 SLC7A3 
solute carrier family 7 (cationic 
amino acid transporter, y+ system), 
member 3 
-1.58 -1.64 1.22 1.07 
BG069063 SLC8A2 
solute carrier family 8 
(sodium/calcium exchanger), 
member 2 
1.53 1.12 1.49 1.54 
BM218509 STXBP6  syntaxin binding protein 6 -1.18 1.02 1.65 2.07 
NM_019929 SUMO-1 SMT3 suppressor of mif two 3 homolog 3 -1.55 -1.04 2.00 2.00 
AW545765 TMED7 transmembrane emp24 protein transport domain containing 7 1.11 -1.07 -1.82 -2.26 
BB429200 VPS54 vacuolar protein sorting 54 -1.66 -1.39 -1.84 -1.48 
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Table 3.23  Differential Expression of Genes of Unknown Function.  Replicate RNA 
samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression.  Positive fold change values indicate an increase, and 
negative values indicate a decrease in gene expression in the IFNγ-expressing groups.  
Values in grey indicate the Student’s t-test p-value was greater than 0.1. 
 
 
   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. Gene Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
AA681807 AGPAT3 1-acylglycerol-3-phosphate O-acyltransferase 3 1.28 1.42 2.55 2.54 
AK005060 AGXT2L1  alanine-glyoxylate aminotransferase 2-like 1 1.48 2.15 1.38 1.49 
U48399 AR androgen receptor -1.17 -1.05 2.28 2.54 
BB167922 ARR3 arrestin 3, retinal 1.21 -1.14 -2.40 -2.02 
AB030194 B3GALT4 
UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypeptide 
4 
-1.03 -1.18 -1.48 -2.18 
BB175696 BAALC brain and acute leukemia, cytoplasmic 1.06 1.22 2.07 2.24 
NM_011793 BCS1L BCS1-like (yeast) -2.18 -1.37 1.32 1.14 
BC018174 BTBD3  BTB/POZ domain containing 3 1.19 -1.05 1.92 1.86 
BB199960 BTBD7 BTB/POZ domain containing 7 -1.05 1.04 1.93 2.80 
NM_133781 CAB39 calcium binding protein 39  -1.04 1.54 2.55 2.90 
BG261945 CALR calreticulin -1.36 1.62 1.40 2.17 
AF251705 CD300D CD300d anigen, immunoglobulin superfamily, member 7 1.00 -1.09 1.68 1.20 
AV375176 CENTD1 centaurin, delta 1 -1.52 -1.09 1.68 1.81 
NM_007755 CPEB2 cytoplasmic polyadenylation element binding protein 2 -1.05 1.06 2.03 2.80 
BM933756 CRHR corticotropin releasing hormone receptor 1 -1.03 -1.42 -1.51 -2.05 
NM_133656 CRKO v-crk sarcoma virus CT10 oncogene homolog (avian) -1.12 1.11 2.85 2.89 
NM_009977 CST8 cystatin 8 (cystatin-related epididymal spermatogenic) 1.08 -2.02 2.21 1.30 
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   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. Gene Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
BC021452 DEAF1 
deformed epidermal 
autoregulatory factor 1 
(Drosophila) 
1.06 -1.19 2.72 2.38 
NM_013642 DUSP12 dual specificity phosphatase 12 1.01 1.16 1.42 2.16 
AK009744 DUTP deoxyuridine triphosphatase -1.51 1.09 2.04 2.20 
NM_019808 ENH enigma homolog  1.04 -1.03 2.22 2.61 
BB817332 FLRT2 fibronectin leucine rich transmembrane protein 2 1.04 1.29 1.45 2.09 
AV026617 FOSB FBJ osteosarcoma oncogene B -1.11 1.07 2.33 3.46 
NM_018734 GCL germ cell-less homolog -1.17 -1.59 2.62 1.11 
NM_010260 GEM GTP binding protein (gene overexpressed in skeletal muscle) 1.10 -1.33 10.94 3.20 
BB315012 GLA galactosidase, alpha 1.25 1.12 1.90 2.82 
AK011217 GTL3 gene trap locus 3 -1.91 -1.09 1.74 1.64 
NM_019440 GUCY1B3 guanylate cyclase 1, soluble, beta 3 1.32 1.08 6.96 2.80 
AK013709 HNRPAB heterogeneous nuclear ribonucleoprotein A/B -2.06 -1.15 1.54 1.53 
BB390704 LAMP2 lysosomal membrane glycoprotein 2 -1.21 -1.17 2.05 1.83 
BB041834 LASP1 LIM and SH3 protein 1 -1.09 -1.06 1.37 2.04 
BB440867 LT1 Lurcher transcript 1 1.27 1.21 1.98 2.43 
AB076722 MURR1 U2af1-rs1 region 1 -1.29 -1.30 -1.31 -2.01 
AU067119 NAPB 
N-ethylmaleimide sensitive 
fusion protein attachment protein 
beta 
-1.33 1.29 2.98 3.73 
AU067119 NAPB 
N-ethylmaleimide sensitive 
fusion protein attachment protein 
beta 
-1.35 1.21 2.54 3.08 
BQ033138 OAZ3 ornithine decarboxylase antizyme 3 -1.73 -2.41 3.45 1.32 
AK013804 P2RY2 purinergic receptor P2Y, G-protein coupled 2 -1.45 -1.01 1.62 2.03 
BC027089 PAP pancreatitis-associated protein 1.15 1.04 1.90 2.09 
AA389937 PCNT2 pericentrin 2 -1.35 1.12 1.93 2.13 
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   Fold Change (IFN-γ-expressing / non-expressing) 
Accession 
No. Gene Symbol Gene Name 11wk-E 11wk-L 14wk-E 14wk-L 
BB320388 PCNX pecanex homolog  1.05 -1.12 -1.73 -2.00 
BB428358 PEX2 peroxisome biogenesis factor 2 -1.04 1.07 1.67 1.75 
BG916808 POP7 Pop7 homolog  1.06 -1.17 3.32 1.66 
BB823786 PUM1 pumilio 1 -1.25 1.08 1.96 2.11 
AV364488 RAB40B Rab40b, member RAS oncogene family -2.10 -1.18 1.68 1.52 
BB667227 RBBP4 retinoblastoma binding protein 4 -1.02 -1.02 -2.27 -1.74 
BC004607 REEP3 receptor expression enhancing protein 3 1.02 1.03 1.46 1.98 
NM_009776 SERPINI1 EST 1.02 -1.01 2.61 1.73 
BC026135 SH2BP1 SH2 domain binding protein 1 -1.22 -1.14 2.21 2.02 
AK018248 TCBA1  T cell lymphoma breakpoint associated target 1  -1.72 -1.12 1.86 1.74 
BG065782 TCEB1L cysteine-rich hydrophobic domain 1 -1.15 1.17 1.70 2.11 
AV026664 TDG thymine DNA glycosylase -1.57 1.27 2.00 2.53 
NM_011579 THAP4 THAP domain containing 4  2.05 1.63 13.98 2.93 
BB707122 TIPARP TCDD-inducible poly(ADP-ribose) polymerase 1.04 1.07 1.70 2.02 
BQ177170 TM4SF6 transmembrane 4 superfamily member 6 -1.93 -1.45 2.61 2.12 
BB310819 TSGA8 testis-specific protein A; zinc finger protein 1.18 1.16 -2.75 -2.05 
BF682223 UGP2 UDP-glucose pyrophosphorylase 2 -1.47 1.04 1.83 2.08 
AV370025 UGP2 UDP-glucose pyrophosphorylase 2 -1.36 -1.06 2.00 2.11 
AF424698 UGP2 UDP-glucose pyrophosphorylase 2 -1.52 1.05 2.29 2.44 
AK009297 WDR33  WD repeat domain 33 -1.30 1.10 1.75 2.11 
BM938007 ZSWIM6 zinc finger Zswim6 1.08 1.02 2.15 1.76 
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Table 3.24  Differential Expression of ESTs.  Replicate RNA samples from each treatment 
group were hybridized to separate arrays.  The average of replicate normalized expression 
estimates for each sample group was used to calculate the fold change difference in 
expression.  Positive fold change values indicate an increase, and negative values indicate a 
decrease in gene expression in the IFNγ-expressing groups.  Values in grey indicate the 
Student’s t-test p-value was greater than 0.1. 
 
 
 Fold Change (IFN-γ-expressing / non-expressing) 
Accession No. 11wk-E 11wk-L 14wk-E 14wk-L 
BQ174667 1.89 2.83 -1.98 1.01 
BB703394 1.68 1.04 1.12 1.11 
NM_008935 1.55 1.34 1.19 1.07 
BQ175915 1.51 1.23 1.18 1.16 
BE946605 -2.22 -2.17 1.19 1.09 
BI655075 -2.19 -2.17 2.39 1.68 
NM_026526 -2.04 -2.17 2.04 1.57 
AI596632 -1.99 -2.17 1.53 1.65 
BG071076 -1.89 -1.43 1.01 1.15 
BF100837 -1.85 -2.17 1.37 1.36 
BQ175587 -1.83 -2.17 1.28 1.15 
BB795206 -1.79 -2.17 1.35 1.45 
BG060788 -1.69 -1.73 1.29 1.21 
AW108203 -1.67 -2.17 1.26 1.01 
BC024944 -1.66 -2.17 1.30 1.10 
BB731805 -1.64 -2.17 1.72 1.59 
BG067009 -1.58 -2.17 1.79 1.80 
AW121365 -1.57 -2.17 -1.98 -1.72 
AK012222 -1.57 -2.17 1.22 1.13 
BG975168 -1.53 -1.32 1.14 -1.72 
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 Fold Change (IFN-γ-expressing / non-expressing) 
Accession No. 11wk-E 11wk-L 14wk-E 14wk-L 
BF018149 -1.52 -1.20 1.39 1.13 
BM118290 -1.52 -1.30 1.33 1.36 
AF408433 -1.52 -2.17 1.33 1.43 
AK003715 -1.52 -1.20 1.31 1.25 
BB239907 -1.51 -2.17 1.41 1.38 
AW550321 -1.51 -2.17 1.55 1.49 
BQ176278 -1.51 -1.23 1.40 1.40 
BI690696 -1.50 1.05 1.24 1.14 
AV338249 -1.79 -1.55 -1.98 -1.72 
BI440542 -1.79 -1.70 -1.98 -1.72 
BB297094 1.18 1.78 -1.98 2.05 
BB130348 1.16 -2.17 2.93 3.37 
BM211445 1.40 1.33 2.28 3.31 
BM941198 1.02 1.05 2.45 3.24 
BG069278 -1.79 -2.17 2.92 3.04 
BB026312 -1.79 1.07 2.80 2.68 
BB484070 1.15 1.11 2.83 2.60 
BB303443 1.26 1.11 2.81 2.40 
AI746482 1.77 1.08 1.64 2.38 
BQ174216 1.08 1.26 1.77 2.33 
AK020915 1.23 -2.17 2.11 2.25 
AI646720 1.38 1.32 1.69 2.19 
BB325849 -1.79 1.01 2.18 2.18 
BE955100 1.52 1.03 1.85 2.16 
AK003329 -1.79 -2.17 2.08 2.14 
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 Fold Change (IFN-γ-expressing / non-expressing) 
Accession No. 11wk-E 11wk-L 14wk-E 14wk-L 
BB534387 -1.79 -2.17 2.22 2.14 
BM238331 1.15 1.09 1.53 2.14 
AK012260 1.02 -2.17 3.11 2.13 
BE692107 1.21 1.01 2.04 2.08 
BG093966 1.24 1.23 2.07 2.07 
BF158817 -1.79 1.08 2.64 2.06 
BB256501 -1.79 1.29 1.59 2.05 
BM123174 -1.79 1.01 1.87 2.04 
BB667201 -1.79 1.22 1.93 2.04 
AK018550 -1.79 -2.17 1.65 2.03 
AK017198 -1.79 1.06 1.93 1.94 
BB245259 1.46 -2.17 1.63 1.93 
AK020045 1.06 1.35 1.58 1.92 
AW146109 -1.79 -2.17 2.02 1.90 
BB736474 -1.79 -2.17 1.94 1.80 
BF660952 1.06 -2.17 1.82 1.79 
BG064688 1.05 1.17 1.76 1.76 
C86506 -1.79 -2.17 1.99 1.76 
BB397845 1.03 -2.17 1.56 1.67 
BB277237 -1.79 -2.17 1.50 1.64 
BI076831 1.18 1.11 1.54 1.63 
BE647363 -1.79 1.03 1.50 1.63 
BF158817 -1.79 1.16 1.92 1.61 
AV173139 1.22 1.13 1.56 1.59 
BM241342 -1.79 -2.17 1.92 1.59 
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 Fold Change (IFN-γ-expressing / non-expressing) 
Accession No. 11wk-E 11wk-L 14wk-E 14wk-L 
AU046270 -1.79 1.11 1.53 1.53 
BB029886 1.00 1.01 1.62 1.52 
AK019515 -1.79 1.08 1.56 1.51 
AV087417 -1.79 -2.17 1.58 1.50 
BM238672 1.29 1.33 1.81 3.03 
BG066534 -1.79 1.10 2.17 2.69 
BB455080 1.28 -2.17 1.83 2.68 
NM_134017 -1.79 1.34 2.41 2.68 
BE825099 -1.79 1.13 2.39 2.61 
AK018202 -1.79 -2.17 1.89 2.59 
BM249924 1.01 1.11 1.68 2.55 
AK009258 -1.79 -2.17 1.62 2.55 
AV313375 -1.79 -2.17 2.35 2.50 
AK017401 1.04 1.13 1.52 2.50 
AK016275 -1.79 1.07 2.49 2.42 
BG066534 -1.79 1.06 1.88 2.41 
AU040379 1.67 -2.17 1.82 2.41 
BG070342 -1.79 1.11 1.99 2.37 
BB118847 -1.79 1.10 1.85 2.27 
BM198273 1.17 -2.17 2.55 2.22 
BM937727 -1.79 -2.17 1.51 2.22 
AW123199 1.05 1.14 1.62 2.21 
AK007420 -1.79 -2.17 1.33 2.20 
AV340255 -1.79 1.12 1.71 2.19 
BB277790 1.01 1.20 1.87 2.19 
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 Fold Change (IFN-γ-expressing / non-expressing) 
Accession No. 11wk-E 11wk-L 14wk-E 14wk-L 
BB215068 -1.79 1.06 1.71 2.19 
BG797225 -1.79 -2.17 1.69 2.19 
BM239943 -1.79 1.20 1.49 2.18 
AK011527 1.22 1.07 1.59 2.13 
AK012530 -1.79 -2.17 1.68 2.12 
BB179947 -1.79 1.20 1.39 2.10 
BG075224 -1.79 1.11 1.60 2.06 
AU067727 -1.79 1.05 1.53 2.00 
BB748887 1.13 1.01 1.75 2.00 
BB153043 1.20 1.22 1.36 1.98 
BB648310 1.35 1.32 1.47 1.97 
BQ174527 1.55 1.25 1.59 1.95 
AI597033 1.21 -2.17 1.15 1.95 
BQ033939 1.16 1.10 1.50 1.93 
BE979956 1.50 -2.17 2.35 1.90 
AV029732 -1.79 1.33 1.70 1.88 
BB131938 1.06 1.15 1.54 1.87 
AV168216 -1.79 1.00 1.60 1.80 
BF134200 1.18 -2.17 1.28 1.80 
BF467246 -1.79 1.03 1.55 1.79 
BE980200 1.42 1.16 1.31 1.78 
NM_130879 1.14 1.00 1.48 1.78 
BF465935 -1.79 1.17 1.40 1.76 
BM211160 -1.79 -2.17 1.66 1.76 
BB162048 -1.79 -1.21 1.53 1.75 
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 Fold Change (IFN-γ-expressing / non-expressing) 
Accession No. 11wk-E 11wk-L 14wk-E 14wk-L 
BM942252 1.34 1.23 1.21 1.74 
BF714941 1.14 -2.17 1.19 1.73 
BB028677 1.25 1.08 1.21 1.73 
AV108872 -1.79 1.02 1.43 1.72 
BG918834 1.09 1.12 1.52 1.71 
BB306048 1.28 1.11 1.32 1.70 
BG069269 1.27 -2.17 1.48 1.69 
AV104668 1.04 -2.17 1.46 1.67 
BB632261 -1.79 1.08 1.83 1.64 
BM117570 1.36 -2.17 1.42 1.63 
BG067686 1.18 1.31 1.18 1.61 
AB041803 1.35 1.12 1.13 1.61 
BG067058 1.33 1.09 1.20 1.61 
BB038914 1.19 1.19 1.41 1.60 
AU046270 -1.79 1.27 1.54 1.59 
BM125576 -1.35 -2.17 1.46 1.58 
AV320152 -1.79 1.01 -1.98 1.57 
BM205987 -1.79 -2.17 1.27 1.56 
BM217857 1.29 1.16 1.22 1.56 
BG063085 1.00 1.04 1.23 1.56 
AW489349 1.07 -2.17 1.47 1.55 
BM240795 1.25 1.30 1.18 1.53 
BE951394 -1.79 1.02 1.48 1.53 
AV338133 -1.79 -2.17 1.19 1.52 
BB256400 1.20 1.25 1.38 1.52 
 252
 Fold Change (IFN-γ-expressing / non-expressing) 
Accession No. 11wk-E 11wk-L 14wk-E 14wk-L 
BB259670 -1.26 -2.17 1.40 1.52 
BB266350 -1.79 1.12 1.02 1.52 
BB360713 -1.79 1.03 1.46 1.51 
AA124924 1.03 -2.17 1.30 1.51 
BB206107 1.03 -2.17 1.24 1.51 
BC006682 -1.79 1.06 1.44 1.50 
BG076081 -1.79 -2.17 1.41 1.50 
BG092512 1.12 -2.17 6.02 1.82 
BM241271 -1.79 -2.17 2.49 1.24 
BC010291 -1.79 -2.17 2.30 1.05 
BC021340 1.02 -2.17 2.30 1.37 
NM_134083 -1.79 -2.17 2.24 1.96 
BB668084 1.03 -2.17 2.13 1.03 
BC021353 -1.79 -2.17 1.86 1.47 
D45203 -1.79 1.21 1.76 1.65 
AV334671 -1.79 -2.17 1.73 1.33 
BG075830 -1.79 1.05 1.66 1.61 
AJ428067 1.12 1.12 1.65 1.35 
AW552116 1.30 1.10 1.61 1.41 
BB183736 -1.79 1.03 1.60 1.44 
BB284338 -1.79 1.02 1.59 1.50 
BB317673 -1.79 -2.17 -2.16 -2.35 
BB396413 1.07 -2.17 -2.06 -2.24 
AY037804 -1.79 -2.17 -1.94 -2.09 
AI467657 1.69 1.14 -1.85 -2.07 
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 Fold Change (IFN-γ-expressing / non-expressing) 
Accession No. 11wk-E 11wk-L 14wk-E 14wk-L 
AW539538 -1.79 -2.17 -2.92 -2.02 
BB699319 -1.79 -2.17 -1.59 -1.99 
AV377712 1.04 -1.21 -1.79 -1.86 
AV277957 -1.79 -1.16 -1.68 -1.79 
BG073424 -1.79 -2.17 -1.71 -1.75 
AW491150 1.13 -2.17 -1.63 -1.72 
AK019929 -1.79 1.05 -2.41 -1.71 
AK020028 1.01 -2.17 -1.50 -1.64 
BF225441 -1.79 -2.17 -1.75 -1.62 
BB536648 -1.79 -2.17 -1.70 -1.52 
AV069567 -1.79 -2.17 -1.98 -2.67 
BB458460 -1.79 -2.17 -1.98 -2.38 
BE992311 -1.79 -2.17 -1.98 -2.23 
BB209438 1.06 -2.17 -1.98 -2.20 
BC021536 -1.79 -2.17 -1.47 -2.13 
BB400326 1.00 -2.17 -1.98 -2.13 
BB035728 1.03 -2.17 -1.98 -2.11 
BB440272 1.11 -2.17 -1.98 -2.10 
BC024693 -1.79 -1.16 -1.98 -2.10 
BB108987 1.04 -2.17 -1.98 -2.05 
BB258427 1.12 -2.17 -1.98 -2.02 
BB541793 1.16 -2.17 -1.98 -2.02 
BB794177 1.18 -2.17 -1.98 -1.96 
BB122985 1.35 -2.17 -1.98 -1.96 
AI415469 -1.79 -1.34 -1.40 -1.88 
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 Fold Change (IFN-γ-expressing / non-expressing) 
Accession No. 11wk-E 11wk-L 14wk-E 14wk-L 
BM936011 -1.79 -2.17 -1.98 -1.87 
BB321110 -1.79 -2.17 -1.98 -1.82 
BB284482 -1.79 -2.17 -1.98 -1.79 
W65070 -1.79 -2.17 1.15 -1.78 
BB251205 1.04 -2.17 -1.98 -1.74 
AV249015 1.05 1.02 -1.42 -1.72 
AV347904 -1.79 -2.17 -1.32 -1.68 
BM899529 -1.79 -2.17 -1.98 -1.67 
BB397392 -1.79 -2.17 -1.98 -1.64 
AV056885 -1.18 -1.22 -1.98 -1.64 
BB049966 -1.79 -2.17 -1.98 -1.64 
BG797460 -1.79 -2.17 -1.98 -1.60 
BI320076 -1.79 -2.17 -1.39 -1.58 
BG067784 1.03 1.06 -1.98 -1.57 
N28111 -1.79 -2.17 -1.26 -1.57 
BB172440 1.03 1.00 -1.41 -1.57 
BB487787 -1.79 1.05 -1.32 -1.56 
BC013667 1.09 -2.17 -1.98 -1.56 
BC024955 1.01 -2.17 -1.25 -1.55 
BB258011 1.02 1.00 -1.98 -1.52 
AV175293 -1.79 -2.17 -1.46 -1.51 
BF459077 1.04 1.00 -1.98 -1.50 
BG069690 1.05 -2.17 -1.31 -1.50 
BB238478 -1.79 -2.17 -2.14 -1.72 
BB309880 1.10 1.00 -2.12 -1.72 
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 Fold Change (IFN-γ-expressing / non-expressing) 
Accession No. 11wk-E 11wk-L 14wk-E 14wk-L 
BM117872 1.00 -2.17 -1.95 -1.72 
BE685667 2.35 1.04 -1.78 -1.72 
AW456636 -1.79 -2.17 -1.74 -1.72 
AV343258 -1.79 -2.17 -1.66 -1.72 
BB811311 1.07 -1.14 -1.57 -1.47 
BM118846 1.14 1.01 -1.57 -1.72 
AI503942 -1.79 -1.21 -1.55 -1.72 
C77386 1.00 -2.17 -1.53 -1.72 
BM243944 -1.79 1.05 -1.52 -1.72 
 
 
 
 
 
 
 
 
 
CHAPTER FOUR 
 
CONCLUSION 
 
 
1.  Affymetrix GeneChip® Technology 
    The manufacturing of Affymetrix GeneChips® can be viewed in detail at 
www.affymetrix.com.  Briefly, a GeneChip® is comprised of a small quartz wafer that is 
reactive to light energy by covalently-linked surface molecules.  Photolithographic masks are 
used to direct the placement of ATCG nucleotides in a series of reactions that results in the 
synthesis of 25-mer oligonucleotides covalently linked to the array surface.  These 
oligonucleotides, or “probes,” are designed to complement specific, usually unique, mRNA 
sequences.  For each gene or EST (hereafter referred to as gene) represented on the array, 
there are perfect match (PM) probes, which are exact complements of their target sequence; 
and for each PM probe, there is a mismatch (MM) probe, which is mutated at the 13th base.  
A “probe pair” then is a single set of PM and MM probes.  For each target sequence, there 
are 11-20 probe pairs (collectively the “probe set”), depending on the specific GeneChip,® at 
different locations on the array.  Altogether on a single mouse genome array (MOE 430), for 
example, there are ~45,000 target sequences represented by ~100 million probes.   
    Target RNA is amplified by first reverse transcribing to cDNA; then in vitro transcription 
incorporating biotin is used to synthesize biotin-labeled cRNA.  The labeled cRNA is 
fragmented, added to control target sequences, and hybridized to the probe sequences on the 
array.  Post hybridization, the array is washed and stained with R-phycoeurythrin-
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streptavidin, which has a very high affinity for biotin.  The array is then scanned for R-
phycoerythrin signal and the individual intensity for each PM and MM probe is recorded.  
These intensity values must be summarized to generate a single, meaningful, estimate of 
expression for each gene and EST on the array.   
 
 
2.  Microarray Analysis 
    On Affymetrix GeneChips® the PM probes measure the specific binding of a particular 
target sequence, and the MM probes are intended to measure non-specific binding.  In order 
to generate a single value of expression that accurately represents the relative amount of 
starting target sequence in a sample, the hybridization signals for the probe set must be 
mathematically summarized.  The first algorithm offered by Affymetrix, Microarray Suite 
(MAS) 4.0, simply subtracts the MM signal from its corresponding PM signal and averages 
(Tukey biweight) the differences for the probe set (Affymetrix, 1999).  This algorithm 
assumes the variance is equal for all probes, which is not the case, since the variance 
increases with increasing signal values (Irizarry et al., 2003a).  The inaccuracy of MAS 4.0 
spawned the evolution of several different algorithms, each attempting to provide precise, 
statistically and biologically sound measure of expression.   
    Using spike-in and dilution experiments, Irizarry et al. (2003a) formed a detailed 
comparison of the most widely used analysis programs.  They evaluated the current 
Affymetrix algorithm, MAS 5.0 (Affymetrix, 2001), which is an improvement over MAS 4.0 
in that it substitutes the MM value with a CT value, where CT = MM when MM < PM, and 
CT is a value less than PM when MM ≥ PM, which is the case for approximately one-third of 
all probes (Irizarry et al., 2003b; Naef et al., 2002).  While MAS 5.0 is more accurate than 
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MAS 4.0, it is still dependent on the variance between probes, which is problematic since the 
variance between probes is great.  In fact, the standard deviation between probes is 
approximately 5 times greater than the standard deviation between arrays (Li and Wong, 
2001; Irizarry et al., 2003b).   
    Li and Wong (2001) developed a multiplicative model (dChip) where the expression 
estimate is the PM-MM value minus the error estimate, divided by an estimate of the probe 
affinity effect.  Estimating probe affinity effects, however, requires numerous arrays, and the 
error in this model is assumed to have normal distribution (Irizarry et al., 2003a).  The Miles 
group (Zhang et al., 2002; Kennedy et al., 2006) developed the S-score analysis tool, which 
provides an accurate determination of statistically significant differential expression 
compared to the RMA algorithm used in our experiments here; however, it does not 
determine relative gene expression estimates.  Therefore, one may know whether a gene is 
expressed at significantly different levels between samples, but not the relative robustness of 
expression in each sample.   
    The RMA model was chosen for this work based on its success in spike-in and dilution 
experiments compared to the algorithms described above (Irizarry et al., 2003a).  RMA is a 
log scale linear model in which the PM value is corrected for background, normalized across 
sets of arrays, and log transformed to give T(PM).  T(PM) is then equal to the sum of the log2 
scale expression value on the arrays, the log scale affinity effects for the probe sets, and the 
error estimate (Irizarry et al., 2003a).  Importantly, this model ignores the MM value based 
on evidence that mathematical and biological subtraction of the non-specific binding MM is 
meant to represent is not always the same (Irizarry et al., 2003a).  Spike-in and dilution 
experiments indicate that RMA is superior to MAS and dChip models in expression estimate 
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precision, fold change consistency, and specificity and sensitivity of determining differential 
expression (Irizarry et al., 2003a). 
 
3.  Limitations of Microarray Experiments 
    Microarray technology allows entire genomes to be surveyed for transcription regulation 
changes simultaneously in response to external stimuli, transgene expression, gene 
mutations, disease, and many other treatment schemes.  In many experiments, certain 
outcomes or genes of interest may be predicted; however, unexpected, uncharacterized and 
unknown genes are often found to be differentially regulated and can lead to the 
identification of novel genes and novel gene functions.   
    Microarray analysis is an excellent launching pad for plucking out a small number of 
potentially important genes among thousands; however, as with any technology, there are 
limitations.  Controlling the variance between samples and between arrays is essential in 
order to maximize the usefulness of array results.  The Affymetrix system used here has 
demonstrated excellent precision across numerous arrays with spike-in control RNA such 
that the variance between arrays has become nearly negligible (https://www.affymetrix.com/ 
support/downloads/manuals/data_analysis_fundamentals_manual.pdf).  RNA isolation, 
amplification reactions, and hybridization are more real potential sources of variability.  In 
all of experiments described here, the equipment, reagents, and techniques were extremely 
consistent.  Also, the ratios of RNA to protein (260/280 absorbance) were within the 
acceptable range (1.8 -2.1), and gel electrophoresis indicated that the RNA was not degraded.  
Probe pairs are designed with a 3’ bias for target sequences; whereas, control sequences have 
both 5’ and 3’ probes.  The ratio of 5’ to 3’ binding of the controls was very low, also 
 260
indicative of in tact RNA.  The largest source of variability between samples, therefore, was 
most likely from biological inconsistencies between experimental animals and primary cell 
cultures.  This notion has also been suggested in Affymetrix technical manuals 
(www.affymetrix.com/support).  Ideally, a large cohort of replicates would be analyzed for 
control and experimental groups; however, there are obvious limitations to the number of 
replicates that can feasibly be achieved when working with cell cultures, transgenic animals, 
and relatively costly technology.   
    Biological variability is difficult to control and, the author believes, warrants adjustment of 
the parameters that determine statistical significance between control and experimental 
samples.  For this reason, a p-value cutoff of 0.1 was used instead of the more traditional 
0.01 or 0.05, proposing that this results in fewer false negatives than it causes false positives.  
An argument for this is the observation that the largest fold changes in gene expression are 
principally measured when a gene is not constitutively expressed (or expressed at very low 
levels) in one group and highly expressed in another.  Analysis of these and other data 
support the concept that it is at these high levels of transcription the biological variance 
expands.  With few replicate samples, small degrees of variance quickly lead to large p-
values, even when a biologically significant difference in expression is evident.  On the other 
side of the coin, increasing the p-value cutoff opens the door for false positives when genes 
that are constitutively expressed in one group are moderately up- or downregulated in 
another group.  Here, it becomes more difficult to determine whether larger standard 
deviations among replicates are the result of normal biological variance or due to sample 
processing error or array artifact.  For smaller fold change values between constitutively-
expressed genes, it becomes more important to restrict significance to lower p-values as there 
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is a greater probability of obtaining false positives.  These caveats have been taken into 
consideration when reporting array analysis results for these experiments.       
    
4.  Immature OLs Respond Differently to IFN-γ than Mature OLs 
    Reported effects of IFN-γ on oligodendrocytes cultures have varied among groups.  
Vartanian et al. (1995) observed cell death in both developing and mature OLs exposed to the 
cytokine; whereas, other groups found cell metabolism and proliferation to be disrupted 
(Agresti et al., 1996), but no IFN-γ-induced cell death (Agresti et al., 1996; Turnley et al., 
1991).  Previous studies in our lab demonstrated apoptotic cell death in immature OLs after 2 
days of IFN-γ exposure and necrotic cell death in mature populations after 4-7 days of 
cytokine exposure (Baerwald et al., 1998).   
    As is discussed in further detail in section 5, evidence is mounting that suggests not only 
the developmental stage of OLs, but also the timing and dose of IFN-γ exposure are 
important factors in its effect on OLs and (re)myelination (Gao et al., 2000; Lin et al., 2005, 
2006, unpublished data).  For example, Turnley et al. (1991) treated developing OL cultures 
with 20U/mL of IFN-γ and observed no cell death.  In contrast, Baerwald et al. (1998) 
showed that after 2 days of IFN-γ exposure at 100U/mL, developing OLs extended fewer 
processes and a higher percentage of cells underwent apoptosis (as measured by TUNEL 
assay).  Baerwald et al. (1998) also examined the effect of IFN-γ on mature cells by allowing 
progenitors to develop for 7 days in culture before treating them with 100U/mL IFN-γ for 
several days.  After 2 and 4 days of cytokine exposure they observed a decrease in MBP, 
PLP, CGT, MAG and CNP message, and an increase in MHC class I and GAPDH message.  
They did not see evidence of apoptosis, but rather necrosis in these cells.   
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    Here we treated progenitor cells with 100U/mL IFN-γ for 24 hours, and with the same 
dose for 48 hours, we treated OLs that had been allow to mature for 3 days in differentiation-
promoting medium.  We measured mRNA expression by microarray hybridization and 
predicted that the immature and mature OL populations would respond differently to IFN-γ 
exposure.  Accordingly, we found some differential gene regulation between the two groups 
of cells as summarized in Table 4.1.   
    After 1 day of IFN-γ exposure, immature cells showed an increase in message for myelin 
proteins MBP, PLP, and CNP compared to non-treated controls (Table 4.1).  Cholesterol 
biosynthesis enzymes, including the rate-liming enzyme HMGCR, along with the cholesterol 
transporter ApoE were also upregulated in these cells.  In contrast, we found either no change 
or only a slight decrease in these genes in mature OLs exposed to IFN-γ.  One possible 
explanation for the increase in myelin-related gene expression in the immature but not 
mature OLs is a link between IFN-γ exposure and the stage of development.  Another 
possibility, however, is that a short course (24hrs) of IFN-γ elicits different effects than the 
longer courses (2-4 days) that have resulted in downregulation of myelin genes (Baerwald et 
al., 1998; Lin et al., 2005). 
    The most robust changes in expression were observed in MHC genes and in genes 
involved in protein processing and degradation.  Both MHC class I and class II genes were 
upregulated in immature and mature OLs exposed to IFN-γ.  The upregulation of class I and 
class I processing genes was more robust in mature cells, while the induction of class II and 
class II processing genes was more robust in immature cells.   
    The expression of IFN-γ receptor did not change significantly upon IFN-γ exposure in 
either cell population; though, immature cells treated with the cytokine expressed 
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approximately 57% more receptor than did IFN-γ-treated mature cells.  Nevertheless, the 
mature cells were exposed to IFN-γ longer than the immature cells (2 days versus 1 day), 
which perhaps accounts for the increase in class I expression.   
    An explanation for the increased class II expression in the immature cells is that progenitor 
cells have been shown to express more class II than mature OLs (Turnley et al., 1991), 
although, mature OLs in the presence of physiological levels of glucocorticoid are also able 
to express some class II (Bergsteindottir et al., 1992).  It is likely, then, that the immature 
cells in culture are intrinsically capable of higher class II expression. 
    We hypothesized that since OLs are already generating large amounts of membrane lipid 
and protein, which must go through the ER, the additional robust expression of MHC and 
protein processing machinery (Table 4.1), which also utilize the ER, could compound the ER 
stress; and moreover, this ER stress would be the source of apoptotic death in OLs.  Cells 
respond to ER stress by upregulating protein folding chaperones, increasing retrograde 
transport of molecules out of the ER, increasing protein degradation, and decreasing protein 
translation (Rutkowski and Kaufman, 2004; Rao et al., 2004; Ma and Hendershot, 2001).  
We observed an upregulation that was more robust in IFN-γ-treated immature than mature 
cells in protein folding chaperones including HSPA9A and HSPCA and in the translation 
initiation factor eIF2A.  Concurrently, in response to IFN-γ treatment of mature OLs, Lin et 
al. (2005) observed an increase in the ER stress markers BIP and CHOP, and an increase in 
the phosphorylation of eIF2A, which has been shown to attenuate protein  translation in 
response to ER stress (Lin et al., 2005; Jousse et al., 2003).            
    Additionally, we observed a decrease that was more prominent in immature than mature 
IFN-γ-treated OLs in additional translation initiation factors including eIF2C1 and eIF4E, 
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which may represent a decrease in protein translation (Table 4.1).   Furthermore, several 
genes involved in ubiquitin-mediated and 26S proteasome-mediated protein degradation 
were upregulated, but were not consistently higher in the immature or mature cells after 
cytokine exposure.   
    There was also evidence of an oxidative stress response in the immature OLs by the strong 
upregulation of the oxidase inhibitor CYBA along with antioxidant-inducing transcription 
factors NFE2L2 and NFkB1.  Moreover, we found evidence of increased apoptosis in the 
immature cells by the upregulation of the DNA fragmentation gene CIDE-B, and its 
downregulation in mature cells.  This is consistent with reports that mature OLs are more 
resistant to IFN-γ-induced cell death (Baerwald et al., 1998).  Additionally, IGF-1, which 
promotes early differentiation in progenitor cells and has a protective effect on OL survival 
(Ye et al., 1995; Mason et al., 2000; Gao et al., 2002), was robustly expressed in non-treated 
immature OLs, ~10 times the average expression on the array and ~6 times higher than in 
non-treated mature OLs.  This agrees with the expectation that there would be more actively 
differentiating cells after 1 day in differentiation-promoting medium than after 5 days.  In 
both immature and mature populations, IFN-γ treatment resulted in a decrease in IGF1; 
however, the decrease was considerably less in the mature cells, which may again point to 
their resistance against the harmful effects of IFN-γ. 
    Taken together, these data suggest that while there is robust MHC and protein processing 
genes in both immature and mature OLs in response to IFN-γ exposure, there may be more 
severe ER stress elicited in the immature cells, which may then lead to apoptosis.  Therefore, 
it would appear that the detrimental effects of IFN-γ on OLs are influenced by the 
developmental stage of the cells and perhaps the length of time they are exposed to IFN-γ.  
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Moreover, these data suggest that the deleterious effects are a result of robust induction of 
antigen presenting and protein processing genes, which tax the ER and elicit stress.  Since 
microarray analysis measures mRNA, determining the protein levels of these genes and the 
phosphorylation state of eIF2A will provide a clearer understanding of the ER stress response 
and apoptosis in immature versus mature cells exposed to IFN-γ.   
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Table 4.1  Results Summary of Immature and Mature OLs Exposed to IFN-γ.  Replicate 
RNA samples from each treatment group were hybridized to separate arrays.  The average of 
replicate normalized expression estimates for each sample group was used to calculate the 
fold change difference in expression for each gene.  Positive fold change values indicate an 
increase, and negative values indicate a decrease in gene expression in the IFNγ-treated 
groups.  Values in gray indicate the Student’s t-test p-value was greater than 0.1; the asterisk 
indicates there was one sample for each treatment.  Underlined values indicate the gene was 
represented by more than one accession number on the array and the fold change values were 
averaged. 
 
 
 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs)  
Gene Name Immature Mature Gene Function 
IFN-γ Signal Transduction    
IFN-γ receptor -1.32 -1.19* receptor for IFN-γ 
JAK  1.52  1.35* binds IFN-γ receptor and is phosphorylated 
STAT1  19.7  17.3 
binds phosphorylated JAKs, 
translocates to nucleus, induces GAS 
sequence-containing genes 
SOCS-1  1.75  2.15* binds phosphorylated JAKs, prevents STAT1 gene induction 
    
Myelin-Related  Genes    
CNP  2.38  1.03 cell membrane extension 
MBP  3.43  1.12 myelin compaction 
PLP  2.14 -1.34 myelin compaction 
HMGCR  1.54  1.18 rate-limiting step in cholesterol synthesis
APOE  2.13  1.09 cholesterol transport & recycling 
    
Protein Processing    
MHC Class I  6.59  9.41 presents antigen recognized by CD8+     T cells 
B2M  6.96  11.5 transport of class I antigen to cell surface
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 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs)  
Gene Name Immature Mature Gene Function 
TAP1  15.7  21.5 protein transport in and out of ER 
PSMB9  25.5  30.5 20S proteasome-mediated protein degradation 
MHC Class II  6.94  3.87 presents antigen recognized by CD4+ T cells 
MHC class II transactivator  8.11  3.49 transports class II from nucleus to endosome 
CD74 invariant chain  25.2  21.6 transports class II out of  the endosome 
cathepsin S  3.51  2.37 class II endosomal processing 
HERC6 ubiquitin ligase  4.22  7.01 ubiquitin-mediated protein degradation 
ubiquitin D  14.9  33.9 ubiquitin-mediated protein degradation 
cathepsin Y  8.36  1.44* proteolysis & peptidolysis 
poly(ADP-ribose) polymerase 9 (PARP9)  11.3  13.4* proteolysis & peptidolysis 
    
ER Stress Response    
heat shock protein, A  (HSPA9A)  3.17  1.14 protein folding chaperone 
heat shock protein 1a (HSPCA)  2.62  1.74* 
protein aggregation prevention, protein 
folding chaperone, ubiquitin-mediated 
protein degradation 
eIF2A  4.01  3.10 
protein translation initiation 
(phosphorylated form attenuates protein 
translation) 
eIF2C1   -1.93 -1.13* protein translation initiation 
eIF4E -1.89 -1.37* protein translation initiation 
    
Oxidative Stress Response    
cytochrome b558 alpha (CYBA)  5.26  1.44 inhibits oxidase 
NF-E2-related factor 2 (NFE2L2)  3.58  1.32 transcription factor that induces anti-oxidant genes 
NF kappa B p105 subunit (NFkB1)  2.53  1.35 transcription factor that induces anti-oxidant genes 
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 Fold Change 
(IFN-γ-tx OLs / Non-tx OLs)  
Gene Name Immature Mature Gene Function 
Apoptosis    
cell death-inducing DNA fragmentation 
factor, alpha subunit-like effector B 
(CIDE-B)  
 2.85 -1.54* DNA fragmentation - induction of apoptosis 
    
Survival    
insulin-like growth factor I  -3.57 -2.00 promotes cell survival 
    
Miscellaneous Genes    
complement component 1, q 
subcomponent, gamma polypeptide 
(C1QG) 
 7.31  1.26* classical complement activation 
serine (or cysteine) proteinase inhibitor, 
clade G (C1 inhibitor), member 1 
(SERPING1) 
 4.44  7.09 complement activation inhibitor 
chemokine (C-X-C motif) ligand 11   21.6  3.03* induces chemotactic response in activated T cells 
Fc IgG receptor III  6.44  2.11 promotes macrophage activation & cytokine release 
integrin alpha L  2.14  1.11* T cell induction of EAE 
leukocyte antigen MRC-OX44 (CD53)  4.52  1.34 may promote cell survival and resistance to H2O2 
CD9 antigen  2.16 -1.59 
associates with integrins at cell surface, 
upregulated in response to brain 
pathogenesis 
coronin, actin-binding protein 1B  2.85  1.18 regulates cell motility 
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5.  Timing of IFN-γ Induction Influences the Outcome of Remyelination 
    Increasing evidence suggests that the timing of IFN-γ expression relative to a 
demyelinating insult influences the outcome of remyelination (Gao et al., 2000; Lin et al., 
2005, 2006, unpublished data).  Transgenic animals expressing low levels of IFN-γ 
commensurate with MBP expression are asymptomatic and resistant to cuprizone-induced 
demyelination (Gao et al., 2000); whereas, under the same transgenic system, animals 
expressing elevated levels of IFN-γ exhibit tremor, astrogliosis and hypomyelination (Corbin 
et al., 1996; Horwitz et al., 1997).  In the cuprizone model, IGF1 expression increases with 
increasing demyelination (Komoly et al., 1992; Mason et al., 2000; Jurevics et al., 2002).  In 
low IFN-γ-expressing animals, IGF1 expression is markedly increased prior to the 
demyelinating insult, and demyelination is less severe (Gao et al., 2000).  In addition, there is 
a slight increase in the number of astrocytes and microglia present in the corpus collosum 
prior to demyelination in the low-level expressers; however, there is very little sign of 
microglia activation, astrogliosis, or oligodendrocyte cell loss during cuprizone treatment in 
these animals (Gao et al., 2000).   
 
The timing of IFN-γ induction does not affect demyelination or EAE severity. 
    The double transgenic (GFAP/tTA x TRE/IFN-γ) mice used in the experiments reported 
here express elevated levels of IFN-γ, are hypomyelinated, and tremor (Lin et al., 2004, 
2005, 2006).  IFN-γ was effectively suppressed in these animals with doxycycline from 
conception to 6 weeks of age.  The early expressers were released from dox at the same time 
cuprizone treatment began and showed appreciable levels of IFN-γ two weeks later when 
demyelination was evident, but not yet complete.  In the late expressers, IFN-γ was induced 
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two weeks into cuprizone treatment and was again detected two weeks later when the corpus 
collosum was fully demyelinated.  The difference in the timing of IFN-γ induction did not 
affect the extent of demyelination by cuprizone (Lin et al., 2006, unpublished data).  In a 
separate experiment, the double transgenic animals were immunized with MOG to induce 
EAE, and IFN-γ induction was timed such that marked cytokine levels occurred 
concomitantly with the peak of disease severity; therefore, IFN-γ did not affect the degree of 
demyelination.   
    Very few oligodendrocytes remain in the corpus collosum at 11wks when demyelination is 
maximal (Matsushima and Morell, 2001; Mason et al., 2000; Lin et al., 2006), thus, the 
changes in gene regulation we measured at 11wk-E and 11wk-L likely originated from the 
large population of astrocytes that appear upon OL loss, and NG2+ progenitors, which 
infiltrate the corpus collosum beginning around 4wks of cuprizone treatment.  A summary of 
these results in gene regulation is shown in Table 4.2.   
    The only substantial change in gene regulation in the late IFN-γ expressers at the peak of 
demyelination was in MHC class I, and this induction was still significantly less than that 
observed in the early expressers (Table 4.2).  In these experiments, MHC induction may have 
occurred in astrocytes and/or the few remaining OLs left in the corpus collosum at 11wks.    
    In the early expressers, IFN-γ was present before demyelination reached maximum; 
therefore, more OLs were presumably exposed to the cytokine.  Accordingly, we found 
measurable induction of MHC class I and II in the early expressers (Table 4.2).  There was 
also evidence of decreased protein synthesis by the downregulation of RNU22 and several 
ribosomal proteins including RPS4X, as well as a decrease in genes involved in cell 
metabolism including PHGDH and PHPT1 (Table 4.2).  This decrease in global protein 
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synthesis and metabolism message may represent a shutting down of NG2+ progenitors in 
response to IFN-γ.  This is supported by observations from previous experiments in our lab 
that detected an initial increase in NG2+ cells at 10wks, but a decrease in progenitors at 
12wks in the early expressers (Lin et al., 2006; Lin and Popko, unpublished data).  
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Table 4.2  Results Summary of Gene Regulation at Peak Demyelination in Response to  
IFN-γ Expression.  Replicate RNA samples from each treatment group were hybridized to 
separate arrays.  The average of replicate normalized expression estimates for each sample 
group was used to calculate the fold change difference in expression for each gene.  Positive 
fold change values indicate an increase, and negative values indicate a decrease in gene 
expression in the IFNγ-treated groups.  Values in gray indicate the Student’s t-test p-value 
was greater than 0.1.  Underlined values indicate the gene was represented by more than one 
accession number on the array and the fold change values were averaged. 
 
 
            Fold Change 
(IFN-γ-expressing / non-expressing) 
Gene Name 11wk-E 11wk-L Gene Function 
IFN-γ Signal Transduction    
IFN-γ receptor -1.08 -1.18 receptor for IFN-γ 
JAK -1.03 -1.15 binds IFN-γ receptor and is phosphorylated 
STAT1 -1.05 -1.43 
binds phosphorylated JAKs, 
translocates to nucleus, induces 
GAS sequence-containing genes 
SOCS-1 -1.21 -1.26 binds phosphorylated JAKs, prevents STAT1 gene induction 
    
Protein Processing    
MHC Class I  10.9  3.62 presents antigen recognized by CD8+ T cells 
proteasome subunit beta type 3  -1.74 -1.09 20S proteasome-mediated protein degradation 
MHC Class II  6.61  1.51 presents antigen recognized by CD4+ T cells 
ubiquitin-specific ligase 11 -1.96 -1.10 ubiquitin-mediated protein degradation 
amyloid beta (A4) precursor protein-binding, 
family A, member 1 binding protein  -2.18 -1.09 proteolysis & peptidolysis 
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            Fold Change 
(IFN-γ-expressing / non-expressing) 
Gene Name 11wk-E 11wk-L Gene Function 
ER Stress Response    
heat shock binding protein 1  -1.56 -1.14 protein folding chaperone 
heat shock protein E1  -1.59 -1.38 protein folding chaperone 
RNA, U22 small nucleolar -2.76 -1.69 protein synthesis 
ribosomal protein S4, X-linked -2.36 -1.23 protein synthesis 
    
Miscellaneous Genes    
cyclin-dependent kinase 4 -2.31 -1.33 cell cycle 
activating transcription factor 5  -2.60 -1.82 differentiation 
metallothionein-like 5 -2.35 -1.48 differentiation 
anaphase promoting complex 5 -1.89 -1.11 cell growth 
mini chromosome maintenance deficient 7  -1.95 -1.33 cell growth 
enhancer of rudimentary -2.03 -1.13 metabolism 
3-phosphoglycerate dehydrogenase -2.25 -1.26 metabolism 
phosphohistidine phosphatase 1 -2.01 -1.05 metabolism 
coronin, actin-binding protein 1A -2.53 -1.24 regulates cell motility 
coronin, actin-binding protein 1C -2.20 -1.27 regulates cell motility 
cadherin 13 -1.81 -1.21 cell adhesion 
H3 histone 3B -1.81 -1.18 nucleic acid binding 
RNA binding motif protein 5  2.08 -1.07 nucleic acid binding 
membrane associated guanylate kinase, WW 
and PDZ domain containing 1 -2.02  1.25 signal transduction 
Rab2b -2.23 -1.32 signal transduction 
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Early expression of IFN-γ suppressed remyelination.   
    After 6 weeks of cuprizone treatment and 2 weeks of recovery without the toxicant, 
control animals showed an increase in myelin gene expression, an increase in mature OLs 
with a proportionate decrease in progenitor cells, and a ~48% recovery of remyelinated axons 
(Lin et al., 2006).  In contrast, the early expressers showed a decrease in myelin gene 
expression, fewer mature OLs, an increase in the number of astrocytes and macrophages, and 
a ~27% recovery of remyelinated axons (Lin et al., 2006).   
    Microarray analysis revealed robust upregulation of a large cohort of antigen presenting 
and processing genes in the early expressers.  These results are summarized in Table 4.3.      
Both MHC class I and class II were upregulated along with genes involved in their 
processing and assembly, including B2M, TAP1 and proteasome genes PSMB9 and PSME1, 
CD74 invariant chain, and cathepsin S.  The processing of class I occurs in the ER, and 
several recent experiments have indicated that the robust upregulation of MHC class I by 
IFN-γ in OLs, particularly actively myelinating OLs, leads to ER stress and that this ER 
stress is at least partially responsible for the observed OL cell death during remyelination 
(Lin et al, 2005, 2006, unpublished data).  In addition to the large induction of MHC and 
protein processing genes, we also observed an increase in genes involved in protein 
degradation, including ubiquitin-specific ligase 18, cathepsin C and PARP9 (Table 4.3).  
These data point toward an ER stress condition in the remyelinating corpus collosum; 
however, we did not find appreciable induction of protein folding chaperones, 
downregulation of protein translation initiators, or an upregulation of apoptotic genes.  
Additional experiments in our lab, however, have demonstrated robust induction of MHC 
and a ~2-fold increase in the ER stress markers BIP and CHOP in the early expressers (Lin et 
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al., 2005).  CHOP protein was also found to be upregulated ~1.8-fold at this time point (Lin 
et al., 2005).  Moreover, our lab has also reported that early IFN-γ expression results in a 
~66% reduction in the number of mature CC1+ OLs and only ~27% remyelination compared 
to ~48% in controls at 14wks (Lin et al., 2005).   
    Our analysis indicated a ~2.5-fold upregulation JAK and a ~3.3-fold upregulation of 
STAT1, which are downstream modulators of IFN-γ signaling.  Altogether, these data 
strongly suggest that IFN-γ induction prior to the completion of demyelination results in 
decreased remyelination and fewer mature OLs, which may, at least in part, be due to ER 
stress induced by robust induction of MHC and protein processing genes. 
     
Late expression of IFN-γ enhanced remyelination. 
    Compared to controls, animals in which IFN-γ had been induced two weeks into cuprizone 
treatment showed an increase in myelin gene expression, an equal number of mature OLs, an 
increase in the number of astrocytes that was equal to the early expressers, an increase in 
macrophages that was less than the early expressers, and remarkably, an increase in 
remyelination (55% vs. 48% in controls, p<0.05) (Lin et al., unpublished data).   
    Concordantly, in our array experiments, we observed a much weaker induction of 
downstream IFN-γ signaling genes.  To that end, while JAK was upregulated slightly more in 
the late expressers (~2.9-fold) than in the early expressers (~2.5-fold), STAT1 was 
upregulated only slightly in the late expressers (~1.5-fold) compared to early expressers 
(~3.3-fold) (Table 4.3).       
    In accordance with diminished IFN-γ signal transduction, we observed less induction of 
MHC class I and II and very little upregulation of MHC processing and transport genes than 
in the early expressers.  Furthermore, there was no increase, or only a slight increase, in 
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expression of IFN-γ-sensitive genes that were upregulated in the early expressers, including 
interferon-inducible protein 1, interleukin 6 receptor alpha, interleukin 13 receptor alpha 1, 
macrophage activation 2, and IFN-γ-induced GTPase (Table 4.3).   
    Consistent with previous experiments in our lab, we found an increase in myelin gene 
expression, including MBP, MAL, and QK, which supports the observation of increased 
remyelination in the late IFN-γ expressers compared to non-expressers (Lin et al., 
unpublished data).  Together, these data support other work in our lab suggesting IFN-γ 
expression after complete demyelination has a beneficial effect on subsequent remyelination.   
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Table 4.3  Results Summary of Gene Regulation during Robust Remyelination in Response 
to IFN-γ Expression.  Replicate RNA samples from each treatment group were hybridized to 
separate arrays.  The average of replicate normalized expression estimates for each sample 
group was used to calculate the fold change difference in expression for each gene.  Positive 
fold change values indicate an increase, and negative values indicate a decrease in gene 
expression in the IFNγ-treated groups.  Values in gray indicate the Student’s t-test p-value 
was greater than 0.1.  Underlined values indicate the gene was represented by more than one 
accession number on the array and the fold change values were averaged. 
 
 
            Fold Change 
(IFN-γ-expressing / non-expressing) 
Gene Name 14wk-E 14wk-L Gene Function 
IFN-γ Signal Transduction    
IFN-γ receptor -1.18 -1.09 receptor for IFN-γ 
JAK  2.54  2.94 binds IFN-γ receptor and is phosphorylated 
STAT1  3.32  1.48 
binds phosphorylated JAKs, 
translocates to nucleus, induces 
GAS sequence-containing genes 
SOCS-1 -1.21 -1.26 binds phosphorylated JAKs, prevents STAT1 gene induction 
    
Myelin-Related  Proteins    
myelin and lymphocyte protein 1.58 1.61 axo-paranode adhesion 
myelin basic protein 1.49 1.73 myelin compaction 
quaking 2.14 3.13 stabilizes MBP mRNA, regulates MAG splicing 
    
Protein Processing    
MHC Class I  51.0  21.9 presents antigen recognized by CD8+ T cells 
B2M  3.59  2.51 
transport of class I antigen to cell 
surface 
TAP1  1.98 -1.06 protein transport in and out of ER 
proteasome subunit beta type 9 (PSMB9)  4.62  1.57 20S proteasome-mediated protein degradation 
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            Fold Change 
(IFN-γ-expressing / non-expressing) 
Gene Name 14wk-E 14wk-L Gene Function 
proteasome 28 subunit, alpha (PSME1)  2.28  1.46 immunoproteasome-mediated protein degradation 
MHC Class II  39.4  9.43 presents antigen recognized by CD4+ T cells 
CD74 invariant chain  6.36  2.07 transports class II out of  the endosome 
cathepsin S  1.79  1.50 class II endosomal processing 
ubiquitin-specific ligase 18  2.34  1.25 ubiquitin-mediated protein degradation 
cathepsin C  2.15  1.66 proteolysis & peptidolysis 
poly(ADP-ribose) polymerase 9 (PARP9)  2.06  1.48 proteolysis & peptidolysis 
    
Protein Synthesis    
ribosomal protein 24 -1.48 -1.96 protein biosynthesis 
ribosomal protein L27 -1.22 -1.74 protein biosynthesis 
ribosomal protein 35 -1.40 -2.06 protein biosynthesis 
ribosomal protein 37a -1.13 -1.63 protein biosynthesis 
    
Miscellaneous Genes    
interferon-inducible protein 1  3.56  1.64 immune response 
interleukin 6 receptor, alpha  2.05  1.07 immune response 
interleukin 13 receptor, alpha 1  2.11  1.61 immune response 
macrophage activation 2  8.41  1.77 immune response 
cadherin 11  2.06  3.29 cell adhesion 
vascular cell adhesion molecule 1  2.06  1.72 cell adhesion 
zinc finger CCDC domain containing 6  3.04  2.14 nucleic acid binding 
Kruppel-like factor 4  1.32  2.19 transcription factor 
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           Fold Change 
(IFN-γ-expressing / non-expressing) 
Gene Name 14wk-E 14wk-L Gene Function 
nucleotide binding oligomerization domain 27  3.05  1.70 transcription factor 
period homolog 2  1.85  3.83 transcription factor 
prolactin regulatory element binding  -2.81 -3.17 transcription factor 
RNA-binding region containing protein 2  2.45  3.47 transcription factor 
IFN-γ-induced GTPase  5.44  2.18 signal transduction 
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Possible indirect effects of IFN-γ on remyelination. 
    The amount of astrogliosis was the same in the early and late expressers during 
remyelination; however, there were fewer macrophages in the late expressers.  Therefore, it 
is reasonable to surmise that IFN-γ may also exert indirect damaging effects on OLs and 
remyelination via these cells (Lin et al., 2006, unpublished data).  Activated macrophages 
release TNFα, which has been shown to negatively affect OLs in culture and exacerbate 
demyelination in vivo; and its cytotoxic effects are made worse by the presence of IFN-γ 
(Andrews et al., 1998; Merrill et al., 1993; for additional references see Plant et al., 2004).  
Macrophages have the role of phagocytosing debris, which at lesion sites would include 
apoptotic OLs and corresponding myelin sheath, thus perhaps the presence of macrophages 
in lower numbers in the late expressing animals plays a beneficial role in preparing lesion 
sites for remyelination, while in the early expressers the increase in IFN-γ recruits a 
detrimental number of macrophages (see also Lin et al., 2006).   
    Studies in our lab have also demonstrated a larger number of astrocytes after 4 weeks of 
cuprizone treatment in the corpus collosum of late-expressing animals compared to early 
expressers (Lin et al., 2006, unpublished data).  Perhaps, then, the increase in astrocytes prior 
to remyelination has some suppressive effect on macrophage and T cell recruitment and/or a 
positive effect on progenitor cells recruited to the lesion site (see also Lin et al., 2006).  This 
remains to be demonstrated, however.    
    Altogether, previous experiments in our lab and our results here make a strong argument 
for a dual role for IFN-γ, one that is time- and dose-dependent, on oligodendrocyte survival 
and remyelination after immune- and non-immune-mediated demyelination.  Immature OLs 
in culture die after a shorter course of IFN-γ treatment than do mature OLs (Baerwald et al., 
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1998).  In addition, expression of IFN-γ before the peak of demyelination negatively affects 
the outcome of remyelination; whereas, expression of the cytokine at full demyelination 
enhances remyelination as evidenced by a decrease in the number of mature OLs and the 
number of remyelinated axons in the early expressers compared to an increase in the number 
of mature OLs and the number of remyelinated axons in the late expressers (Lin et al., 2006, 
unpublished data).  Furthermore, microarray analysis presented here demonstrates that 
immature OLs exposed to IFN-γ yield a greater increase in genes involved in MHC antigen 
presentation, protein processing, ER stress response, oxidative stress response, apoptosis, and 
the immune response.  The concomitant upregulation of myelin-associated, proliferation, and 
survival genes may be attributed to sampling at a time IFN-γ exerted both beneficial and 
harmful effects.  Differential gene expression was observed in the same functional groups of 
genes in mature OLs exposed to the cytokine, but overall the response was diminished 
compared to immature OLs.  We also observed a more robust induction of immune response, 
MHC antigen and protein processing, and possibly ER stress response genes during 
remyelination when IFN-γ had been present prior to the height of demyelination.  Moreover, 
IFN-γ expressed later not only resulted in a suppressed immune response, but also an 
increase in myelin-associated genes and differentiation-promoting genes.  Sorting out the 
downstream factors, both direct and indirect, in response to IFN-γ stimulus at the different 
time points has potentially therapeutic benefit in mitigating immune-mediated demyelination 
and promoting myelin repair.   
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6.  Future Directions 
A.  Investigation of selected differentially expressed genes.  While microarray technology is 
a useful tool for global gene expression survey, further investigation is necessary to 
corroborate the level of differential expression and downstream protein translation as well as 
elucidate gene function.  In both experiments presented here, several less well characterized 
genes and numerous ESTs were significantly differentially regulated, and these are excellent 
candidates for further investigation by quantitative RT-PCR, ELISA or Western blot as well 
as gain-of-function (targeted expression) or loss-of-function (knock-out or mutation) 
analysis.  Other example candidate genes of interest would be those with potential T cell 
recruiting and activation properties.  ER stress seems to be a key factor in OL cell death in 
response to IFN-γ, and certain genes have been identified as important in the ER stress 
response in OLs, nevertheless, our analysis provides preliminary data that may identify 
additional key genes involved in that process.   
 
B.  Virtually all cells express the IFN-γ receptor, therefore, even though the corpus collosum, 
which is densely populated by oligodendrocytes, was used in our analysis, and the OL cell 
cultures used in these experiments were highly selective for OLs, other cell types were also 
present.  Combining a knock-out line of mice for one IFN-γ receptor subtype with a 
transgenic line with forced expression of the knocked out receptor subtype targeted to 
oligodendrocytes in a second combination with double transgenic IFN-γ expressing animals 
would allow evaluation of the response solely of OLs to the presence of IFN-γ at different 
time points relative to cuprizone-induced demyelination and EAE immunization.  Primary 
mix glial cultures could also be studied in this way from knock-out X transgenic animal lines.  
Such experiments have been initiated in the lab of Brian Popko.   
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C.  The JAK-STAT pathway is activated in response to IFN-γ-receptor binding and leads to 
the induction of several IFN-sensitive genes, which likely contribute to its adverse effects on 
OLs.  Both JAK and STAT were found to be robustly upregulated in response to IFN-γ in 
these experiments.  Suppressor of cytokine signaling-1 (SOCS1) interrupts JAK-STAT 
binding and thwarts IFN-γ signaling.  Exploiting SOCS1 expression in OLs has a potential 
therapeutic benefit, and initial experiments in our lab have demonstrated very promising 
results (see addendum:  Balabanov et al., in press).   
 
    Given the dual nature of IFN-γ signaling and its differential effects on demyelination and 
myelin repair, therapeutic strategies aimed at diminishing demyelination and promoting 
reparative myelin will likely depend on the timing of IFN-γ suppression.  Other challenges 
include the complex cascade of cross-reactive signal transduction and transcription regulation 
that may be both detrimental and beneficial, if not necessary, for mitigating the effects of 
immune-mediated demyelinating disorders.   
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ABSTRACT: 
    Interferon-gamma (IFN-γ) is a pleiotropic cytokine produced by T cells and natural killer 
(NK) cells that has been implicated as a deleterious factor in the immune-mediated 
demyelinating disorder multiple sclerosis.  In vitro, purified developing and mature 
oligodendrocytes have been shown to die in the presence of IFN-γ by apoptosis and necrosis, 
respectively.  Moreover, transgenic expression of IFN-γ in the CNS of mice during 
development results in tremor, hypomyelination and oligodendrocyte cell loss; and IFN-γ 
expression in adult animals following demyelinating insults inhibits remyelination.  In order 
to examine the molecular mechanisms of IFN-γ-induced oligodendrocyte injury, we 
generated a transgenic mouse line (PLP/SOCS1) that exhibits diminished oligodendrocyte 
responsiveness to IFN-γ due to the targeted expression of the suppressor of cytokine 
signaling 1 (SOCS1) in these cells.  We demonstrate that oligodendrocytes in the 
PLP/SOCS1 transgenic mice are protected against the injurious effect of IFN-γ.  Our data 
indicate that IFN-γ exerts a direct deleterious effect on developing oligodendrocytes.  The 
capacity of SOCS1 to inhibit the effects of IFN-γ suggests a therapeutic approach toward 
protection of myelinating oligodendrocytes against the harmful effects of inflammation. 
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INTRODUCTION: 
    Interferon-gamma (IFN-γ) is a pleiotropic cytokine produced by T cells and natural killer 
(NK) cells that is involved in a number of immune processes (Billiau, 1996).  IFN-γ is 
critical to the immunoregulation of autoimmune demyelinating disorders of the central 
nervous system (CNS) (Panitch et al, 1987; Galbinski et al., 1999; Tran et al., 2000; 
Skurkovich et al., 2001, Steiman 2001).  In addition, IFN-γ provides an intricate link between 
inflammation and oligodendrocyte injury.  Upon stimulation with IFN-γ, oligodendrocytes 
upregulate the expression of major histocompatibility (MHC) class I molecules, as well as 
other surface ligands and receptors (e.g., Fas, Hsp70, and TNF-αR) that are believed to 
facilitate cell-mediated cytotoxicity (Agresti et al., 1998; Pouly et al., 2000; Trougott et al., 
2001).  
    IFN-γ has the capacity to adversely affect oligodendrocytes and the process of 
myelination.  In vitro, developing oligodendrocytes die by apoptosis and mature 
oligodendrocytes succumb to necrosis in the presence of IFN-γ (Agresti et al., 1996; 
Baerwald et al., 1998; Andrews et al., 1998; Lin et al., 2005).  Transgenic expression of IFN-
γ in the CNS of mice during the first few weeks of postnatal development results in 
hypomyelination and oligodendrocyte cell loss (Corbin et al., 1996; LaFerla et al., 2000; Lin 
et al., 2005).  Moreover, the induction of IFN-γ expression following demyelinating insults 
significantly inhibits the remyelination process (Lin et al., in press).  Oligodendrocyte injury 
in these models has been related to dysregulation of protein synthesis and trafficking, 
accumulation of unfolded proteins in the endoplasmic reticulum (ER), and triggering of a 
proapoptotic stress response (i.e. ER stress response) (Baerwald et al., 2000; Lin et al., 2005). 
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    The molecular mechanism of IFN-γ–mediated injury to developing oligodendrocytes, 
however, remains unclear. Because of the global effects of IFN-γ on the CNS, either direct or 
indirect (via microglia) modes of oligodendrocyte injury are possible.  Therefore, 
differentiating between oligodendrocyte-specific and multicellular effects would allow for a 
better understanding of the molecular mechanisms involved in IFN-γ–mediated 
oligodendrocyte injury.  
    Suppressors of cytokine signaling (SOCS) are a family of proteins that inhibit intracellular 
Jak/Stat signaling and effectively “switch off” the signal transduction pathway (Starr et al., 
1997; Song and Shuai 1998; Stark et al., 1998; Sakamoto et al., 2000; Levy and Darnell, 
2002).  SOCS proteins are key intracellular regulators of cytokine-mediated homeostasis, 
ensuring a controlled cellular response (Yasukawa et al., 2000; Kubo et al., 2003).  SOCS1 is 
of particular interest because of its function as a regulator of cellular responsiveness to IFN-γ 
(Starr et al., 1998; Bullen et al., 2001; Alexander et al., 1999; Tunley et al., 2001, 2002; 
Chong et al., 2001; Federici et al., 2002).  Interestingly, the levels of SOCS1 expression in 
the CNS under both normal and inflammatory conditions are very low and virtually 
undetectable in oligodendrocytes (Polizzotto et al., 2000; Wang and Campbell, 2002; Maier 
et al., 2002). 
    In this report we describe a transgenic line of mice that ectopically expresses SOCS1 in 
oligodendrocytes under the transcriptional control of the gene encoding the myelin protein 
proteolipid protein (PLP).  PLP/SOCS1 mice exhibit a normal phenotype with diminished 
oligodendrocyte responsiveness to IFN-γ.  Moreover, we demonstrate that enforced 
expression of SOCS1 protects oligodendrocytes against the injurious effects of IFN-γ during 
development. 
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MATERIALS AND METHODS: 
PLP/SOCS1 mouse line 
    The transgenic mouse line PLP/SOCS1 was generated using a construct containing a PLP 
expression cassette and SOCS1 cDNA (Figure 1A).  The PLP expression cassette (a kind gift 
of Dr. Wendy Macklin, Cleveland Clinic, Cleveland, OH) has been described elsewhere and 
has been used for oligodendrocyte-specific expression of a number of transgenes (Wight et 
al., 1993; Fuss et al., 2000; Doerflinger et al., 2003; Gonzales et al., 2005). We used a 
SOCS1 cDNA clone (kindly provided by Douglas Hilton [Walter and Eliza Hall Institute, 
Melbourne, Australia]) (Starr et al., 1998) that contained a Flag-epitope sequence that served 
as a marker for SOCS1 expression in polymerase chain reaction (PCR)-based or anti-Flag 
antibody-based detection methods (Einhauer and Jungbauer, 2001).  Briefly, the Flag-SOCS1 
cDNA was excised from the original expression vector pEF-FLAG-I/m4A2 with XbaI.  The 
fragment was Klenow filled and subcloned into an intermediate vector (modified pNEB/193 
vector) at the SmaI restriction site. The resulting pNEB193/SOCS1 vector was further 
digested with AscI (partial digestion) and PacI to release the Flag-SOCS1 fragment, which 
was subcloned into the polylinker region of the PLP expression cassette at the same 
restriction sites.  The PLP/SOCS1 vector was digested with ApaI and SacII (partial digestion) 
and a linear 15-kb transgene was isolated for microinjection into fertilized (C57BL/6J × 
DBA/2J) oocytes.  Offspring positive for the transgene were identified by amplifying tail 
DNA by PCR using transgene-specific primers.  The identified founders were subsequently 
bred with C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) establishing a transgenic 
line. 
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IFN-γ–overexpressing Mice  
    The transgenic mice MBP/IFN-γ (line 172) and GFAP/tTA × TRE/IFN-γ (lines 184/110 
and 184/67) that overexpress IFN-γ in the CNS have been described elsewhere (Corbin et al., 
1996; Gao et al., 2000; Lin et al., 2004, 2005).  Briefly, MBP/IFN-γ (line 172) mice are 
transgenic animals in which IFN-γ expression is driven by the myelin basic protein (MBP) 
transcriptional control region (Gao et al., 2000).  GFAP/tTA × TRE/IFN-γ are double-
transgenic mice obtained by mating single-transgenic GFAP/tTA (line 184) to single-
transgenic TRE/IFN-γ (lines 110 and 67) mice.  The two TRE/IFN-γ mouse lines, line 110 
and line 67, used in the experiments produce different amounts of IFN-γ when crossed to 
GFAP/tTA mice (184/110 and 184/67) (Lin e al., 2004, 2005).  GFAP/tTA × TRE/IFN-γ is a 
tetracycline-off-inducible system in which the glial fibrilary acidic protein (GFAP) 
transcriptional control region drives the expression of tTA, which in turn, binds to the TRE 
(tet responsive element) and initiates the expression of IFN-γ.  Administration of doxycycline 
suppresses tTA DNA binding and IFN-γ expression, and doxycycline removal allows for 
temporally-controlled induction of IFN-γ expression (Gao et al., 1999).  
  
Mouse breeding and examination 
    IFN-γ-overexpressing mice were crossed to the PLP/SOCS1 mice in double-transgenic, 
(MBP/IFN-γ × PLP/SOCS1) and triple-transgenic (GFAP/tTA × TRE/IFN-γ × PLP/SOCS1) 
mating systems. MBP/IFN-γ × PLP/SOCS1 (172 × PLP/SOCS1) mating was performed 
according to a standard mating protocol.  The GFAP/tTA × TRE/IFN-γ × PLP/SOCS1 
matings were performed in a 2-step mating process: GFAP/tTA mice (line 184) were initially 
crossed to PLP/SOCS1mice, and double-positive (184 × PLP/SOCS1) offspring were then 
 290
crossed to the TRE/IFN-γ lines 110 and 67, separately.  This second mating step was 
performed according to the previously described “tet-off” protocol.  Doxycycline 0.05mg/ml 
(Sigma-Aldich) was added to the water of impregnated female mice until embryonic day 14, 
after which the animals were switched back to normal water, thereby allowing initiation of 
IFN-γ transcription, which peaks during the postnatal period (Lin et al., 2005).  
    The litters of the mating systems (F1 generation) were examined daily and sacrificed at 
postnatal day 21.  Clinical evaluation included behavioral observation and challenged ladder 
walking to elicit tremor.  Histological examination included quantitation of the number and 
density of oligodendrocytes and examination of the myelination patterns.  Brain tissue was 
simultaneously obtained from each animal at the time of sacrifice to verify and measure the 
expression of IFN-γ and Flag-SOCS1 (see below).  The clinical and histological findings 
were subsequently stratified according to genotype.  All animal procedures were conducted 
in compliance with the National Institutes of Health Guide for Care and Use of Laboratory 
Animals and were approved by the Institutional Animal Care and Use Committee at The 
University of Chicago. 
 
Polymerase-chain reaction and Genotyping 
    All experimental animals were genotyped using isolated tail DNA (Biotek 2000 automatic 
system, Beckman-Coutler, Fullerton, CA).  PCR (Qiagen,Valencia, CA) for transgene 
detection was performed using the following transgene-specific screening primers: Flag-
SOCS1 sense primer, 5’-CCAGGACGACGATGACAAGA-3’ and Flag-SOCS1 anti-sense 
primer, 5’-TCAGGGGTCCCCA ATAGAAG-3’; MBP/IFN-γ sense primer, 5’-
ATGAGGAAGAGCTGCAAAGC-3’, and MBP/IFN-γ anti-sense primer, 5-
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GGTGACAGACTC CAAGCACA-3’; GFAP/tTA sense primer, 5’-
TCGCTTTCCTCTGAACGCTTCTCG-3’ and GFAP/tTA anti-sense primer, 5’-
TCTGAACGCTGTGACTTGGAGTGTCC-3’; TRE/IFN-γ sense primer 5’-
CGAATTCGAGCTCGG TACCC-3’ and TRE/IFN-γ anti-sense primer 5’-
CCATCCTTTGCCATTCCTCCAG-3’ (Integrated DNA Technologies Inc.).   
 
Northern blots and Quantitative PCR (Q-PCR)   
    Total RNA was isolated from the examined animals with TRIzol reagent (Invitrogen 
Corp., Carlsbad, CA).  Northern blots were performed by separating 20µg of total RNA in a 
1.2% denaturing agarose gel.  The samples were transferred to a nylon membrane and 
hybridized overnight with a SOCS1 probe that had been randomly labeled by PCR 
(GenAmp2400; Perkin-Elmer, Welleslay, MA) with [α-32 P] dCTP and [α-32 P] dATP (New 
England Nuclear/Perkin-Elmer, Welleslay, MA).  Kodak film was exposed to the hybridized 
membrane at −80ºC for 48hrs and was developed using the M7B Kodak processor (Kodak, 
Rochester, NY).  To evaluate the relative levels of total RNA present in each lane the 
membrane was stripped and hybridized with a radiolabeled probe specific for the 28S 
ribosomal RNA (Baerwald et al., 1998). 
    Quantitative (Q-PCR, or real-time PCR) was performed by first reverse transcribing    1µg 
of DNAaseI-treated (Invitrogen) total RNA using oligo(dT)12-18 and SuperScript II reverse 
transcriptase (Invitrogen RT-PCR kit).  Q-PCR was performed using 20ng of the cDNA in a 
reaction containing iQSupermix and the following primers and probes for Flag-SOCS1 and  
IFN-γ: Flag-SOCS1 sense primer, 5’-GATGACAAGACGCGCCAG ATG -3’, Flag-SOCS1 
anti-sense primer, 5’-GAGGACGAGGAGGGCTCTGA-3’, and Flag-SOCS1 probe, 5’-
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56FAM-CGCACCCAGCTGGC AGCCGACATT-3BHQ-1/-3’; IFN-γ sense primer, 5’-
GATATCTCGAGGAACTGGCAAAA-3’, 5’- IFN-γ anti-sense primer 5’-
CTACAAAGAGTCTGAGGTAGAAAGAGATAAT-3’, and IFN-γ probe 5’-FAM-
TGGTGACATGAAAATCCTGCAGAGCCA-BHQ1-3’; GAPDH sense primer 5’-
CTCAACTACATGGTCTACATGTTCCA-3’; GAPDH anti-sense primer 5’-
CCATTCTCGGCCTTGACTGT-3’, and GAPDH probe, 5’-5TxRd-
XN/TGACTCCACTCACGGCAAATTCAACG-3BHQ-2-3’ (Integrated DNA Technologies, 
Inc.).  The reactions were performed using a BioRad I-cycler Real-Time PCR unit, under the 
following conditions: 1 cycle at 95ºC for 3 min, 40 cycles at [95ºC for 30 s and 60ºC for 30 
s] (Bio-Rad Laboratories).  The mRNA levels of Flag-SOCS1 and IFN-γ were normalized to 
the expression levels of GAPDH based on threshold cycles (Flag-SOCS1/GAPDH and IFN-
γ/GAPDH ratios) (Lin et al., 2005).  
 
Western Blot and Immunoprecipitation 
    Total lysates from brain and spleen of several PLP/SOCS1 mice and wild-type mice were 
obtained by tissue homogenization in RIPA buffer (Santa Cruz Biotechnology, Santa Cruz, 
CA). After incubation on ice for 15 min, lysates were centrifuged at 14,000 rpm for 30 min 
and the supernatants collected.  Protein samples (50µg) were electrophoresed on 15% SDS-
polyacrylamide gels, transferred to PVDF membranes (Trans-blot SD apparatus, Bio-Rad 
Laboratories), incubated overnight with mouse anti-Flag antibody (M2, diluted to 1:1000) 
(Sigma-Aldrich, St. Louis, MO), and detected with ECL Western blot detection reagents 
(Amersham Biosciences, Piscataway, NJ).  Flag protein (Sigma-Aldrich), a polymer of the 
Flag oligopeptide, was used as a positive control for the reaction.  
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    Immunoprecipitation was performed with an immunoprecipitation kit (Roche Molecular 
Biochemicals, Indianapolis, IN) by incubating the protein extracts from the brain and spleen 
of PLP/SOCS1 and wild-type mice with anti-Flag antibody (M2) for 4 hrs at 4˚C, followed 
by overnight incubation with protein A/C agarose at 4ºC.  The immune complexes were 
collected by centrifugation at 14,000 rpm for 20S and the protein was separated from protein 
A/C agarose with kit-supplied reagents.  Western blot of the immunoprecipitated protein was 
performed as described above.  
 
 Immunohistochemistry   
    Animals were anesthetized with 0.01 ml/g of 2.5% Avertin (Sigma-Aldrich) administered 
intraperitoneally and perfused with saline followed by 2% paraformaldehyde for 10 min.  
Brains were removed, postfixed for 1hr with 2% paraformaldehyde, cryopreserved with 30% 
sucrose for 48 h, prepared as frozen blocks (OCT compound, Sacura, Torrance, CA), and 
sectioned at a thickness of 7µm at −20ºC (Leica CM1800 cryostat, Leica Microsystems).  
Prior to immunostaining, the sections were treated with 0.1% Triton X-100 (Sigma-Aldrich) 
for 10 min and incubated with 10% bovine serum albumin (Sigma-Aldrich) or goat serum 
(Invitrogen) for 30 min.  Indirect immunostaining was performed by sequential incubation 
with primary antibodies (for 2 h at room temperature or overnight at 4ºC) and FITC-
conjugated or Cy3-congugated secondary antibodies (for 30 min).  All of the following 
primary and secondary antibodies used in the study were commercially available: mouse and 
rabbit anti-Flag antibody (dilution, 1:100; Sigma-Aldrich), mouse anti-CC1 antibody 
(dilution, 1:20; Oncogene), mouse MHC class I antibody (dilution, 1:100; Chemicon 
International, Temecula, CA), mouse anti-PLP, proteolipid protein, antibody (dilution, 1:100; 
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Chemicon International), mouse and rabbit anti-SOCS1 antibody (dilution, 1:100; Santa Cruz 
Biotechnology, Santa Cruz, CA), rabbit anti-Stat1 antibody (dilution, 1:100; Santa Cruz 
Biotecnology), anti-mouse or anti-rabbit FITC-conjugated secondary antibody (dilution, 
1:100; Jackson Immunoresearch, Bar Harbor, ME), and anti-mouse or anti-rabbit Cy3-
congugated antibody (dilution, 1:500; Jackson Immunoresearch). The immunostained 
sections were mounted using Vectorshield mounting medium containing DAPI nuclear stain 
(Vector Laboratories, Burlingame, CA) and examined using a fluorescent microscope 
(Axoplan; Carl Zeiss Microimaging).   
    Oligodendrocyte cell density was assessed digitally using Axiovision software, at postnatal 
day 21, as previously described (Lin et al., 2005).  The brains were sectioned sagittally 
through the corpus callosum dividing the brain in two symmetrical halves.  Ten frozen 
sections from each half were prepared at 7µm thickness, and numbered in the sequence of 
their preparation. The brains of three animals per study group were prepared in this fashion. 
Following the CC1 immunostaining the corresponding area of corpus callosum of each 
section was digitally selected and the corresponding total area obtained.  CC1 cell counting 
was performed manually within the selected areas of each section, and the number of CC1 
positive cells per square area (mm2) calculated.  The results were presented as mean±SD of 
CC1 (+) cells/ mm2 with n=3 animals per study group. 
 
Electron Microscopy 
    Mice selected for electron microscopy studies were perfused with 4% paraformaladehyde 
and 2.5% glutaraldehyde.  Brains were harvested, and white matter structures were sectioned 
using a stereotype microscope (Wild M3C; Wild AG, Heebrugg, Switzerland).  The tissue 
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was further postfixed in osmium tetroxide and embedded in freshly prepared Epoxy resin 
(Epon-812; Electron Microscope Sciences, Fort Washington, PA) for 48 hrs at 60ºC.  The 
resin blocks were sectioned at 90nm using Leica Ultracut ultramicrotome (Leica 
Microsystems) and stained with 5% uracyl acetate and 2.5% lead citrate.  Utrastructure of the 
tissue samples was examined using the Tecnai-F30 transmission electron microscope (FEI 
Company, Hillsboro, OR).   
    Myelination patterns of the examined animals were assessed at postnatal day 21 by 
calculating the percent unmyelinated axons and ratio of the axon/fiber diameters (G ratio) 
with Image J software (National Institutes of Health, Bethesda, MD) as previously described 
(Lin at al., 2005). The brains were sectioned sagittally through the corpus callosum dividing 
the brain in two symmetrical halves.  Approximately 2mm3 samples from the genu and the 
splenum of both halves of corpus callosum were obtained using a stereotype microscope 
(Wild M3C, Heebrugg, Switzerland).  The orientation of the specimen in the resin blocks 
yielding axonal crosssections (well seen myelin rings) was chosen, and established by 
toluedine blue staining of a few sample sections.  The resin blocks with the chosen 
orientation were processed for electron microscope examination.  Randomly selected areas 
were examined and ten representative pictures from both genu and corpus callosum were 
obtained at 12000X magnification.  The number of unmyelinated axons was assessed by 
manual counting of axons that lacked myelin and were encircled solely by their own plasma 
membrane.  All unmyelinated axons present in the representative images were counted, and 
their percentage calculated by examining a total of five hundred axons per tissue sample.   
The G ratio (axonal diameter/fiber diameter ratio) of myelinated axons was assessed by 
digitally selecting the area encircled by the inner and outer surfaces of the myelin sheath, 
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obtaining the axonal (inner) and the fiber (outer) diameters, and dividing their corresponding 
values (axonal diameter/fiber diameter ratio).  The brains of three animals per group were 
examined, and the G ratios of a total of 150 nerve fibers from both genu and splenum were 
examined.  The results were presented as mean±SD of G ratio and percent unmyelinataed 
axons with n=3 animals per study group.    
     
Mixed Primary Oligodendrocyte Cultures and Stat1 Translocation Assay 
    Mixed primary oligodendrocyte cultures were prepared as previously described (Baerwald 
et al., 2000).  Briefly, brain tissue was harvested from 2-3-day-old newborn pups of 
PLP/SOCS1 and C57Bl/6J matings.  Because the litters contained transgenic and wild-type 
pups, the brain of each animal was processed individually, cultured separately, and later 
genotype matched. Each brain was digested separately using 0.25% trypsin and 10µg/ml of 
DNAaseI (Invitrogen) in Dulbecco’s modified Eagle’s medium (DMEM) for 20 min at 37ºC, 
and cells were cultured on separate poly-D-lysine-coated 75-mm2 flasks (Sigma-Aldrich).  
The cultures were maintained with 10% fetal bovine serum DMEM at 37ºC with 5% CO2 for 
12 days, and then switched to a defined medium containing 5µl/ml of insulin, 50µg/ml of 
transferrin, 30nM of selenium, 10nM of biotin, 10nM of progesterone, 15nM of T3, 0.1% 
bovine serum albumin, and 1% ampicillin-streptomycin (Sigma-Aldrich).  On the fifth day of 
differentiation, the cultures were treated with 100U/mL of IFN-γ (Calbiochem, San Diego, 
CA) for 30 min.  Dual immunostaining for anti-PLP and anti-Stat1 antibodies, and DAPI 
nuclear staining were performed as described above. The Stat1 nuclear translocation assay 
was performed in six separate culture preparations. One hundred PLP positive cells were 
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manually counted in both wild-type and PLP/SOCS1 cultures.  The results were presented as 
mean±SD percent cells positive for Stat1 nuclear translocation. 
 
Statistical analysis 
    All data were generated from 3 independent experiments. Means, standard deviations, and 
p-values were calculated using Average, Stdev, and Anova in Microsoft Excel (Microsoft, 
Redmond, WA).  A statistically significant difference was defined as a p-value of < 0.05.  
 
RESULTS: 
Characterization of the PLP/SOCS1 Transgenic Mouse Line 
    The PLP/SOCS1 transgenic mice, which were generated as described in the Material and 
Methods section, were designed to express Flag epitope-tagged SOCS1 in myelinating cells 
(Fig. 1A).  These mice exhibit no phenotypic abnormalities, breed and produce transgenic 
progeny in a Mendelian fashion, and live a normal life span.  Histological evaluation, 
including electron microscopy, performed at different time points up to 1 year of age 
revealed no significant differences in the myelination patterns or the number, density, or 
morphology of oligodendrocytes (see below) between transgenic and wild-type littermates. 
    Expression of the PLP/SOCS1 transgene was characterized at postnatal day 21using 
several methods.  Northern blot analysis with a SOCS1 cDNA hybridization probe revealed a 
band of increased intensity in RNA samples from the brains of transgenic mice relative to 
control brain samples but not from other tissues (Fig. 1B).  Real-time PCR analysis with 
transgene-specific primers revealed the highest concentrations of transgene-derived SOCS1 
mRNA in brain, spinal cord, and sciatic nerve, with significantly lower levels in other organs 
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including heart, thymus, spleen, and liver (Fig. 1C).  Transgene expression appeared to be 
stable up to 12 months of age (data not shown).  
    Western blot analysis, using an antibody to the Flag tag, revealed a 19-kD band 
corresponding to the expected size of SOCS1 in the PLP/SOCS1 brain lysates, but not in 
wild-type brain lysates or PLP/SOCS1 spleen lysates (Fig. 1D).  To further confirm Flag-
SOCS1 protein expression, we performed immunoprecipitation with the anti-Flag antibody, 
which again detected a 19-kD positive band in the PLP/SOCS1 brain immunoprecipitates, 
but not in the wild-type brain or PLP/SOCS1 spleen immunoprecipitates (Fig. 1E). 
    Indirect immunostaining of wild-type and PLP/SOCS1 brains with both anti-SOCS1 and 
anti-Flag antibodies also demonstrated expression of the transgene (Fig. 1F-I).  We detected 
both anti-Flag and anti-SOCS1 immunopositivity only in PLP/SOCS1 brains.  
    To localize the expression of Flag-SOCS1 in the CNS, we performed dual immunostaining 
of wild-type and PLP/SOCS1 brain tissue with the anti-Flag antibody and either anti-PLP 
antibody, a marker for myelin, or anti-CC1 antibody, a marker for the oligodendrocyte cell 
body.  We found a strong colocalization between anti-PLP and anti-Flag antibodies, as well 
as between anti-CC1 and anti-Flag antibodies (data not shown), suggesting that Flag-SOCS1 
was localized to the white matter and oligodendrocytes (Fig. 2).  Non-colocalizing 
immunopositivity for anti-Flag, anti-PLP or anti-CC1 antibodies was not detected.   
    We were also able to detect the expression of Flag-SOCS1 in primary mixed 
oligodendrocyte cultures established from transgenic animals by dual immunostaining with 
anti-PLP and anti-Flag antibodies (Fig. 3).  Expression of Flag-SOCS1 was detected only in 
cultures from PLP/SOCS1 animals and only in cells expressing PLP. Virtually all PLP-
positive cells were also positive for Flag-SOCS1.  The colocalization between anti-Flag and 
 299
anti-PLP immunoreactivity appeared to involve both the cell body and cell processes (Fig. 
3F).   
 
Oligodendrocytes from PLP/SOCS1 Mice Exhibited Diminished Responsiveness to IFN-γ 
    The responsiveness of PLP/SOCS1 oligodendrocytes to IFN-γ was studied in primary 
mixed glial cultures.  To determine whether expression of transgenic SOCS1 would interfere 
with the nuclear translocation of the IFN-γ-signaling molecule Stat1, the cell cultures were 
treated with 100U/mL of IFN-γ for 30 min and immunostained using anti-PLP and anti-Stat1 
antibodies along with the DAPI nuclear stain (Fig. 4).  Examination of Stat1 subcellular 
localization in wild-type cultures revealed strong colocalization with DAPI-positive nuclei in 
all cells, including PLP-positive oligodendrocytes.  In contrast, subcellular localization of 
Stat1 in PLP/SOCS1 cultures revealed a differential response to IFN-γ.  In transgenic PLP-
positive oligodendrocytes, Stat1 remained in the cytoplasm and did not colocalize with cell 
nuclei in the presence of IFN-γ, (Fig. 4E–H).  This was in contrast to the response of the 
surrounding PLP-negative cells, which, similarly to wild-type cells, responded to IFN-γ with 
Stat1 nuclear translocation.  Virtually all PLP positive oligodendrocytes (96±3 cells) in the 
wild-type cultures responded to IFN-γ stimulation with Stat1 nuclear translocation.  In 
contrast, Stat1 nuclear translocation was detected only in occasional PLP positive 
oligodendrocytes (6±2 cells) following IFN-γ stimulation (p<0.05). 
    We next characterized the responsiveness of PLP/SOCS1 oligodendrocytes to IFN-γ in 
vivo using the induction of major histocompatibilty complex class I (MHC class I) molecule   
expression as an indication of IFN-γ sensitivity.  The capacity of SOCS1 to inhibit IFN-γ–
mediated induction of MHC class I molecule was examined in a double-transgenic system.  
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MBP/IFN-γ (line 172) single-transgenic mice, which express a low level of IFN-γ in the CNS 
(Gao et al., 2000), were mated to PLP/SOCS1 mice, and the single and double transgenic 
progeny were examined for differences in MHC class I molecule expression (Figure 5).  
MHC class I molecule expression was neither detectable in control wild-type mice nor 
PLP/SOSC1 mice (Fig. 5A–D).  Consistent with previous reports, MBP/IFN-γ mice exhibited 
upregulated expression of the MHC class I molecule, with diffuse protein localization along 
the myelin sheath (Fig. 5E, F) (Corbin et al., 1996).  The double-transgenic mice (MBP/IFN-
γ × PLP/SOCS1), however, displayed a differential pattern of MHC class I molecule 
expression (Fig. 5G–J).  As shown in Figure 5, oligodendrocytes and myelin positive for 
Flag-tagged SOCS1 did not express detectable levels of MHC class I molecule, whereas, 
cells negative for transgene expression, and in close proximity to the SOCS1-positive cells, 
demonstrated strong immunoreactivity.  Similar differential upregulation of MHC class I 
molecule expression was observed following the direct administration of IFN-γ in the brain 
of PLP/SOCS1 mice (data not shown).  Together, these data indicate that oligodendrocytes 
from PLP/SOCS1 mice display diminished responsiveness to IFN-γ.  
 
PLP/SOCS1 Mice Were Protected against Injurious IFN-γ Effects During Development 
    Transgenic expression of IFN-γ in the CNS of developing mice results in oligodendrocyte 
loss and hypomyelination (Corbin et al., 1996; Lin et al 2005).  To determine whether 
SOCS1 expression could protect developing oligodendrocytes from the injurious effects of 
IFN-γ, we crossed PLP/SOCS1 mice to three transgenic mouse lines overexpressing IFN-γ in 
the CNS at different levels: MBP/IFN-γ (line 172), GFAP/tTA × TRE/IFN-γ (lines 184/110) 
and GFAP/tTA × TRE/IFN-γ (lines 184/67) and the following three mating systems were 
 301
established (detailed in the Material and Methods): MBP/IFN-γ×PLP/SOCS1 (172 × 
PLP/SOCS1, a double transgenic system) and GFAP/tTA × TRE/IFN-γ × PLP/SOCS1 
(184/110×PLP/SOCS1 and 184/67×PLP/SOCS1, two triple-transgenic systems).  The litter 
(F1 generation) of each mating system was divided into four study groups depending on their 
genotype: wild-type/single transgenic controls, mice expressing IFN-γ only, mice expressing 
SOCS1 only and mice expressing both IFN-γ and SOCS1.  A total of 40 animals per mating 
system (10 animals per each study group) were collected and examined clinically and 
histologically at postnatal day 21.   
    Phenotypic comparisons of littermates were performed from birth to postnatal day 21 and 
evaluation consisted of behavioral observation and challenged ladder walking to elicit 
tremor. MBP/IFN-γ (line 172) mice express low levels of IFN-γ in the CNS and displayed no 
behavioral abnormalities, in accordance with findings reported elsewhere (Corbin et al., 
1996).  Mice from the F1 generation of the MBP/IFN-γ×PLP/SOCS1 (172 × PLP/SOCS1) 
mating system similarly displayed no behavioral abnormalities regardless of genotype.  
Double-transgenic GFAP/tTA × TRE/IFN-γ (lines 184/110) and GFAP/tTA × TRE/IFN-γ 
(lines184/67) mice display mild to moderate tremor that appears during the second postnatal 
week and peaks by 21 days of age (Lin et al., 2004; 2005). Mice from the F1 generation of 
the GFAP/tTA × TRE/IFN-γ × PLP/SOCS1 mating systems exhibited tremor, the incidence 
of which was dependent on genotype (Table 1).  The phenotypes of wild-type mice and 
single-transgenic mice (GFAP/tTA [184], TRE/IFN-γ [67 and 110], and PLP/SOCS1) were 
clinically normal.  The tremoring phenotype, which varied in severity, was identified in 
almost all double-transgenic GFAP/tTA × TRE/IFN-γ mice overexpressing IFN-γ: 80% 
(8/10) of 184/110 mice and 100% (10/10) of 184/67 mice.  Triple-transgenic GFAP/tTA × 
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TRE/IFN-γ × PLP/SOCS1 mice overexpressing both IFN-γ and SOCS1 appeared to be 
protected, because only 10% (1/10) of 184/110 × PLP/SOCS1 mice, and 30% (3/10) of 
184/67 × PLP/SOCS1 mice developed tremor.  
    The clinically examined littermates of all three transgenic mating systems were further 
evaluated for histological abnormalities at postnatal day 21.  Three animals per study group 
from each mating system were examined histologically for oligodendrocyte and myelin 
abnormalities. Brain tissue was obtained from each animal at the time of sacrifice (prior to 
the fixating perfusion) and total RNA isolated. The possibility that SOCS1 expression 
affected the expression of the IFN-γ transgene was examined in all three transgenic mating 
systems using quantitative PCR (Q-PCR) (Fig. 6A).  IFN-γ expression was detected in 
MBP/IFN-γ single-transgenic and MBP/IFN-γ × PLP/SOCS1 double-transgenic littermates of 
the 172×PLP/SOCS1 transgenic system, in GFAP/tTA × TRE/IFN-γ double-transgenic and 
GFAP/tTA × TRE/IFN-γ × PLP/SOCS1 triple-transgenic littermates of the184/110 × 
PLP/SOCS transgenic system, and in GFAP/tTA × TRE/IFN-γ double-transgenic and 
GFAP/tTA ×TRE/IFN-γ × PLP/SOCS1 triple-transgenic littermates of the 184/67 × 
PLP/SOC1 transgenic system.  Two characteristics of IFN-γ expression were observed. First, 
the three mating systems differed in their expression levels; MBP/IFN-γ × PLP/SOCS1 (172 
× PLP/SOCS1) expressed the lowest, and GFAP/tTA × TRE/IFN-γ × PLP/SOCS1 (184/67 × 
PLP/SOC1) expressed the highest IFN-γ levels.  Secondly, the littermates of the same mating 
system, expressing IFN-γ only or both IFN-γ and SOCS1, did not differ in their expression 
levels.  We found no detectible levels of IFN-γ in the wild-type, the GFAP/tTA and 
TRE/IFN-γ single-transgenic, and the PLP/SOCS1 littermates (Fig. 6A).  
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    The cerebra of three animals per study group from all transgenic mating systems were 
processed for immunohistochemical analysis with the CC1 antibody to determine 
oligodendrocyte density (Fig. 6B and Fig. 7).  The MBP/IFN-γ mice expressed the lowest 
levels of IFN-γ in the CNS compared to GFAP/tTA ×TRE/IFN-γ mice, and displayed no 
significant abnormalities in CC1-positive cell density, in accordance with results reported 
previously (Gao et al., 2000).  We found no statistically significant difference in the 
oligodendrocyte density among mice from the F1 generation of the MBP/IFN-γ × 
PLP/SOCS1 (172×PLP/SOCS1) mating system.  In the triple-transgenic systems (GFAP/tTA 
× TRE/ IFN-γ × PLP/SOCS1), we found that the oligodendrocyte density in mice from the 
F1 generation differed depending on genotype (Fig. 6B and Fig. 7).  Wild-type mice and the 
single-transgenic mice (PLP/SOCS1, GFAP/tTA, and TRE/IFN-γ) had comparable 
oligodendrocyte densities.  We found severe dose-dependent oligodendocyte loss in the 
GFAP/tTA × TRE/IFN-γ mice overexpressing IFN-γ, compared with the wild-type and 
single-transgenic littermates: approximately 20% of oligodendrocytes were lost in 184/110 
mice (from 146±6 CC1 (+) cells/mm2 in the wild-type mice to 115±8 CC1 (+) cells/mm2 in 
the IFN-γ mice), and approximately 40% were lost in 184/67 mice (from 144±5 CC1 (+) 
cells/mm2 in the wild-type mice to 79±9 CC1 (+) cells/mm2 in the IFN-γ overexpressing 
mice).  In contrast, GFAP/tTA × TRE/IFN-γ × PLP/SOCS1 triple-transgenic littermates that 
overexpressed both IFN-γ and SOCS1 lost statistically significantly fewer oligodendrocytes 
compared with mice overexpressing IFN-γ only: approximately 8% of oligodendrocytes were 
lost in 184/110 × PLP/SOCS1 mice (from 141±6 CC1 (+) cells/mm2 in the PLP/SOCS1 mice 
to 129±6 CC1 (+) cells/mm2 in the IFN-γ and SOCS1 overexpressing mice), and 
approximately 15% were lost in 184/67 × PLP/SOCS1 mice (from 142±5 CC1 (+) cells/mm2 
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in the PLP/SOCS1 mice to 112±7 CC1 (+) cells/mm2 in the IFN-γ and SOCS1 
overexpressing mice) (Fig. 6B and Fig. 7).   
    Myelination patterns in the harvested cerebra were further evaluated with electron 
microscopy, and the level of myelination was assessed by calculating the G ratio (axon 
diameter/fiber diameter ratio) and the percentage of unmyelinating axons (Fig. 6C and D, and 
Fig. 8).  We found no statistically significant difference in G ratios among wild-type, the 
MBP/IFN-γ (172) and PLP/SOCS1 single-transgenic, and double transgenic littermates from 
the MBP/IFN-γ × PLP/SOCS1 (172 × PLP/SOCS1) mating system.  In the triple-transgenic 
systems (GFAP/tTA × TRE/IFN-γ × PLP/SOCS1), significant differences in G ratios were 
found among the F1 generation mice, depending on genotype (Fig. 6C and Fig. 7).  G ratios 
among the wild-type and the GFAP/tTA, TRE/IFN-γ, and PLP/SOCS1 single-transgenic 
littermates were similar.  IFN-γ-overexpressing GFAP/tTA × TRE/IFN-γ littermates 
displayed significantly increased G ratios (±SD) indicating hypomyelination (defined as a G 
ratio >0.8): 0.89 ± 0.02 for 184/110 mice and 0.95 ± 0.04 for the 184/67 mice (Fig. 6C).  In 
contrast, their triple-transgenic (GFAP/tTA × TRE/IFN-γ × PLP/SOCS1) littermates 
overexpressing both IFN-γ and SOCS1 had significantly lower G ratios (±SD): 0.75 ± 0.03 
(within the normal range) for 184/110 × PLP/SOCS1 mice, and 0.82 ± 0.08 for 184/67 × 
PLP/SOCS1 mice (Fig. 6C and Fig. 8). 
    The myelin abnormalities were further quantified by determining the percentage of 
unmyelinated axons in the various transgenic genotypes (Fig. 6D).  We found no significant 
difference in the percentage of unmyelinated axons (less than 9%) among the F1 generation 
littermates of the MBP/IFN-γ × PLP/SOCS1 (172× PLP/SOCS1) double-transgenic system, 
regardless of genotype (Fig. 6D).  In the triple-transgenic GFAP/tTA × TRE/IFN-γ × 
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PLP/SOCS1 systems, however, the distribution of unmyelinated axons differed depending on 
genotype (Fig. 6D).  There was a significantly increased percentage of unmyelinated axons in 
IFN-γ-overexpressing GFAP/tTA × TRE/IFN-γ littermates compared to wild-type and single-
transgenic control mice: 41% ±6 in 184/110 mice and 57%±7 in 184/67 mice.  In contrast, 
triple-transgenic GFAP/tTA × TRE/IFN-γ × PLP/SOCS1 overexpressing both IFN-γ and 
SOCS1 had a significantly lower percentage of unmyelinated axons compared with mice 
overexpressing IFN-γ alone: only 13%±3 for 184/110× PLP/SOCS1 mice and 17%±4.5 for 
184/67× PLP/SOCS1 mice (Fig. 6D).   Together, these data demonstrate that 
oligodendroglial expression of SOCS1 protects mice from the clinical and morphological 
consequences of IFN-γ expression in the CNS during development. 
 
DISCUSSION: 
    The presence of the T-cell-derived cytokine IFN-γ within the CNS is believed to play a 
critical role in the pathogenesis of immune-mediated demyelinating disorders (Panitch et al, 
1987; Galbinski et al., 1999; Tran et al., 2000; Vartanian et al., 1996; Horwitz et al. 1997; 
Steinman, 2001).  Nevertheless, the cellular target of the cytokine’s effect remains 
unresolved.  In this report we describe the generation of transgenic mice in which the 
oligodendrocytes display a significantly reduced capacity to respond to IFN-γ.  These mice 
are protected from the injurious effect of ectopic expression of IFN-γ within the CNS, 
suggesting that a direct deleterious effect of IFN-γ on oligodendrocytes contributes to 
immune-mediated disease pathogenesis.  As discussed below, the work described has 
significant clinical implications. 
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    Transgenic animals that ectopically express IFN-γ in the CNS during postnatal 
development are hypomyelinated and contain reduced numbers of oligodendrocytes (Corbin 
et al., 1996; LeFerla et al., 2000; Lin et al., 2005).  Moreover, the induction of IFN-γ 
expression in the CNS following demyelinating insults results in reduced oligodendroglial 
repopulation of the demyelinating lesions and impaired remyelination (Lin et al., in press).  
Previously reported data from our laboratory suggests that the presence of IFN-γ in the CNS 
activates an ER stress response in oligodendrocytes, which contributes to the observed 
pathological effects (Lin et al, 2005; in press).  It is unclear, however, if the injurious effect 
of IFN-γ on oligdodendrocytes is a result of a direct action or whether it represents a 
secondary effect, possibly through microglial activation. 
    IFN-γ has also been shown to have harmful effects on oligodendrocytes and their 
progenitors in vitro.  There is considerable evidence to suggest that at least part of the 
injurious effect of this cytokine is mediated through the activation of microglial cells.  IFN-γ-
treated microglia release cytotoxic agents, including nitric oxide and tumor necrosis factor 
alpha, that are known to be damaging to oligodendrocytes (Merrill et al., 1991, 1993, 
Loughlin et al., 1997).  Studies using purified oligodendrocytes in vitro, however, suggest 
that the cytokine may have a direct, harmful effect on oligodendrocytes (Torres et al., 1995; 
Agresti et al., 1996; Baerwald et al., 1998; Andrews et al., 1998; Lin et al., 2005).  IFN-γ has 
been shown to inhibit cell cycle exit of oligodendroglial progenitor cells, which may 
predispose these cells to apoptotic death (Chew et al., 2005).  Additionally, IFN-γ has been 
shown to be a very powerful apoptotic-inducing agent for developing oligodendrocytes 
(Baerwald et al., 1998, 2000; Lin et al., 2005).  Oligodendrocytes that have been allowed to 
differentiate in vitro to the point of expressing mature oligodendroglial markers are less 
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sensitive to the presence of the cytokine, although they do eventually succumb to necrosis 
(Baerwald et al., 1998).   
    In an effort to differentiate direct versus indirect effects of IFN-γ on oligodendrocytes in 
vivo, we generated transgenic mice that exhibited diminished oligodendrocyte-specific 
responsiveness to IFN-γ.  Transgenic mice expressing either the dominant-negative form of 
IFN-γ receptor subunit 1 (IFNGR1) or the suppressor of cytokine signaling 1 (SOCS1) have 
been previously described (Flodstrom et al., 2001; Gonzales at al., 2005, Hindinger et al., 
2005). Overexpression of the dominant-negative form of IFNGR1 resulted in accelerated 
degradation of wild-type IFNGR1 and elimination of the IFN-γ cellular binding sites (Dighe 
et al., 1994).  SOCS1 is an intracellular protein that blocks IFN-γ mediated Stat1 activation 
(i.e., phosphorylation) by Jak kinases (Starr et al., 1997; Song and Shuai 1998; Sakamoto et 
al., 2000; Yasukawa et al., 2000; Kubo et al., 2003; Stark et al., 1998; Levy and Darnell, 
2002).  Mouse mutants with a targeted null mutation in the SOCS1 gene exhibit abnormal 
hypersensitivity to IFN-γ and die of multi-organ failure in the presence of normal levels of 
the cytokine (Starr et al., 1998; Alexander et al., 1999; Bullen et al., 2001).  Moreover, forced 
expression of SOCS1 has been shown to result in a state of IFN-γ unresponsiveness in a 
variety of cell types (Tunley et al., 2001, 2002; Chong et al., 2001, Federici et al., 2002; 
Flodstom et al., 2001).  
    The PLP/SOCS1 mice exhibited no phenotypic or histological abnormalities, indicating 
that Stat1 activation is not required for normal oligodendrocyte development, even though its 
involvement in growth factor signaling has been suggested in vitro (Dell’Albani et al., 1998). 
Our finding is supported by the phenotypic characteristics of Stat1 (−/−) knockout mice, 
which displayed no oligodendrocyte or myelin abnormalities but do have significantly 
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impaired IFN-γ cellular responses (Meraz et al., 1996).  Thus, it appears that Stat1 activation 
plays a differential role in oligodendorocyte injury and development. 
    Functional examination of the PLP/SOCS1 mice further demonstrated a diminished 
oligodendrocyte-specific responsiveness to IFN-γ, including inhibition of Stat1 activation 
(i.e. phosphorylation) and nuclear translocation, and MHC class I molecule upregulation.  
When crossed with transgenic mice overexpressing IFN-γ in the CNS, PLP/SOCS1 mice 
were protected from the deleterious clinical and histological effects of IFN-γ.  IFN-γ-
overexpressing transgenic mice that also carried the PLP/SOCS1 transgene displayed 
significant oligodendrocyte and myelin preservation and lower prevalence of tremor 
compared to IFN-γ expressing mice without the PLP/SOCS1 transgene.  Results of our study 
thereby indicate that IFN-γ exerts a direct injurious effect on developing oligodendrocytes.  
    Overexpression of SOCS1 provided cellular protection to oligodendrocytes, suggesting 
that inhibition of IFN-γ signaling results in reduced cellular effects.  Wild-type 
oligodendrocytes, as reported by others and also observed by us, express nearly undetectable 
amounts of SOCS1 under normal, and even inflammatory conditions, and have much lower 
SOCS1 expression compared to the surrounding glial and inflammatory cells  (Polizzotto et 
al., 2000; Wang and Campbell 2002; Maier et al., 2002).  Such low constitutive expression 
may limit the oligodendrocyte capacity for effective downregulation of IFN-γ/Jak/Stat1 
signaling, resulting in enhanced IFN-γ cellular effects.  The rescuing effect of SOCS1 
overexpression in oligodendrocytes that was observed in our experimental system supports 
this possibility.   
    Circumstantial and experimental evidence suggests that IFN-γ plays a deleterious role in 
the immune-mediated demyelinating disorder multiple sclerosis (Popko et al., 1997, 
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Steinman 2001).  IFN-γ is found in demyelinated lesions and its levels in cerebrospinal fluid 
correlate with disease severity (Vartanian et al., 1996; Calabresi et al., 1998; Becher et al., 
1999; Moldovan et al., 2003).  Administration of IFN-γ to MS patients exacerbated the 
disease, and neutralizing antibodies to IFN-γ have been shown to delay disease progression 
(Panitch et al, 1987; Skurkovich et al., 2001).  Diminishing the local effect of IFN-γ, perhaps 
through the targeted expression of SOCS1 by oligodendrocytes, could prove to be 
therapeutically beneficial.  Remyelinating oligodendrocytes after a demyelinating insult are 
more sensitive to the presence of IFN-γ (Lin et al., in press); therefore, such protection might 
be particularly useful for the promotion of remyelination.   
    Stem cell therapy is rapidly gaining interest as a potential therapeutic approach to 
demyelinating disorders such as multiple sclerosis and adrenoleukodystrophy (review in 
Keirstead 2005).  The success of such an approach would appear to be limited, however, in 
immune-mediated demyelinating disorders, since the harsh environment created by the 
inflammatory response would remain.  Perhaps stem cells engineered to be resistant to the 
harmful cytokines present in the extracellular milieu of the breached CNS would stand a 
better chance of surviving and accomplishing remyelination.  It is, therefore, of therapeutic 
interest to identify signaling pathways that play differential roles in oligodendrocyte injury 
and development.  Our results describing inhibition of IFN-γ–mediated oligodendrocyte 
injury without induction of any observable oligodendrocyte or myelin abnormalities provide 
support for such an approach.   
    In summary, we have demonstrated that the forced expression of SOCS1 in 
oligodendrocytes of transgenic mice protects against the deleterious effects of IFN-γ on 
oligodendrocytes and the process of myelination.  Our results strongly indicate that the 
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deleterious effect of IFN-γ on myelinating oligodendrocytes is due, at least in part, to a direct 
adverse effect on these cells.  Moreover, our work suggests that forced expression of SOCS1 
in oligodendrocytes might provide protection against the harsh environment in immune-
mediated demyelinating disorders. 
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Figure 1. Expression of Flag-SOCS1.  A.  PLP/SOCS1 construct contains 2.4Kb of the PLP  
5’ flanking DNA, exon 1(no ATG), intron 1(diagonally striped boxes), Flag-SOCS1 and 
SV40 polyA signal sequence. Expression of the PLP/SOCS1 transgene was characterized at 
postnatal day 21using several methods. B. Northern blot analysis demonstrated Flag-SOCS1 
expression in PLP/SOCS1 brain, lane 2 (T, transgenic brain), compared to wild-type brain, 
lane 1 (WT, wild-type brain). C. Q-PCR analysis with transgene-specific primers revealed 
the highest concentrations of transgene-derived SOCS1 mRNA were in the brain, spinal cord, 
and sciatic nerve, with significantly lower levels in other organs. D. Western blot. E. 
Immunoprecipitation.  Both demonstrated a single 19 KD Flag positive band, the expected 
molecular weight of SOCS1, only in the lanes loaded with brain samples from PLP/SOCS1 
mice (brain fSOCS1+). Flag protein was used as a positive control for the antibody reaction; 
15% SDS-PAGE, anti-Flag (M2) antibody.  Immunostaining with anti-SOCS1/FITC (F, H), 
and anti-Flag/FITC antibodies (G, I) demonstrated positive signal only in PLP/SOCS1 (H, I, 
green), and not in the wild-type mouse samples (F, G). Cell nuclei were contrastained with 
ethidium bromide (F-I, red).  Coronal section sections of thalamic fiber; Bar=20µm. 
 
 
 312
Figure 2. Colocalization of Flag-SOCS1 and PLP in vivo.  Dual immunostaining of wild-
type (A-C, top row) and PLP/SOCS1 (D-F, bottom row) cerebellar tissue, harvested at 
postnatal day 21, was performed using anti-PLP/Cy3 (A, D, red) and anti-Flag/FITC (B, E, 
green) antibodies, and DAPI nuclear stain (C, F, blue).  PLP positive structures of the wild-
type samples (A, red) demonstrated no immunopositivity for anti-Flag (B) and no signal 
colocalization was established (C).  In contrast, PLP positive structures of PLP/SOCS1 
samples (D) expressed Flag-SOCS1 (E), and strong co-localization between the anti-PLP and 
anti-Flag immunopositivity was detected (F, yellow color signifies co-localization). Sagittal 
sections of cerebellum; Bar=20µm. 
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Figure 3. Colocalization of flag-SOCS1 and PLP in vitro.  Dual immunostaining of wild-
type (A-C, top row) and PLP/SOCS1 (D-F, bottom row) mixed primary oligodendrocyte 
cultures was performed using anti-PLP/FITC (A, D, green) and anti-Flag/Cy3 (B, E, red) 
antibodies.  PLP positive oligodendrocytes in the wild-type culture (A) demonstrated no 
immunopositivity for anti-Flag (B), and no signal colocalization was established (C).  In 
contrast, PLP positive oligodendrocytes (D) in the PLP/SOCS1 cultures expressed Flag-
SOCS1 (E), and strong colocalization between anti-PLP and anti-Flag signals was detected 
(F).  Flag-SOCS1 appeared to be localized in the cell body (large arrows) and cell processes 
(small arrows) of oligodendrocytes. Bar=20µm. 
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Figure 4.  Differential inhibition of Stat1 nuclear translocation.  Mixed primary 
oligodendrocyte cultures from wild-type (A-D; top row) and PLP/SOCS1 (E-H; bottom row) 
mice were stimulated with 100U IFN-γ for 30 min, and dual immunostainings using anti-
PLP/Cy3 (A, E; red), anti-Stat1 (B, F; green), and DAPI nuclear stain (D, H; blue) were 
performed and the fluorescent signals digitally overlayed (C and G, overlay between 
PLP/Cy3 and Stat1/FITC signals; D and H, overlay between PLP/Cy3, Stat1/FITC and DAPI 
signals). In the wild-type cultures, Stat1 was colocalized with DAPI stained nuclei of all 
cells, including the PLP positive oligodendrocytes (small arrows) (B, D, colocalization 
between Stat1 and DAPI).  In the PLP/SOCS1 cultures, Stat1 was colocalized with DAPI 
positive nuclei of the PLP negative cells (small arrows), but not of the PLP positive 
oligodendrocytes (large arrows). Stat1 in the PLP positive oligodendrocytes did not 
colocalize with DAPI stained nuclei, but remained in the cytoplasm (large arrows) (F, H). 
Bar=10µm. 
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Figure 5.  Differential expression of MHC class I molecule in MBP/IFN-γ x PLP/SOCS1 
mice.  Wild-type (A, B), PLP/SOCS1 (C, D), MBP/IFN-γ (E, F) and MBP/IFN-γ × 
PLP/SOCS1 (G, H, I, J) mouse brains, harvested at postnatal day 21, were dual 
immunostained with anti-MHC class I/FITC (A, C, E, G, I; green) and anti-flag/Cy3 (B, D, 
F, H, J; red) antibodies, and DAPI nuclear stain (J, blue). Wild-type samples (A, B) were 
double negative.  PLP/SOCS1 samples were negative for MHC class I molecule (C) and 
positive for Flag (D). MBP/IFN-γ samples were single positive for MHC class I molecule (E) 
and negative for Flag (F).  Double transgenic MBP/IFN-γ × PLP/SOCS1 samples were 
double positive for MHC class I molecule (G) and Flag (H). Higher magnification of 
MBP/IFN-γ × PLP/SOCS1 samples (outlined square in G, H) revealed differential 
distribution of the immunopositivity (I, J); MHC class I positive cells (large arrows) were 
negative for Flag, whereas Flag positive cells (small arrows) were negative for MHC class I 
molecules. Sagittal sections of corpus callosum; Bar=20µm (A-H); Bar=10µm (I, J). 
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Figure 6. SOCS1-mediated protection of oligodendrocytes and myelin. The IFN-γ 
expression (A), oligodendrocyte density (CC1 cells/mm2) (B), G ratio (C), and percent 
unmyelinated axons (D) were examined among littermates of three transgenic systems: 
172×PLP/SOCS1, 184/110×PLP/SOCS1 and 184/67×PLP/SOCS1 at postnatal day 21 (see 
Results for complete description).  The relative amount of IFN-γ expression differed among 
the systems but no statistical difference was found in the levels of expression between 
littermates from the same transgenic system overexpressing either IFN-γ only (IFN-γ) or both 
IFN-γ and SOCS1 (IFN-γ×SOCS1) (A). The IFN-γ overexpressing littermates (IFN-γ) 
displayed significant dose-dependent oligodendrocyte cell loss (B) and hypomyelination (C, 
D) as compared to the wild type, single transgenic control (wt/cntrl) and PLP/SOCS1 
littermates (* p<0.05, n=3 per study animals). The triple transgenic littermates expressing 
both IFN-γ and SOCS1 (IFN-γ×SOCS1) displayed significant oligodendrocyte (B) and 
myelin preservation (C, D) as compared to those overexpressing IFN-γ only (IFN-γ) (** 
p<0.05, n=3 animals per study group).   
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Figure 7.  SOCS1-mediated oligodendrocyte protection.  Representative images of the 
quanitated areas from GFAP/tTA × TRE/IFN-γ × PLP/SOCS1 (184/67× PLP/SOCS1) mice 
at postnatal day 21:  A. Wild-type; B. PLP/SOCS1; C. 184/67 and D; 184/67 ×PLP/SOCS1. 
Immmunostaining with CC1/Cy3 (red) and DAPI nuclear stain (blue). Sagittal sections of 
corpus callosum; Bar=20µm. Note the loss of CC1 positivity in the sample from an IFN-γ-
overexpressing mouse (C) compared to the samples from wild-type (A) and PLP/SOCS1 
mice (B), and the significant oligodendrocyte preservation in the sample from a mouse 
overexpressing both IFN-γ and SOCS1 (D). 
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Figure 8.  SOCS1-mediated myelin protection.  Representative images of the quanitated 
areas from GFAP/tTA × TRE/IFN-γ × PLP/SOCS1 (184/67×PLP/SOCS1) mice at postnatal 
day 21: A. Wild-type; B. PLP/SOCS1; C. 184/67 and D; 184/67×PLP/SOCS1. Electron 
micrographs of corpus callosum; Bar=500nm.  Note the hypomyelination in the sample from 
an IFN-γ-overexpressing mouse (C) compared to the samples from wild type (A) and 
PLP/SOCS1 mice (B), and the significant myelin preservation in the sample from a mouse 
overexpressing both IFN-γ and SOCS1 (D). 
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Table1. Incidence of tremor among the transgenic littermates   
 
   Wild-type/controls SOCS1   IFN-γ  IFN-γ×SOCS1 
 
 
172×PLP/SOCS1  0%  0%  0%  0% 
 
184/110×PLP/SOCS1  0%  0%  80% (8/10) 10% (1/10)  
 
184/67×PLP/SOCS1  0%  0%  100% (10/10) 30% (3/10) 
 
______________________________________________________________________________  
 
Littermates from three transgenic mating systems, 172 × PLP/SOCS1, 184/110×PLP/SOCS1 and 
184/67×PLP/SOCS1 were stratified according to their genotype into four groups: Wild-
type/control mice, mice expressing SOCS1 only, mice expressing IFN-γ only and mice 
expressing both IFN-γ and SOCS1.  Ten mice per group were clinically followed during the 
first three postnatal weeks and the incidence of tremor recorded.   
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